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Abstract 
 
Title: The anti-inflammatory effects of vitamin D receptor agonists on human 
white preadipocytes 
 
Adipose tissue metaflammation in obesity is characterized by increased infiltration of immune 
cells and chronically increased gene expression and secretion of pro-inflammatory factors. It is 
proposed that VDR (vitamin D receptor) agonists could antagonize inflammatory response in 
adipose tissue. Hence, our study aimed to investigate whether VDR agonists [1α,25(OH)2D3 and 
its synthesized analogues ZK15922 and ZK191784] could inhibit inflammatory responses 
stimulated by THP-1-MacCM (macrophage conditioned medium)/IL-1β in human white 
preadipocytes.  
 
Preadipocytes were either cultured alone (control), or with (25%) THP-1-MacCM alone, or with 
IL-1β (0.5 and 2 ng/ml) alone for 24 h. Further groups of cells were pretreated with VDR agonists 
[1α,25(OH)2D3 (0.01-10 nM), ZK15922 (10 nM and 1 μM) and ZK191784 (10 nM and 1 μM)] for 
24 or 48 h, followed by treatment with (25%) THP-1-MacCM/IL-1β (0.5 and 2 ng/ml) and VDR 
agonists for a further 24 h before medium and lysate collection. The cell media were collected for 
measurement of cytokines using arrays and ELISA; the Trizol lysate for qPCR; buffer lysate for 
western blotting. 
 
The results show that THP-1-MacCM/IL-1β enhanced the gene expression and secretion levels of 
IL-1β, IL-6, IL-8, MCP-1 and RANTES, whilst the pre- and treatment with VDR agonists 
significantly inhibited the gene expression and secretion of the major inflammatory factors in 
THP-1-MacCM/IL-1β-stimulated preadipocytes. Moreover, the combination of pretreatment with 
VDR agonists [1α,25(OH)2D3 (0.01-10 nM), ZK159222 (10 nM and 1μM) and ZK191784 (10 nM 
and 1μM)] and treatment with VDR agonist–MacCM significantly reduced the inflammatory gene 
expression and secretion from human preadipocytes, compared with THP-1-MacCM-stimulated 
preadipocytes. Taken together, VDR agonists could exert anti-inflammatory effects on the 
pro-inflammatory gene expression and secretion in THP-1-MacCM/IL-1β-stimulated 
preadipocytes. 
 
In addition, VDR agonists significantly reduced the levels of phosphorylated relA of the NF-κB 
pathway, phosphorylated ERK of the MAPK pathways and phosphorylated eIF-2α of the UPR 
pathway, whilst increasing methylated relA of the NF-κB pathway and phosphorylated eIF-2α of 
the UPR pathway in THP-1-MacCM/IL-1β–stimulated preadipocytes. Therefore, it can be 
speculated that VDR agonists might inhibit metaflammation in adipose tissue by: 1, directly 
reducing pro-inflammatory gene expression; 2, modulating post-translational relAs and blocking 
phosphorylated ERK to attenuate pro-inflammatory gene expression; 3, reducing phosphorylated 
eIF-2α to inhibit the NF-κB pathway; 4, increasing phosphorylated eIF-2α to reduce 
pro-inflammatory translation. 
Zhu JingJing 
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1. Introduction 
 
1.1. Metaflammation 
 
More than 20 years ago, Hotamisligil et al. reported in an elegant series of studies that there is a 
state of inflammation characterized by increased expression levels of (tumor necrosis factor) 
TNF-α in adipose tissue of obese mice as well as humans (1). The discoveries were soon followed 
by a body of research dedicated to understanding the nature of this obesity-induced inflammation 
and the underlying mechanism of its pathogenesis (2-4). 
 
Investigators now agree that this state of inflammation is distinctive and outside of the paradigm 
set up for the classical inflammation, which in addition to redness, swelling, heat and pain, is 
associated with the focused and rapid response to the origin of inflammation (5, 6). Based on the 
research evidence, Hotamisligil and Gregor summarized the hallmarks of the obesity-induced 
inflammation and termed it as “metaflammation”, in order to distinguish it from classical 
inflammation (7).  
 
Studies suggest that it is a metabolically triggered-inflammatory response, characterized by 
dysfunction and infiltration of immune cells in adipose tissue (7). Though the early research 
revealed that metaflammation occurred in adipose tissue of humans and mice, the pancreas (8), 
liver (9), muscle (10) and brain (11) all endure this inflammatory insult (Figure 1.1).  
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Figure 1.1 The occurrences of metaflammation onset and progression in some tissues (adipose 
tissue, muscle), organs (brain, liver), immune system and ecosystem (gut microbiota). Obtained 
from (12). 
 
 
 
 
 
Adipose tissue expansion during the course of obesity is mediated by hypertrophy (enlarged 
adipocytes) and hyperplasia (increased number of adipocytes) (13). It has been proposed that 
metaflammation is highly associated with hypertrophic adipocytes, for its adoption of necrotic-like 
abnormalities, which may lead to disrupted homeostasis in adipose tissue and impaired function 
(14, 15). Moreover, due to a relative reduction in the vascularity as a result of rapid adipose 
expansion, adipose hypertrophy induces hypoxia in the local adipose tissue, up-regulating the gene 
expression levels of pro-inflammatory factors as well as angiogenic factors (16-18). For instance, 
as a transcription factor activated during the process of hypoxia, (hypoxia-inducible factor) 
HIF-1α can augment metaflammation in adipose tissue (19). 
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Another important feature of metaflammation is increased infiltration of immune cells into the 
afore-mentioned metabolic tissues (Figure 1.2). For example, the proportion of macrophage 
population is significantly higher in adipose tissue of mice fed a HFD (high-fat-diet) compared 
with the lean controls (20, 21). The mechanism is not yet fully understood, but it has been 
demonstrated that isolated bone marrow cells migrate towards the adipose explants from obese 
animals (22). The role of immune cells played in the pathogenesis of metaflammation will be 
discussed in details in Introduction Page 31-42.  . 
 
Figure 1.2 Immune cell trafficking in obesity. (A) In lean adipose tissue, alternatively activated 
‘M2’ macrophages are resident and their phenotype is maintained by the presence of T-regulatory 
(Treg) cells, Th2 cells, and eosinophils. (B) As white adipose tissue expands, recruited monocytes 
polarize to pro-inflammatory M1 macrophages. Moreover, the loss of eosinophils, Tregs and Th2 
cells as obesity progresses is accompanied with the infiltration of CD4+ Th1 cells, CD8+ T cells, 
NK cells, and other granulocytes such as neutrophils and mast cells. Obtained from (23).  
 
 
 
 
 
Metaflammation has also been suggested to be characterized by moderate local expression of 
pro-inflammatory factors in metabolic tissues (7). Since the discovery of TNF-α expression in the 
4 
 
obese adipose tissues of both humans and mice, an array of moderately expressed cytokines have 
been detected subsequently, such as IL-1β, IL-6 and other pro-inflammatory factors (critical in the 
induction and maintenance of metaflammation) as well as MCP-1(monocyte attractant protein 1) 
and other chemoattractants (responsible for the infiltration of immune cells into metabolic tissues) 
(24, 25). The underlying mechanisms have also been established based on the related 
investigations (Figure 1.3). For instance, during metaflammation, TNF-α as well as IL-1β 
activates JNK (c-jun N-terminal kinase), IKKβ (inhibitor of κ kinase β) and their down-stream 
cascades including the transcription factors AP-1 (activator protein-1) (by JNK) and (nuclear 
factor) NF-κB (by IKKβ) in the classical receptor-mediated way, thereby up-regulating the gene 
expression and secretion of pro-inflammatory factors (24). Likewise, JNK/AP-1 and IKKβ/NF-κB 
can be activated by pattern recognition receptors such as TLRs (toll like receptors) to mediate 
metaflammation (24). Conversely, the expression of nuclear-receptor (peroxisome 
proliferator-activated receptor) PPARγ was down-regulated when metaflammation occurred in 
adipose tissue (26). This may partly explain why the circulating level of adiponectin (a cytokine 
specifically secreted by adipocytes, essential for maintaining the homeostasis of adipose tissue) 
was negatively correlated with fat mass. TZDs (thiazolidinediones), which are potent PPARγ 
agonists, can significantly raise circulating levels of adiponectin when administered to both 
humans and mice (27, 28). 
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Figure 1.3 The integration of metaflammatory signaling occurs at multiple levels, including at the 
receptor, organelle, kinase pathways, and gene expression. The three most heavily studied 
examples, PKC, JNK and IKK, can signal a multitude of immune (both innate and adaptive 
responses, resolution of inflammation) and metabolic responses (glucose, insulin and fatty acid 
metabolism). Obtained from (29). 
 
 
 
 
 
There is evidence that metaflammation is chronically maintained without apparent resolution (7). 
Metaflammation is characterized by maintenance in a chronic state, by contrast with the acute 
inflammatory response which is rapidly followed by resolution at the site of the insult. The 
plausible mechanism is that when induced merely by adipose expansion, metaflammation is not 
strong enough to stimulate a rapid and full program of resolution (7). Time-course analysis of the 
onset and progress of metaflammation by examining immune cell infiltration in adipose tissue has 
thoroughly been investigated in the mice on a HFD; wild-type C57BL/6J mice from the Jackson 
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Laboratory were on diet containing 10%, 45%, or 60% kcal from fat; from 4-5 weeks of age, and 
until 16 to 26 weeks. Global transcriptional profiling in these mice showed significantly enhanced 
gene expression of many macrophage-specific genes, such as MCP-1, MIP-1α (macrophage 
inflammatory protein) and MAC-1(macrophage antigen 1, CD11b). Moreover, this up-regulation 
appeared as early as 3 weeks after the initiation of HFD. Thus it was concluded that the expression 
of pro-inflammatory genes was positively correlated with the duration of fat mass expansion (20). 
In addition, adipose tissue can secrete IL-8 (a chemokine) which predominantly attracts 
neutrophils (30). Elgazar-Carmon et al. found that the number of infiltrating neutrophils in visceral 
fat of mice transiently increased at 3 and 7 days after starting HFD feeding (31). In parallel, the in 
vitro cellular system demonstrated that the interaction between adipose tissue and neutrophils was 
mediated by forming a protein complex (neutrophil CD 11b: adipocyte ICAM-1, intracellular 
adhesion molecule 1) (31). These results further reflect the chronicity of metaflammation, since it 
is in accordance with the characteristic of the progress of the chronic inflammation, which is that 
the transient infiltration of circulating neutrophils precedes the predominant infiltration of 
monocytes into the inflamed tissues. In the case of metaflammation, the infiltration largely 
consists of macrophages, as these tend to predominate in chronic inflammatory states (32). 
 
 
 
1.2. Metaflammation in obesity 
 
The accumulated evidence suggests that metaflammation is induced by excessive 
adiposity-obesity. 
 
Obesity is attributed to excessive net energy gain, and characterized by accumulation of body fat. 
The World Health Organization reported that in 2014 more than 1.9 billion adults, 18 years and 
older, were overweight (body mass index-BMI is greater than or equal to 25 kg/m2), of these over 
600 million were obese (BMI is greater than or equal to 30 kg/m2). More shocking is that 41 
million children under the age of 5 were overweight or obese. Without intervention, these numbers 
are expected to rise in the future (33). An important contributor to the pandemic of obesity is the 
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so-called obesogenic environment, which is pictured as the modern, computer-dependent, 
sleep-deprived, physically inactive humans living chronically stressed in a society of food 
abundance (34). Although mild obesity is associated with some health benefits [i.e. now scarcely 
needed but apparent protection against starvation in times of food shortage (35), potential 
protection from osteoporosis and fractures in the elderly, etc (36)], nowadays obesity has become 
a leading global public health problem and is considered as a risk factor of a variety of diseases, 
such as T2D (type 2 diabetes), hepatic steatosis, biliary disease, neurodegeneration, cardiovascular 
diseases, musculoskeletal abnormalities and even some cancers (6). These obesity-associated 
maladies subsequently lead to reduced life expectancy and premature death. Hence, prevention of 
obesity-related diseases and treatment of obesity at the individual as well as population level is an 
important public health priority. Promotion of a life style combining balanced diet, healthy eating 
habits and moderate physical activity is critical to the treatment of obesity and prevention of its 
detrimental outcomes. Although weight loss is one approach to obesity management, it is not 
always effective, and if extreme may damage health. An alternative approach is to support weight 
loss with treatments that ameliorate the pathological processes that link obesity to disease, such as 
metaflammation (34). Moreover, weight loss does not significantly lower the risk of the 
obesity-associated metabolic diseases in a subgroup of obese individuals, who are classified as 
being MHO (metabolically healthy obese) (37).  
 
MHO individuals are generally characterized as having a BMI greater or equal to 30 kg/m2 but 
displaying favorable metabolic profiles. The concept of being MHO was initially described in the 
1980s (38). Epidemiological evidence suggests that the proportion of MHO individuals may be up 
to 30% of the obese population (39). Although the existence of this subtype of obesity has been 
well recognized nowadays, the adequate standards to identify MHO individuals are yet to be 
established. The common clinical and biological criteria applied to identify MHO individuals 
include the absence of metabolic disorders (such as metaflammation, dyslipidemia and 
hypertension, etc) and presence of preserved insulin sensitivity (40). Most studies have used 
insulin sensitivity to divide obese individuals into being MHO and MAO (metabolically abnormal 
obese). Insulin sensitivity can be determined by the hyperinsulinemic–euglycemic clamp 
technique (invasive, expensive and time consuming) (41), the Matsuda index (oral glucose 
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tolerance test derived index) (42) or the homeostasis model assessment (fasting surrogate index) 
(43). Kloting et al. (44) reported that compared with MAO, MHO individuals have significantly 
lower mean omental adipocyte size (528 ± 76 vs. 715 ± 81 pl), a favorable metaflammation profile 
including lower number of macrophages in omental adipose tissue (4.9 ± 0.8 vs. 13.2 ± 1.4%), 
circulating CRP (C-reactive protein), progranulin, chemerin and retinol-binding protein-4 (all P 
values <0.05) and higher serum adiponectin (6.9 ± 3.4 vs. 3.4 ± 1.7 ng/ml, P<0.01). The strongest 
predictors of being MHO were macrophage infiltration together with circulating adiponectin (r2 = 
0.98, P<0.0001). Furthermore, Shin et al. (45) reported that plasma CRP (P<0.001), IL-6 (P<0.05) 
and oxidized LDL (low density lipoprotein) (P<0.001) were significantly lower in the MHO 
compared with the MAO individuals. Noteworthy, after a weight loss program for 12-week (the 
degree of weight loss between the two groups was similar and averaged 3.11% of initial body 
weight), the levels of CRP (P<0.05) and oxidized LDL (P<0.01) were significantly reduced in the 
MAO but not in the MHO group. Collectively, a favorable metaflammation profile may 
predispose, delay or protect obese individuals against obese-induced metabolic diseases. The 
mechanisms regarding the different metabolic outcomes of being obese still need to be clarified.  
 
Adipose tissue expansion, characterized mainly by adipocyte hypertrophy and hyperplasia or both, 
is a potential contributor to metaflammation in obesity. Adipocyte hypertrophy as well as 
hyperplasia is regulated by environmental and genetic factors (13). However, it is still not clear 
how these two modes of expansion are regulated at the molecular level. The association of 
adipocyte hypertrophy with dysregulated adipocyte metabolism and increased adipocyte stress 
raised the hypothesis that adipocyte hypertrophy leads to obesity-associated adipocyte death. It 
has been subsequently demonstrated (46) that in the obese mice, humans and HSL-/- 
(hormone-sensitive lipase-deficient) mice (a model of adipocyte hypertrophy without 
increased adipose mass), the frequency of adipocyte death is positively correlated with 
hypertrophic adipocyte size, the WAT (white adipose tissue) of HSL-/- mice exhibited a 15-fold 
increase in necrotic-like adipocyte death and formation of macrophage syncytia, which coincides 
with the increased gene expression levels of metaflammation indicators including MAC-2 (a 
potent macrophage chemoattractant that promotes macrophage aggregation and survival at sites of 
inflammation due to its anti-apoptotic ability) and TNF-α by 7 and 5-fold (P<0.05) respectively in 
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perirenal WAT. Paradoxically, results generated from a large study of moderately obese, 
weight-stable individuals (47) showed that, an increased proportion of small adipose cells 
(hyperplasia) was positively correlated with metaflammation, as demonstrated by increased gene 
expression levels of IL-6 and MCP-1 (P<0.05) in subcutaneous adipose tissue, but the size of 
mature adipose cells (hypertrophy) was not. Therefore, based on the observed association between 
hypertrophic adipocyte size/hyperplasic small adipose cells and metaflammation, it is possible that 
other than adipocyte death, impaired adipogenesis and/or terminal differentiation in obesity is also 
closely associated with the pathogenesis of metaflammation. 
 
ER stress, oxidative stress and hypoxia induced by adipose tissue expansion are potential triggers 
of metaflammation in obesity. 
 
ER stress 
 
Protein synthesis as well as folding takes place in the ER (endoplasmic reticulum). As a 
consequence of adipocyte hypertrophy (induced by excessive intake of energy and nutrients) in 
obesity, enhanced protein synthesis and insufficient chaperone proteins (helping correctly fold 
newly synthesized proteins) are thought to trigger ER stress (48). Since many chaperones belong 
to the family of HSP (heat shock proteins) that protect cells against conditions of chronic and 
acute stress, by either heat shock treatment or pharmacological means, the up-regulation of Hsp72 
can inhibit JNK activation, thereby protecting against obesity-induced insulin resistance in mice 
(49). Similarly, exogenous chaperone proteins could alleviate ER stress in mouse fibroblasts and 
improve insulin sensitivity in the adipose tissue of obese and diabetic mice (50). Also, ER stress 
can be relieved by UPR (unfolded protein response) (Figure 1.4). The accumulation of incorrectly 
folded proteins in cytosol (the outcome of enhanced protein synthesis and insufficient chaperone 
proteins) triggers the UPR by activating PERK (PKR-like eukaryotic factor 2α kinase), IRE-1 
(inositol-requiring enzyme-1) and ATF-6 (activating transcription factor-6) (48). The activation 
results in inhibition of protein synthesis, enhanced expression of chaperone proteins and clearance 
of incorrectly folded proteins, as well as stimulated ER biogenesis (51). However, by activating 
PERK or IRE-1, the UPR can induce crosstalk with the NF-κB pathway (52, 53). Activation of 
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IKK releases NF-κB, which in the nucleus acts as a key transcription factor mediating the 
inflammatory and immune response (54). When the UPR gets out of control, by activation of 
IRE-1, it leads to adipocyte apoptosis by inducing the crosstalk with JNK (51). JNK, on the other 
hand, can promote inflammatory gene expression by activation of AP-1 (55). Moreover, ER stress 
can increase the production of C/EBP (CCAAT enhancer binding proteins) homologous protein, 
which attenuates synthesis of adiponectin (18), thereby aggravating the inflammation (56).  
 
Furthermore, in addition to protein synthesis, ER in adipocytes also controls lipid droplet 
formation, FFA (free fatty acids) uptake and synthesis; it has been shown that suppressed 
lipid-droplet formation in ER stress leads to massive FFA release from adipocytes into the 
circulation (57). 
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Figure 1.4 The UPR is mediated by three proximal ER stress sensors, IRE-1α, PERK and ATF-6 
and their respective signaling cascades. IRE-1α dimerization and autophosphorylation activates its 
kinase and endoribonuclease functions required to generate a potent transcription factor XBP-1s 
and protein cascade including TRAF-2, ASK-1 and (phosphorylated) JNK. Similarly, PERK 
dimerizes and autophosphorylates, activating the kinase domain that phosphorylates eIF-2α to 
abate general mRNA translation. Selective translation of the transcription factor ATF-4 under 
these conditions regulates the expression of genes involved in metabolism, redox control and 
nutrient uptake. ATF-6 on the other hand, moves to the Golgi complex to generate an active 
transcription factor [ATF-6(p50)] that mediates the expression of genes encoding ER chaperones, 
ER associated degradation components and enzymes involved in ER biogenesis. However, under 
conditions of irresolvable ER stress, expression levels of the transcription factor CHOP 
(CCAAT-enhancer-binding protein homologous protein) induced by ATF-4, and Cyt c 
(cytochrome complex) induced Ca2+ and Mfn-2 (mitofusin) can reach a threshold that allows the 
execution of its pro-apoptotic activity via the regulation of various transcriptional targets. 
Obtained from (58).  
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Oxidative stress 
 
Oxidative stress can be taken as an integral part of ER stress and the UPR, because protein folding 
depends on redox potential (59). Importantly, oxidative stress arises when oxidative damage in 
cells, caused by ROS (reactive oxygen species, formed by reduction of molecular oxygen or by 
oxidation of water to yield superoxide radical, hydrogen peroxide and a hydroxyl radical) and 
exceeds antioxidant activity (54). Obesity induces oxidative stress by excessive formation of ROS, 
because important sources of oxidants are ER oxidoreductases and various membrane bound  
(nicotinamide adenine dinucleotide phosphate) NADPH-oxidases (59, 60); adipocytes synthesize 
and secrete all components of the RAS (renin-angiotensin system) including angiotensinogen, AT1 
(angiotensin II type 1) and AT2 (angiotensin II type 2) receptors; the reinforced sympathetic 
nervous system induces RAS activation in obese adipose tissue (61), and then the local RAS 
production and activity subsequently leads to NADPH-oxidase activation via AT1 receptors and 
generation of ROS (62). Moreover, oxidative stress triggers metaflammation in 3T3-L1 adipocytes 
by activation of (protein kinase) PKB and JAK/STAT (Janus kinase/signal transducers and 
activators of transcription), thereby inhibiting the secretion of adiponectin and enhancing the 
expression of pro-inflammatory cytokines IL-6 and PAI-1 (plasminogen activator inhibitor-1) (63). 
Likewise, oxidative stress could induce metaflammation via activation of IKK (54). In turn, the 
expressed inflammatory cytokines, such as TNF-α, can further exacerbate oxidative stress by 
increasing ROS production (64).  
 
Furthermore, by inhibiting FFA β-oxidation, the impaired mitochondrial biogenesis as well as 
function contributes to accumulated FFA in the cell and elevated FFA in blood, since ROS (mainly 
generated from mitochondria) severely damage the mitochondria themselves ( i.e. mtDNA, lipids, 
oxidative enzymes and other proteins). This phenomenon has been observed in adipose tissues as 
well as skeletal muscle, blood vessels, pancreas, liver and heart (54, 57). 
 
FFA 
 
Accumulated FFA in adipose tissue generated by ER stress (which could occur as a result of 
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increased FFA oxidation or decreased synthesis) and oxidative stress could stimulate TNF-α 
secretion from macrophages (65). Furthermore, TNF-α can promote the metabolism of FFA to 
fatty-acyl-CoA, DAG (diacylglycerol) and ceramides, these in turn activate serine/threonine 
kinases including MAPK (mitogen-activated kinase) family members [JNK , ERK (extracellular 
regulated kinase)], IKK, mTOR (mammalian target of rapamycin) and different types of 
conventional and atypical PKCs in adipose tissue, liver and skeletal muscle, to trigger 
inflammation and insulin resistance (6, 66). Leptin resistance (known to be associated with 
reduced appetite-suppressing action on hypothalamic centers to inhibit food intake, also leads to 
increased ER and oxidative stress and impairment of its peripheral action to promote FFA 
oxidation, which all contribute to lipotoxicity and metaflammation in obesity (67). 
  
Hypoxia 
 
Hypoxia can be seen as an adaptive response that prevents generation of toxic levels of ROS in 
oxidative stress (68), and concomitantly enhances proteins involved in the UPR to alleviate ER 
stress (69). The adipose tissue of obese mice is hypoxic, which was demonstrated by enhanced 
expression of hypoxia-inducible genes (18). This could partly be explained as the maximum 
adipocyte size was approximately 180 μm in diameter (70), while the diffusion distance of oxygen 
is 100 μm (71). Moreover, adipose tissue hypoxia is closely associated with inhibited adiponectin 
expression and enhanced expression of pro-inflammatory factors in diet-induced obesity in mice 
(17). An important contributor to metaflammation in obesity was shown to be HIF-1 (72). HIF-1 is 
a heterodimer consisting of HIF-1β and HIF-1α subunits, and the latter acts as an oxygen sensor. 
When O2 level is sufficient, HIF-1α is continuously synthesized, but afterwards degrades. The 
degradation is accomplished through two-step hydroxylation by PHD (prolyl hydroxylase domain) 
enzymes and von Hippel-Lindau protein. Once combined with von Hippel-Lindau protein, HIF-1α 
is targeted to the degradation in the proteasome. When O2 level is insufficient, PHD enzymes are 
inhibited to enable HIF-1α binding to (cyclic adenosine monophosphate) cAMP-binding 
protein/p300 subunit cofactor, thereby constitutively synthesizing HIF-1β. This renders HIF-1 to 
function as a transcription factor that up-regulates genes involved in inflammation, cellular stress, 
angiogenesis and extracellular matrix formation, etc. (69). For instance, the inhibited expression of 
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adiponectin and enhanced gene expression of angiopoietin-like factor 4, leptin, macrophage 
migration inhibitory factor, PAI-1, IL-6 and VEGF (vascular endothelial growth factor), were 
observed in human adipocytes cultured in media with 1% O2, compared 21% O2. In addition, 
except IL-6, the expression of these genes appeared to be HIF-1 dependent (73).  
 
 
 
1.3. Adipose tissue in metaflammation 
 
Although adipose tissue is the main site where metaflammation occurs, it is not homogeneous 
through the body. There are three types of adipose depots existing in the humans that are 
commonly classified by their color appearance: the white, the brown and the beige adipose tissue. 
Their specificities are tightly associated with cell composition, localization, pathways for 
homeostatic control, metabolic responsiveness and endocrine capacities. For instance, WAT stores 
energy as fat. Conversely, BAT (brown adipose tissue) burns fat to homeostatically maintain body 
temperature. Moreover, under certain circumstances, bAT (beige adipose tissue) characterized by 
thermogenic properties similar to BAT, emerges in WAT (74). Therefore, it’s not hard to imply that 
these adipose depots may differentially contribute to or even counteract metabolic disorders (i.e. 
metaflammation, insulin resistance) induced by obesity. 
 
 
1.3.1. White adipose tissue 
 
The main white adipose depots can be divided into the SAT (subcutaneous adipose tissue) and 
VAT (visceral adipose tissue), which represent 80% and 20% of total body fat storage respectively 
(75). In humans, SAT can be anatomically divided by a stromal fascia (fascia superficialis) into 
superficial (sSAT) and deep subcutaneous adipose tissue (dSAT), whilst VAT can be further 
divided into perirenal, epididymal or perigonadal, epicardial, retroperitoneal, mesenteric and 
omental depots. Those adipose depots differ by their localization, venous drainage system as well 
as by their metabolic activity (75-77). 
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The distribution of SAT and VAT exhibits person-to-person variations and is dependent upon 
several factors including age, sex, nutrition and the energy homeostasis of the individual adipose 
tissue (78). For instance, visceral obesity is referred to as central abdominal obesity, while 
subcutaneous obesity mainly emphasizes excessive fat accumulation on hips and thighs. Hence the 
waist-to-hip ratio reflects the relative increase in visceral (waist) versus subcutaneous (hip) 
adiposity (74). 
 
Though the total adipose tissue is important for the development of obesity associated metabolic 
disorders, it has been shown that some fat depots are more strongly associated with the risk factors 
than others, probably due to the existence of intrinsic differences in angiogenic capacity among 
different fat depots (79). For instance, recent tracing studies in mice revealed that the embryonic 
and stem cell precursor of preadipocytes differ in fat depots (80). During the course of obesity, 
progenitor cells (i.e. preadipocytes and adipocytes) from different depots have different potentials 
of proliferation and differentiation (81), which might determine the different metabolic outcomes 
of obesity. 
 
Therefore, in the context of obesity or its related mal-metabolism, the differences in human 
adipose tissues entail caution when choosing which depots to study (82). 
 
Subcutaneous adipose tissue 
 
SAT is less metabolically active than VAT but important for storing TG (triglycerides) in periods 
of excess energy intake, and supplying the organism with FFAs in periods of fasting, starvation, or 
exercise. Another suggested role of SAT is playing as a buffer during intake of dietary lipids, thus 
to protect other tissues against lipotoxicity (83).  
 
SAT has a higher expandability compared with VAT, because it has higher capillary density per 
adipocyte and angiogenic growth capacity (79, 81). Therefore, the enhanced expandability of 
storing lipids subcutaneously is realized by stimulation of adipogenesis rather than by hypertrophy 
in obesity, which might protect against early manifestation of obesity-associated metabolic 
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diseases. For example, MHO individuals appeared to have a preserved SAT expandability (44). 
However, the protection is relative and when adipogenesis is impaired, hypertrophic SAT 
subsequently participates in the pathogenesis of obesity associated metabolic disorders (i.e. insulin 
resistance and metaflammation), as obese animal models and humans (21, 84). 
 
Though metaflammation is more important in VAT than in SAT (85), in the majority of the studies 
about obesity and metaflammation in the adipose tissue of humans, the authors analyzed the SCAT 
but not the VAT, because it is more readily accessible (86, 87). Moreover, Bigornia et al. 
concluded that by examining visceral and subcutaneous tissues during bariatric surgery, 
metaflammation in SAT could reflect that in VAT in the context of severe obesity (88). However, 
whether this is the general case in MAO individuals still remains to be clarified. 
 
Visceral adipose tissue 
 
VAT is a key risk factor to determine obesity associated metabolic complications, when compared 
with SAT, due to its intrinsic properties regarding, lipolytic activity, angiogenic potential, anatomy 
(89).  
 
Firstly, it has been observed that the adipocytes of VAT have more mitochondria (the density of 
which was estimated by mitochondrial and genomic DNA) than those of SAT in rats, which 
confirms that VAT is metabolically more active, since in principle the metabolic activity of a cell 
is dependent on its mitochondrial content (90, 91). Moreover, VAT displayed increased lipolytic 
activity (75, 77) and protein secretion (91), compared with SAT. Similarly, by examining adipose 
tissues from the obese individuals undergoing bariatric surgery, the relative OXPHOS (oxidative 
phosphorylation) activity was found to be higher in omental VAT than SAT (92). 
 
Secondly, the expandability of VAT is limited compared with SAT, since the adipogenesis of VAT 
is relatively restrained and depends largely on adipocyte hypertrophy, which is highly associated 
with obesity associated metabolic disorders, particularly metaflammation and insulin resistance 
(76).  
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Last but not least, the anatomical site of VAT could contribute to an increased cardio-metabolic 
risk, because VAT drains directly to the liver through the portal vein, the metabolites (i.e. FFA), 
adipokines as well as pro-inflammatory mediators have a hepatic first reach and pass at high 
concentration (75, 77, 93). 
 
WAT is composed of mature white adipocytes (accounting for one third to two-thirds of total WAT 
cells) and a SVF (stromal vascular fraction) enclosing fibroblasts, endothelial cells, immune cells 
(i.e. macrophages) and preadipocytes (94). White adipocytes store energy as triglycerides. 
Triglycerides synthesis occurs in periods of positive energy balance. Whilst during energy 
deprivation, it is cleaved to release FFA and glycerol. Positive energy balance and its accumulated 
energy storage would eventually lead to excessive adiposity (obesity) (76), which not only induces 
metaflammation characterized by multi-immune cells infiltration (i.e. macrophages) and secretion 
of pro-inflammatory factors, but also contributes to a series of metabolic disorders, especially 
insulin resistance. 
 
Adipocytes 
 
Hypertrophy 
 
Due to its ability to secrete a variety of pro-inflammatory and diabetogenic factors as well as a 
high capacity of lipolysis, hypertrophied adipocytes contribute to metaflammation and insulin 
resistance in obesity (95). 
 
It has been shown that the size of human subcutaneous adipocytes was positively correlated with 
the secretion levels of pro-inflammatory cytokines including leptin, IL-6, IL-8, MCP-1 (96), basal 
and catecholamine-stimulated lipolysis (97), while negatively correlated with the levels of 
insulin-sensitivity related adipokines (e.g. adiponectin and IL-10) (44, 96, 98). Moreover, 
adipocyte hypertrophy is highly associated with loss of insulin sensitivity in both lean and obese 
conditions (44, 99, 100). Recently, a human adipocyte volume threshold of significantly increased 
risk for developing T2D has been described (99). Even though the threshold is most likely to be 
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cohort-specific, due to biological variations and technical differences in adipocyte size 
measurements, the concept of an adipocyte size threshold for increased T2D risk remains to be 
tested in different human populations (99), however there is probably a biological limit for 
adipocyte size of approximately 180 μm, above which there may be an increased risk of ectopic 
fat accumulation in liver, muscle and pancreas (101).  
 
In addition, toxins may accumulate and induce intracellular stress in hypertrophic adipocytes (102, 
103), which may trigger adipocyte apoptosis or autophagy, probably as a protective cellular event. 
These events may subsequently lead to impaired adipogenesis, adverse fat distribution, and 
chronically altered metabolic and immune signals from adipose tissue. 
 
Apoptosis 
 
Adipocyte apoptosis may represent an early event in immune cell infiltration and metaflammation 
by defining macrophage localization and function in adipose tissue (46, 104).  
 
It has been reported that adipocyte apoptosis was increased in mice with DIO (diet-induced 
obesity) as well as humans (105-107). Increased Fas expression is associated with apoptosis (108) 
and its expression was found to be higher in isolated adipocytes from obese individuals compared 
with the lean controls, and in patients with T2D compared with the normal glucose tolerant control 
(105). Moreover, the activation of Fas in adipocytes, not only enhanced the expression of 
pro-inflammatory factors, but also interfered with insulin-stimulated glucose uptake and induced 
basal lipolysis (109, 110). Furthermore, apoptosis was significantly reduced in adipocytes from 
mice with genetic inactivation of Bid (a key pro-apoptotic molecule) and this also prevented 
immune cell infiltration of adipose tissue and protected against insulin resistance (107). Likewise, 
adipocyte specific deletion of the death receptor Fas (CD95), a member of the TNF receptor 
family, which plays a critical role in promoting apoptosis, significantly improved the insulin 
sensitivity and reduced hepatic steatosis as well as metaflammation in adipose tissue of mice fed a 
HFD (111).  
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Collectively, these data from mouse models suggest that adipocyte apoptosis may initiate 
macrophage infiltration into adipose tissue and induce insulin resistance in obesity, although this is 
yet to be confirmed in humans. 
 
Autophagy 
 
As mentioned before, autophagy (the naturally regulated destructive mechanism of the cell 
disassembling unnecessary or dysfunctional components) (112), has been considered as a cell 
protection mechanism against various stresses induced by obesity, and thus promotes cell survival. 
It has been demonstrated that autophagy is important for the regulation of lipid metabolism and 
pathophysiology of obesity (113, 114). However, the expression of autophagy genes was 
positively correlated with the degree of obesity, visceral fat distribution as well as adipocyte 
hypertrophy in both humans and rodent models (114, 115). For instance, it has been found that 
markers of autophagy, such as (autophagy-related) Atg5, Atg12-Atg5 complex as well as 
(microtubule-associated protein 1A/1B-light chain 3) LC3II were up-regulated in subcutaneous 
and (especially) visceral (omental) adipose tissue of obese persons (114). The mass of WAT were 
significantly reduced in mice with deletion of Atg7 gene, specifically in adipose tissue, compared 
with the wild type control (116). Moreover, insulin resistance was associated with up-regulation of 
different autophagy markers (Atg5, Atg7, LC3-II/LC3-1 ratio) in the subcutaneous and visceral 
(epididymal) adipose tissue of obese Wistar Ottawa Karlsburg W rats (115). 
 
Taken together, it remains controversial whether autophagy may protect against obesity associated 
adipocyte dysfunction or be a symptom of impaired adipocyte function. 
 
Preadipocytes 
 
Differentiation/Hyperplasia 
 
Adipocyte hyperplasia is realized by adipocyte precursor cells (i.e. preadipocytes) differentiating 
into adipocytes, which is a process regulated by various transcription factors and hormones.  
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Several ex vivo and in vivo studies have identified the types of adipocyte precursor cells (117, 118). 
In human subcutaneous WAT, adipocyte precursor cells are abundant among (cluster of 
differentiation) CD31 negative (-) and CD34 positive (+) stromal vascular fractions (117). In mice, 
the cell surface markers of highly pro-adipogenic precursor cells (subcutaneous and parametrial) 
include CD45–, CD31–, Ter119–, CD29+, CD34+, Sca-1+ and CD24+ (119). Subsequent studies 
have demonstrated that when transplanted into A/Zip lipodystrophic mice, these subpopulations of 
preadipocytes could differentiate into adipocytes and proliferate into fully functional WAT 
deposits in vivo. The transcription factors involved in regulating adipocyte hyperplasia include 
PPARγ and C/EBP (CCAAT enhancer binding protein) families, which play an important role in 
regulating the induction and maintenance of adipogenesis (120, 121); extracellular signals, such as 
BMPs (bone morphogenetic proteins), insulin-like growth factors and WNT, which modulate 
preadipocyte differentiation (122-124); and SREBP1c (sterol regulatory element-binding 
transcription factor 1c), which is responsible for enhancing the expression of lipogenic genes (e.g. 
acetyl-CoA carboxylase, fatty acid synthase and saturated fatty acid dehydrogenase). Moreover, it 
has been shown that the activation of ADD1 (adipocyte determination and 
differentiation-dependent factor 1)/SREBP1c could act as endogenous PPARγ ligands (lipid 
molecules) to initiate adipogenesis (demonstrated by enhanced mRNA expression of FASN and 
LPL) (125, 126) (Figure 1.5).  
 
Interestingly, as mentioned in Introduction Page 7-8, a distinguishing feature of the MHO 
population is a lower number of infiltrated immune cells and a higher proportion of relatively 
small adipocytes in adipose tissues (40, 44). There also have been several mouse models showing 
similar MHO phenotype (127, 128). Moreover, de novo small adipocytes and enhanced 
insulin-dependent glucose uptake were detected in obese db/db mice treated with rosiglitazone [a 
TZD derived anti-diabetic reagent that promotes adipogenesis by binding to PPARγ to enhance the 
differentiation of preadipocytes (129, 130). 
 
Collectively, although the molecular mechanisms of adipocyte hyperplasia and differentiation in 
normal and obese conditions remain elusive, these findings suggest that not only could de novo 
preadipocytes differentiating into adipocytes improve insulin sensitivity by providing additional 
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capacity to store excess energy, but also exert beneficial effects against metabolic complications 
induced by adipocyte hypertrophy in obesity (13). 
 
Figure 1.5 Preadipocyte differentiation is accompanied by an increased expression of C/EBPβ, 
which then induces the expression of PPAR-γ and C/EBPα forming a positive feed-back loop by 
activating each other’s expression. This is followed by the coordinated expression of proteins 
responsible for establishing the mature adipocyte phenotype. CHOP is a major negative regulator 
of adipocyte differentiation. It blocks the transactivation of pro-adipogenic C/EBPs. The 
expression of CHOP is induced by the curcumin-like compound piceatannol. Obtained from (131).  
 
 
 
 
 
Interaction with macrophages 
 
Several studies have shown that pre/adipocyte and monocyte/macrophage lineages have many 
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features in common. For instance, in inflammatory conditions, preadipocytes of the 3T3-L1 cell 
line as well as preadipocytes in primary culture exhibit phagocytic and microbicidal activities 
similar to that of macrophages (132, 133). Moreover, murine pre/adipocytes secrete numerous 
pro-inflammatory factors (i.e. IL-6) by LPS (lipopolysaccharide) activation (134). The link 
between pre/adipocyte and macrophage lineages was further strengthened by the detection of 
MOMA-2 (monocyte/macrophage marker antibody) antigen expressed on preadipocytes and 
adipocytes, which is also a marker of monocyte-macrophage lineage (133). Noteworthy, Charriere 
et al. demonstrated that having been injected into the peritoneal cavity of nude mice, the 3T3-L1 
preadipocyte cell line rapidly and massively acquired high phagocytic activity, and 60-70% of 
preadipocytes expressed five macrophage-specific antigens: F4/80, Mac-1, CD80, CD86 and 
CD45 (135). In parallel, the in vitro experiments showed that cell-to-cell contact between 
preadipocytes and peritoneal macrophages partially induced this phenotype conversion (135). 
Therefore, not only preadipocytes and macrophages share some biological behaviors and 
characteristics, but also preadipocytes have the potential to be very efficiently and rapidly 
converted into macrophages, under certain situations. 
 
More importantly, macrophages play a key role in influencing the proliferation, survival and 
differentiation of preadipocytes.  
 
Firstly, even though Maumus et al. (136) reported that MacCM (macrophage conditioned medium) 
reduced adipose progenitor proliferation in culture, a body of evidence has shown that 
macrophages promote preadipocyte proliferation (137, 138). The proliferative effect is further 
supported by enhanced proliferation in situ, which is typically seen in obesity and characterized by 
increased infiltration of macrophages into human adipose tissue (139).  
 
Secondly, it has been observed that 3T3-L1 preadipocytes undergo apoptosis when deprived of 
growth factors (serum withdrawal), but MacCM could exert cell protective and survival effects on 
serum deprived 3T3-L1 mouse preadipocytes. Further molecular studies identified that PDGF 
(platelet-derived growth factor) released by J774A.1 macrophages is a key component accounting 
for much of the survival of preadipocytes activity (140). Moreover, signaling as well as inhibitor 
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studies indicated that macrophage-secreted factors activate the PI3K-Akt and MEK-ERK1/2 
pathway to promote the survival of preadipocytes (141). However, LPS-stimulated J774A.1 
macrophages lost the suppressing effect on the apoptosis of 3T3-L1 preadipocyte, though PDGF 
activated signaling pathways are not attenuated, TNF-α expression in macrophages was 
significantly up-regulated. The pro-apoptotic effect of TNF-α was further shown by the 
observation that immuno-neutralization of TNF-α in the MacCM could restore its full pro-survival 
activity (142). 
 
Last but not least, Constant et al. (143) reported that MacCM from mouse or human macrophage 
cell lines inhibited the differentiation of mouse 3T3-L1 and human preadipocytes. Furthermore, 
several macrophage-secreted factors also contribute to the anti-differentiating/adipogenic ability of 
MacCM, particularly IL-1β and Wnt-5a. For example, Lu et al. reported that the anti-adipogenic 
effect of macrophages (demonstrated by impaired preadipocyte differentiation) was significantly 
associated with the up-regulated expression of IL-1β, whereas immuno-neutralization of Wnt-5a 
in the J774-MacCM could antagonize the anti-adipogenic effect on 3T3-L1 preadipocytes (144). 
 
In parallel, the signaling pathways involved in the anti-adipogenesis have also been clarified. For 
instance, THP-1-MacCM inhibited 3T3-L1 preadipocyte differentiation by acutely activating 
ERK1/2 phosphorylation. Pharmacological inhibition of the MEK-ERK1/2 pathway with 
PD98059 could partially block the anti-adipogenic effect (145). Moreover, the anti-adipogenic 
effect was associated with IKKβ phosphorylation and activation of NF-κB in the context of human 
THP-1-MacCM and human primary adipose progenitor cells, whereas the IKKβ inhibitor sc-514 
could totally abrogate the anti-adipogenic ability of THP-1-MacCM and promote the 
differentiation of human preadipocytes (146).  
 
Insulin resistance 
 
Insulin is a pleiotropic hormone produced by beta cells of the pancreatic islets. It can stimulate 
nutrient (e.g. glucose) transport into cells, modify enzymatic activity, and regulate gene expression 
and energy homeostasis (147, 148). These functions are exerted across a variety of insulin target 
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tissues (e.g. liver, skeletal muscle and adipose tissue) through several intracellular signaling 
pathways. In skeletal muscle, insulin promotes glucose uptake by stimulating the translocation of 
(glucose transporter) GLUT-4 to the plasma membrane. In liver, insulin inhibits the expression of 
key gluconeogenic enzymes to suppress hepatic glucose production, and promotes glycogen and 
protein synthesis and accumulation of triglyceride in hepatocytes. In WAT, insulin prevents FFA 
efflux from adipocytes by down-regulating the activity of hormone sensitive lipase, and 
stimulating glucose uptake which is subsequently used for synthesis of glycerol for triglyceride 
formation (149).  
 
Insulin signaling involves insulin receptor-IRS (insulin receptor substrate), which includes four 
distinct family members, IRS1-4; and its complex downstream signaling cascade. The signaling 
cascade branches into two main pathways. One is the (phosphatidylinositol 3-kinase) PI3K-Akt 
(also called PKB) pathway, which is largely responsible for insulin mediated glucose uptake and 
suppression of gluconeogenesis, the other is the Ras-MAPK pathway which regulates the gene 
expression, and exerts the crosstalk with the PI3K-Akt pathway to control protein synthesis, cell 
growth and differentiation (150). 
 
The signaling pathways start from the activation of IRS1 by tyrosine phosphorylation, thereby 
initiating signal transduction. In obesity, elevated circulating FFA (released mainly by white 
adipocytes) lead to an increase in intracellular lipid products, including fatty acyl-CoA and 
ceramide (151-153), which consequently inhibit the insulin signaling cascade by activating a 
serine/threonine kinase – PKCθ. Moreover, if IRS1 is alternatively phosphorylated on serine 307, 
its downstream signaling ability is attenuated (154). The serine kinases that phosphorylate serine 
307 include IKKβ of the NF-κB pathway and JNK1 of the JNK/AP-1 pathway, both of which can 
be activated during metaflammation (154). Other inflammation-related negative regulators of IRS 
proteins include the SOCS (suppressor of cytokine signaling). For instance, SOCS1 and SOCS3 
(i.e. induced by macrophage polarization in metaflammation), can promote the ubiquitylation and 
subsequent degradation of IRS proteins (155). All of these cellular signals triggered by obesity 
contribute to exacerbated insulin sensitivity/insulin resistance. 
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As before mentioned, insulin sensitivity is the most important metabolic indicator to divide MAO 
and MHO, since insulin-resistant⁄compensatory hyperinsulinemic individuals are at greatly 
increased risk of being somewhat glucose-intolerant, dyslipidemic and hypertensive (156, 157). 
Furthermore, glucose intolerance/insulin resistance, dyslipidemia and essential hypertension 
represent important risk factors for cardiovascular disease. Last but not least, when 
insulin-resistant individuals cannot secrete the increased amounts of insulin to compensate for the 
insulin resistance, T2D occurs (157, 158). 
 
Interleukin-1β 
 
IL-1 is a potent endogenous pyrogen and plays an important role in many inflammatory diseases 
by initiating and potentiating immune and inflammatory responses. It consists of two major 
proteins, IL-1α and IL-1β. They have similar biological properties by binding to IL-1RI (IL-1 type 
I receptor), but minimal sequence homology. Moreover, they are fundamentally different in 
localization, maturation and secretion. IL-1α is secreted as a biologically active form, whereas 
IL-1β is translated as pro–IL-1β and has no biological activity until it is processed by the cysteine 
protease caspase-1 in the cytoplasm (159, 160). 
 
Koenen et al. reported that the expression level of activated IL-1β was approximately 10-fold 
higher in the VAT (visceral adipose tissue), compared with the subcutaneous depot of overweight 
subjects (161). However, the main source of it is unclear. It has been proposed that infiltrated 
macrophages secrete high levels of IL-1β during the development of obesity, but adipocytes do 
express high levels of caspase-1 and are able to produce IL-1β, albeit at lower levels when 
compared with macrophages (161).  
 
Besides participating in metaflammation, several studies suggest that IL-1β is involved in 
obesity-associated insulin resistance. Firstly, IL-1β could significantly inhibit the expression of 
insulin sensitivity genes PPARγ, adiponectin and GLUT-4, thereby attenuating adipocyte 
differentiation and inducing insulin resistance (162). Secondly, it has been shown that prolonged 
IL-1β treatment reduced the insulin-induced glucose uptake in murine 3T3-L1 adipocytes, which 
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was demonstrated by a marked inhibition of GLUT-4 translocation to the plasma membrane in 
response to insulin (163). Thirdly, IL-1β knockout mice were more insulin-sensitive, compared 
with the wild type control. The result was in parallel with that IL-1β-knockout protected the mice 
against HFD-induced metaflammation (164). Finally, it has been further shown that the treatment 
with IL-1 receptor antagonist anakinra has beneficial effects on patients with T2D (165).  
 
Autophagy is a homeostatic mechanism that degrades large intracellular organelles or protein 
aggregates to change cellular structure during differentiation or to generate essential nutrients in 
times of nutrient deprivation (166, 167). It has been shown that adipose tissue of obese human 
individuals exhibited higher autophagic activity compared with the lean controls (114, 168). 
Hence, Tack et al. proposed that the pro-inflammatory factors, particularly IL-1β, released during 
metaflammation are highly associated with increased autophagy (169), and autophagy reciprocally 
functions to control the expression of IL-1β in adipose tissue, thereby alleviating metaflammation 
in obesity (170). 
 
Interleukin-6 
 
IL-6 is considered as an adipokine, since adipose tissue secretes one third of circulating IL-6 in 
healthy individuals. In the WAT only a fraction of IL-6 is produced by adipocytes, with the 
majority originating from macrophages (21). Importantly, IL-6 is a multifaceted, pleiotropic 
cytokine and plays a central role in the development of obesity-induced metabolic disorders (i.e. 
metaflammation, insulin resistance) (171). Hence, understanding and clarifying its role in the 
regulation of metabolism is of utmost importance. 
 
Like leptin, it has been proved that the levels of circulating IL-6 are positively correlated with the 
percentage of body fat (172). Mice with a genetic deletion of IL-6 also developed adult-onset 
obesity, which suggests that IL-6 is involved in the chronic physiologic regulation of energy 
balance and decreased IL-6 signaling is highly associated with weight gain (173). Furthermore, 
Plata-Salaman reported that IL-6 is a powerful catabolic reagent that decreases food intake and 
increases energy expenditure in the CNS (central nervous system) (174). In conclusion, IL-6 
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secreted by adipose tissue contributes to energy homeostasis in the CNS in an endocrine manner, 
while inhibiting the secretion could potentially worsen obesity by negative feedback to 
hypothalamic areas that govern energy balance. 
 
Moreover, IL-6 is a likely mediator of pro-inflammatory signaling in adipose tissue. Firstly, the 
plasma level of IL-6 is almost exclusively determined by whole-body adiposity, therefore it is not 
difficult to suggest that IL-6 is closely associated with obesity induced mal-metabolism, 
particularly metaflammation (175). Secondly, IL-6 action targeting endothelial cells and vascular 
smooth muscle cells leads to the increased expression of adhesion molecules and activation of 
local renin-angiotensin pathways, which may contribute to vascular wall inflammation and 
damage (175). Finally, IL-6 governs the production of CRP from human hepatocytes (176), and 
CRP is one of the strongest indicators of metabolic risk and may participate directly in inducing 
atherosclerotic lesions and cardiac events (177).  
 
However, the role regarding IL-6 played in the pathogenesis of obesity and associated metabolic 
disorders are still controversial and unresolved. As mentioned previously, IL-6 is a potent 
catabolic agent that stimulates lipolysis, and increases FFA levels and whole body fat oxidation 
(178). It also inhibits the secretion of other adipokines, notably adiponectin as well as other 
markers of adipocyte differentiation in human adipocytes (179). Moreover, IL-6 could induce 
insulin secretion via enhancing the expression of GLP-1 (glucagon-like peptide-1) in pancreatic 
cells (180). All of these cellular events triggered by IL-6 may contribute to insulin resistance. 
Therefore, it is not surprising to have found that patients with obesity-related insulin resistance 
had significantly higher levels of IL-6, compared with the lean controls (181). In addition, IL-6 
may enhance mesenchymal stem cell proliferation, thus to maintain the cells in an undifferentiated 
state and inhibit adipogenesis (182). Paradoxically, IL-6 has been demonstrated to increase 
glucose uptake in rat skeletal muscle, thereby promoting myogenesis and AMPK (5’ adenosine 
monophosphate-activated protein kinase)-mediated fatty acid oxidation during exercise (183). 
Taken together, IL-6 appears to function in a tissue and metabolic state-dependent manner (184). 
 
Monocyte chemoattractant protein-1 
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MCP-1 secreted by hypertrophic adipocytes is thought to be responsible for macrophage 
infiltration in obese WAT. Kim et al. reported that MCP-1 secretion is significantly enhanced 
locally and in plasma of obese rodents and humans (185). 
 
It has been long considered that the interaction of MCP-1 with its receptor [(C-C chemokine 
receptor) CCR-2] is pivotal for the recruitment of macrophages and pathogenesis of insulin 
resistance in obesity. Several groups have revealed that not only mice with CCR-2- or 
MCP-1-deficiency mice exhibit reduced number of infiltrated macrophages and attenuated 
metaflammation in the WAT, but also were protected against HFD-induced insulin resistance (185, 
186). Moreover, adipose tissue-specific over-expression of MCP-1 was sufficient to increase the 
number of macrophages and induce insulin resistance in WAT of mice (187); db/db mice treated 
with a pharmacological antagonist of CCR-2 displayed decreased macrophage infiltration and 
improved insulin sensitivity in the WAT, as well as a decrease in body weight (188).  
 
However, recently the role of MCP-1 in promoting macrophage recruitment and insulin resistance 
in adipose tissue has been challenged. For instance, MCP-1-deficient mice didn’t exhibit reduced 
macrophage infiltration or improved metabolism (189, 190). Moreover, although Ccr-2−/− obese 
mice had fewer infiltrated macrophages in their WAT than that of the Ccr-2+/+ obese mice, the 
number of macrophages in WAT or the level of insulin sensitivity of the CCR-2 deficient obese 
mice wasn’t normalized to that of Ccr-2−/− lean control (186). These findings suggest that 
macrophage recruitment and insulin resistance in WAT are also regulated by MCP-1/CCR-2 
independent signaling pathways. 
 
C-C chemokine receptor type 5 
 
CCR-5 is a G protein–coupled receptor functioning as a chemokine receptor in the C-C chemokine 
group. The cognate ligands of CCR-5 include (C-C ligand) CCL-3 (MIP-1α), CCL-4 (MIP-1β), 
CCL-3L1 and CCL-5 (RANTES, regulated on activation, normal T cell expressed and secreted) 
(191, 192). Kitade et al. identified and characterized a critical role for CCR-5 in the regulation of 
obesity-induced inflammatory response and insulin resistance in WAT (193). Firstly, the 
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expression of CCR-5 and its ligands including CCL-3, CCL-4, CCL-5, were significantly 
enhanced in the WAT of genetically (ob/ob) and HFD-induced obese mice, whereas 
CCR-5−/−mice were protected against HFD-induced insulin-resistance (characterized by 
hyperinsulinemia and glucose intolerance) by reducing macrophage accumulation in WAT. 
Secondly, the macrophage infiltration and crown-like structure formation were markedly reduced 
in obese WAT of CCR-5−/− mice, despite there being no significant difference in adipocyte size 
between the CCR-5−/− and the wild type control. Finally, CCR-5 deficiency led to the 
polarization of anti-inflammatory M2 macrophages in WAT, which suggests that interventions to 
reduce CCR-5 levels or an antagonist might have a beneficial therapeutic role to reduce adipose 
tissue inflammation in obesity. In addition, recent studies have also shown that the expression 
level of CCR-5 was positively correlated with the number of infiltrated macrophages in the WAT 
of morbidly obese individuals (194). Taken together, reducing CCR-5 activity may be a promising 
therapeutic target to attenuate metaflammation and improve insulin sensitivity in obesity. 
 
 
1.3.2. Brown adipose tissue 
 
BAT is composed of adipocytes containing numerous mitochondria, which contain iron, thus 
giving the darker color to BAT. In the presence of UCP-1 (uncoupling protein-1) which is 
specifically found in the mitochondria of BAT and bAT, energy from mitochondrial oxidation is 
dissipated as heat rather than coupled to ATP (adenosine triphosphate) synthesis. Contrary to the 
prevailing concept that BAT is only present in human neonates and young children, adults do have 
functional BAT and its activity is systematically reduced in obese individuals (195). 
 
Due to its apparent thermogenic properties by depot enlargement via hypertrophic and hyperplasic 
processes (196), in the past BAT was mainly considered as a heat producing tissue to maintain the 
body temperature in human newborns upon cold exposure (197, 198). However, Rothwell et al. 
revealed that the activation of BAT upon overeating (‘diet-induced thermogenesis’) limited weight 
gain in rats (198). Furthermore, mice fed on HFD intermittently exposed to cold temperature, were 
not only protected against body weight gain, but also exhibited improved glucose homeostasis 
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(199), though the latter change was transient and subsequently counterbalanced by feeding a 
continuous HFD. Hence, a new concept has emerged based on these facts: it may be possible to 
treat obesity by activation of fat burning in BAT.  
 
In addition, brown adipocytes express numerous factors, which have been demonstrated to act 
locally in an autocrine or paracrine manner, thereby modulating BAT metabolism. For instance, 
even though mainly produced by liver, activated BAT secretes FGF-21 (fibroblast growth factor) 
into the circulation (200), which is recognized as a protective factor against weight gain by 
increasing energy expenditure, and insulin resistance by promoting glucose utilization in many 
organs (201). Moreover, through a BAT transplantation study, Stanford et al. proposed that IL-6 
production in brown adipose tissue could participate in preserving insulin sensitivity in 
endogenous BAT, WAT and heart muscle, which might protect against metabolic complications 
associated with obesity (202).  
 
 
1.3.3. Beige adipose tissue 
 
bAT is enclosed by WAT and composed of adipocytes with thermogenic properties. As with brown 
adipocytes, beige adipocytes have numerous mitochondria and high expression levels of UCP-1. 
However, unlike BAT expressing UCP-1 in the basal state, bAT only express it in response to 
specific activation (e.g. chronic cold exposure, agonists of the b-adrenergic receptor or PPARγ) 
(197). It has been described by Barbatelli et al. that bAT abundantly developed in the inguinal 
WAT of rodents in response to chronic cold exposure (203). Noteworthy, the switch from white to 
beige adipocytes is reversible. For example, in 5 weeks of warm adaptation, beige adipocytes will 
lose their UCP-1 activity and reverse to white adipocyte like cells without thermogenic properties 
(204). Similarly, it has been demonstrated that HFD over a long period of time could stimulate 
potent beige adipocyte precursors to differentiate into white adipocytes in mice (205). Whether 
this conversion from WAT to bAT to BAT (and the reverse) occurs within mature adipocytes or is 
a result of development of new adipocytes from preadipocytes, thus altering the ratio of cell types 
within adipose tissue is uncertain. 
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Even though global consequences of WAT transforming to bAT on adipose metabolism and insulin 
sensitivity are yet to be revealed, it can be anticipated that bAT may play a protective role by 
dissipating energy. 
 
 
 
1.4. Immune cells in metaflammation 
 
Adipose tissue can be isolated into an adipocyte fraction and a SVF by enzymatic digestion. The 
SVF is composed of innate and adaptive immune cells, preadipocytes, endothelial cells etc. In 
obese subjects, adipose tissue accounts for up to 50% of total body mass. Moreover, the studies of 
different adipose depots also have revealed that immune cells represent approximately two thirds 
of the SVF, which contains approximately 2 to 5 million cells/g of tissue (206). Among these 
immune cells, infiltrated macrophages (the hallmark of metaflammation) can make up to 75% of 
the whole immune population in the SVF (207). Therefore, the immune cells, especially 
macrophages in SVF, play a major role in the maintenance of metaflammation. 
 
 
1.4.1. Neutrophils 
 
Neutrophils present fundamental mechanisms of effector cells (e.g., complement activation, 
regulation of inflammation), participating in initiation of immune response as well as resolution of 
inflammation. It has been reported that low circulating adiponectin could induce the activity and 
increase the number of neutrophils in the peripheral blood of obese subjects (208). Moreover, a 
recent study revealed that a rapid increase in neutrophil number, lasting up to 90 days, and an 
increased expression of neutrophil elastase in parallel, occurs in the adipose tissue of DIO mice 
(31). Though the immediate trigger regarding the neutrophil infiltration into the adipose tissue 
following DIO is unknown, HFD is thought to induce acute stress after a brief surge in adipocyte 
precursor proliferation and this stress may be involved in recruiting neutrophils into the adipose 
tissue (209), whereas elastase deficiency or chemical inhibition of elastase alleviated the 
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metaflammation in mice upon 12 weeks of HFD feeding, compared with the wild type control. 
The plausible mechanism is that elastase seemed to promote macrophage infiltration and M1 
polarization, since M2 macrophages were prevalent in obese mice that lacked this enzyme (210).  
 
 
1.4.2. Eosinophils 
 
Eosinophils play a critical role in local macrophage activity and polarization, they are the major 
IL-4-expressing cells in adipose tissue and activation of anti-inflammatory M2 macrophages is 
mainly driven by IL-4 (211). It has been shown that the M2 macrophage number was significantly 
decreased, when eosinophils were absent in adipose tissue (211).  
 
 
1.4.3. Mast cells 
 
Mast cells are important sensors of acute inflammation and play an important part in allergic 
reactions (212). They grow and proliferate in response to growth factors, such as SCF (stem cell 
factor), NGF (nerve cell growth factor) as well as cytokines (IL-3, IL-4, IL-9 and IL-10), and 
respond to microenvironment by releasing preformed contents of granules (histamine, heparin, 
tryptase and chymase) or de novo synthesis of pro-inflammatory cytokines such as IL-6, IL-8 and 
TNF-α. It has been demonstrated that mast cells accumulate in adipose tissue of DIO mice 
(213-215). Similarly, obese diabetic db/db mice were found to have a higher number of mast cells 
in adipose tissue (213). Furthermore, the development of obesity in diabetic db/db mice was 
associated with recruitment of largely immature mast cells from bone marrow into adipose tissue, 
whose maturation was in parallel with the metabolic abnormalities, whereas mast cell 
KitW-sh/W-sh deficient mice (lacking only mature mast cells) are resistant to diet-induced obesity 
(213), and the analysis of the VAT revealed the significantly reduced expression of 
pro-inflammatory factors and decreased number of macrophages (215), which suggests that the 
arrival of mast cell in adipose tissue precedes the infiltration of macrophages in the development 
of metaflammation. 
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In addition, in spite of the similar morphology of mast cells in both of the lean and obese subjects, 
the latter group has an increased rate of degranulation, whilst pharmacological inhibition of mast 
cell degranulation reproduced the metabolic phenotype seen in KitW-sh/W-sh-deficient mice 
(resistant to obesity and metaflammation) (216). Likewise, anti-fibrotic compounds such as 
angiotensin-converting enzyme inhibitors, silymarin, coupled with dietary intervention, could 
prevent mast cell maturation and degranulation, thus to reduce obesity associated metabolic 
disorders especially metaflammation (217).  
 
 
1.4.4. Dendritic cells 
 
DCs can be found in almost all tissues and are a heterogeneous group of mononuclear cells 
capable of acquiring, processing and presenting antigens to naïve T cells. Based on their 
phenotype and functional characteristics, they are divided into the following: 
conventional/myeloid DCs (CD11+), plasmacytoid DCs (CD11c−CD303+) and inflammatory 
DCs (inf-DCs), which are generated from in situ activation of monocytes recruited into the site of 
inflammation (218). Bertola et al. (219) revealed for the first time the accumulation of specific 
inf-DCs CD11chighF4/80low in adipose tissue of obese mice and CD11c+CD1c+ in adipose 
tissue of obese patients. The accumulation of these DCs was positively correlated with BMI and 
induced pro-inflammatory (T helper) Th17 cell responses as well as macrophage accumulation in 
obesity. It has been further demonstrated that adipose tissue DCs are among the early arrival of 
immune cells to maintain metaflammation induced by adipocyte expansion (220). In turn, by 
recruiting and activating other immune cells especially macrophages, the DCs could augment the 
inflammatory response in adipose tissue (220). 
 
In parallel with these studies, it has been shown that in response to HFD, DCs (CD11+) expressed 
significantly higher levels of CCL-20 (a ligand of CCR-6) as well as IL-6, (transforming growth 
factor) TGF-β and IL-23 in adipose tissue, compared with the lean mice controls. Importantly, 
these cytokines are essential for Th17 cell proliferation and differentiation, thus to maintain and 
aggravate metaflammation (221). By contrast, the mice lacking DCs had a decreased number of 
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macrophages in the adipose tissue, whereas DC replacement in DC−/−mice can reverse this 
phenomenon (221). Similarly, the lean wild-type mice that received bone marrow-derived DCs 
exhibited macrophage infiltration in the adipose tissue, while the mice lacking DCs were resistant 
to the DOI induced weight gain and its subsequent metabolic disorders (220). 
 
 
1.4.5. Natural killer cells and natural killer T cells 
 
NK cells are a type of cytotoxic lymphocyte and function in the innate immune system analogous 
to cytotoxic T cells in the adaptive immune system. Compared with that of neutrophils, the 
increase in the numbers of NK cells appears to be delayed, occurring in weeks, rather than days 
after the initiation of HFD feeding in mouse adipose tissue (210). In contrast from neutrophils that 
are primarily of peripheral origin (210), NK cells increased partially or completely by proliferation 
of tissue-resident populations in adipose tissue. For instance, when the mice on HFD were 
intravenously injected with the labeled NK cells, only a small number of NK cells reach the 
adipose tissues from the periphery (migration), but BrdU labeling, as a marker of proliferation, 
was significantly increased in resident NK cells of adipose tissue, but not in splenic NK cells of 
peripheral origin (222). 
 
It is now known that NKT cells can bridge innate and adaptive immune responses (223). There are 
three types of NKT cells: iNKT (invariant NNK), non-iNKT (non-invariant NKT) and NKT-like 
cells. iNKT and non-iNKT cells are both CD1d dependent (224). It has been shown that the NKT 
cell population and CD1d expression were significantly higher in adipose tissue of obese mice as 
well as that of humans, compared with the lean controls (225). For example, the iNKT and 
non-iNKT cell-deficient CD1d−/−mice gained little weight on HFD and displayed less 
metaflammation in the liver, compared with the wild type mice on the same diet (226). 
Paradoxically, the iNKT cell-deficient Jα18−/−mouse model on HFD became more obese and 
exhibited enhanced metaflammation in the adipose tissue since the early stage of DIO (225). 
Taken together, these data suggest NKTs especially iNTKs and non-iNTKs, play an ambiguous 
but important role in sustaining metaflammation in adipose tissue. 
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1.4.6. T cells 
 
Adaptive immune cells including B and T lymphocytes can activate innate immunity 
induced-inflammatory response (227), whereas regulatory T cells (Tregs) can suppress 
metaflammation in the adipose tissue of obese mice (228).  
 
For instance, Poutahidis et al. (229) found an association between western diet-associated obesity 
and CD4+ Th17 prevalent T cell phenotype in human subjects and mouse models. Similarly both 
CD4+ and CD8+ T cells have been found in the adipose tissue, and their number was positively 
correlated with BMI in obesity (230). Furthermore, adoptive transfer of CD8+ cells to 
CD8-deficient mice could induce M1 macrophage polarization and exacerbate metaflammation in 
adipose tissue (227). By contrast, the depletion of CD8+ cells or T cell receptor−/−in the obese 
mice was accompanied by a decreased number of macrophages in the adipose tissue and lowered 
expression of TNF-α and IL-6 (231). In addition, a novel subset of Tregs, Th22 has been shown to 
be associated with metaflammation induced by obesity. The proportion of circulating Th22 cells 
significantly increased in parallel with serum IL-22 level in the obese patients, when compared 
with lean subjects (232). 
 
Paradoxically, Tregs could maintain tolerance/anti-inflammatory microenvironment by inducing 
IL-10 production. Yu et al. reported that the Tregs were abundant in VAT of the lean mice, whereas 
the number was significantly decreased in the DIO mice (228). Similarly, a reduced number of 
Foxp3+ Treg cells was found in VAT of obese humans (233). Moreover, Priceman et al. reported 
that the activity of STAT3 (signal transducer and activator of transcription) increased in parallel 
with the expression of IL-6 (a known inhibitor of Treg function) in adipose tissue of the obese 
mice, while the ablation of STAT3 could alleviate metaflammation and increase the ratio of 
Treg/Th1 cells as well as the number of anti-inflammatory M2 macrophages (234). Equally, by 
inducing Foxp3+Tregs and IL-10, the display of the profile of previously-mentioned 
proinflammatory immune cells could be prevented (229). 
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1.4.7. Macrophages 
 
Diversity and plasticity are the hallmarks of macrophages. The phenotypes of 
activated-macrophages include classical M1 and alternative M2. The M1 phenotype is stimulated 
by microbial products (i.e. LPS, TLR ligand) or pro-inflammatory cytokines [(interferon) IFN-γ, 
TNF)] (235). M1 macrophages produce many pro-inflammatory cytokines including TNF-α, IL-1, 
IL-6, IL-12, Type I IFN, CXCL1-3, CXCL-5 and CXCL8-10, etc (236). In contrast, the M2 
phenotype is observed “resting” in healing-type circumstances without infection and such resting 
and healing can be further amplified by IL-4, IL-10, or IL-13 (237). M2 macrophages produce 
anti-inflammatory cytokine such as IL-10 and very low level of pro-inflammatory cytokines such 
as IL-12 (238). 
 
Under different pathophysiologic conditions, macrophages acquire distinguished functions by 
undergoing M1/M2 polarization. The polarization is a highly dynamic process and the phenotype 
of polarized macrophages can be switched (239, 240). Various inflammatory mediators, signaling 
molecules, and transcription factors are involved in regulating the process of polarization. Among 
them, canonical NF-κB and (interferon regulatory factor) IRF/STAT signaling pathways are 
central players. For example, the activation of IRF/STAT (via STAT1) by IFNs and TLR ligand 
will skew macrophage function towards the M1 phenotype, while the activation of IRF/STAT (via 
STAT6) signaling pathways by IL-4 and IL-13 will skew macrophage function toward M2 
phenotype (236). The polarization can also be regulated by local microenvironmental conditions, 
such as hypoxia (241). Various diseases are highly associated with imbalances of the polarization. 
For instance, switching to M1 macrophages initiates and sustains the chronic inflammation, while 
skewing towards M2 means the anti-inflammatory resolution under such circumstance (237).  
 
M1 macrophages 
 
NF-κB signaling pathway (Figure 1.6) 
 
In obese mice, macrophages make up to 40% of all cells of the adipose tissue, compared with 10% 
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of the lean control (21). Serum levels of FFAs, cholesterol and especially, LPS [a cell wall 
component from Gram-negative bacteria, associated with changes in the gut microbiota (metabolic 
endotoxemia)] are also elevated in obesity (242). TLR signaling, particularly TLR4 stimulated by 
LPS and other microbial ligands preferentially switches macrophages to M1 phenotype associated 
with chronic inflammation. MyD88 (myeloid differentiation primary response gene 88) and TRIF 
(toll-like receptor adaptor molecule 1) as adaptors mediate the signaling downstream of TLR4 
(243). The signaling pathway through the MyD88 adaptor leads to the activation of NF-κB by 
activating a cascade of kinases, including IRAK4, TRAF6 and most importantly, IKKβ (243). 
When upstream signals converge at the IKK complex, firstly they activate IKKβ via 
phosphorylation, and then the activated IKKβ phosphorylates I-κB. Subsequently IκB degrades 
and releases NF-κB p65/p50 heterodimer from the NF-κB/I-κB complex. The NF-κB p65/p50 
heterodimer translocates to the nucleus and binds to the promoters of inflammatory genes (244). 
As a key transcription factor associated with macrophage M1 activation, NF-κB regulates the 
expression of a large number of pro-inflammatory genes including TNF-α, IL-1β, COX2 
(cyclooxygenase 2), IL-6, IL-12, MCP-1, as well as receptors including CCR-2 and CCR-5, which 
in turn augment metaflammation by recruiting more monocytes and other leukocytes into (murine) 
adipose tissue (244). In addition to binding to TLRs, some PAMPs (pathogen-associated molecular 
patterns, including LPS and other microbial ligands) are also recognized by a family of cytosolic 
nucleotide-binding receptors and NLRs (NOD-like receptors) (245). As the most well 
characterized members of the NLR family, (nucleotide-binding oligomerization) NOD1 is 
ubiquitously expressed and NOD2 is restricted to monocytes, macrophages, DCs (246). Both 
NOD1 and NOD2 induce the activation of NF-κB in a TLR-independent manner (247). Upon 
NOD1 or NOD2 stimulation, RICK/RIP2 (receptor-interacting serine/threonine-protein kinase 2, 
anaserine threonine kinase) undergoes polyubiquitination at K209 to activate IKK via TAK1 
(transforming growth factor β-activated kinase 1), which is an essential step of the 
NOD1/NOD2-mediated activation of NF-κB (by phosphorylation and degradation of IκBs) and 
MAPKs. However, A20 deubiquitinase could severely decrease the ubiquitination to dampen the 
signaling activation (248, 249).  
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Figure 1.6 IKKβ/NF-κB signals promote M1-type macrophage activation. The activation of the 
IKK complex (e.g. in response to TLR- or IL-1–mediated signals) leads to phosphorylation of IκB, 
triggering its proteasomal degradation. IκB degradation frees NF-κB to translocate to the nucleus 
and drive the expression of pro-inflammatory genes. In addition, the deletion of IKKβ in 
macrophages increases STAT-1 activation and promotes a shift toward the M1 phenotype. 
Obtained from (250). 
 
 
 
 
 
Inflammasome mediated pathways 
 
The NLRs recognition leads to the activation of caspase-1 and subsequent proteolytic conversion 
of potent pro-inflammatory cytokines IL-1β and IL-18 from their precursors pro-IL-1β and 
pro-IL-18, respectively (251). This proteolytic conversion is mediated by a cytosolic caspase 
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1-activating protein complex, which is termed as inflammasome (251). The activation of 
switching to M1 macrophages is mediated by assembly of the NLR inflammasome and caspase-1 
activation, which subsequently leads to the conversion of IL-1β and IL-18 into secreted active 
forms (252). With the cryptopyrin/NLRP3 (NLR pyrin domain containing 3) inflammasome 
serving as a sensor of obesity-associated metabolic signals, the progression of obesity can switch 
macrophages from “M2-like” to “M1-like” cells. For instance, Caspase-1 and IL-1β are both 
induced in the adipose tissue of DIO mice, whereas Nlrp3- and caspase-1-deficient mice both 
demonstrate a resistance to the DIO-induced inflammation (253). The mechanism underlying the 
protective effect may be driven by switch to M2 macrophages, since the nlrp3-knockout mice 
exhibit decreased M1, but increased M2 gene expression in macrophages of the adipose tissue. 
 
IRF/STAT signaling pathways 
 
As mentioned before, MyD88 and TRIF as downstream adaptors mediate the signaling pathways 
of M1 macrophages, which are activated by LPS. For instance, the TRIF-mediated signaling 
pathway activates transcription factor IRF3, which subsequently leads to the expression and 
secretion of type 1 IFN, such as IFN-α and IFN-β; by binding to the receptor of IFN, the secreted 
type 1 IFN consequently activate transcription factor STAT1 (243). It has been widely reported 
that IRF3 and IRF5 are involved in modulating M1 polarization and inducing the expression of 
M1-associated genes (254, 255), such as chemokine (c-x-c motif ligand) CXCL-9 and CXCL-10 
(256), which are characteristic of classical M1 macrophage activation.  
 
MicroRNAs 
 
miRNAs, a class of 19–24 nucleotides  non-coding RNAs that induce gene silencing at the 
post-transcriptional level, have emerged as an important factor in regulating gene expression in 
many immune cells including monocytes and macrophages (257). Functional miRNAs associated 
with macrophages have been identified. For instance, miR-155 could be induced in 
LPS-stimulated M1 macrophages; miR-146 might silence TNF receptor-associated factor 6 and 
IL-1 receptor-associated kinase 1 genes to attenuate TLR and cytokine signaling (258, 259). These 
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findings strongly suggest that miRNAs can modulate macrophage polarization in the course of 
various diseases (260).  
 
Moreover, Zhuang et al. (261) reported that miR-223 modulates metaflammation in obesity via 
regulating macrophage activation. Though they demonstrated that miR-223 was up-regulated in 
LPS-stimulated macrophages (M1 like) but down-regulated in IL-4-stimulated mouse BMDMs 
(bone marrow-derived macrophages) (M2 like), the miR-223-deficient macrophages were 
hypersensitive to LPS-stimulation, and exhibited a delayed response to IL-4 compared with wild 
type mouse controls. Likewise, the miR-223-deficient mice exhibited an increased adipose tissue 
inflammatory response and decreased insulin sensitivity. In addition, Pknox1 (PBX/knotted 1 
homeobox 1) as a miR-223 target in partially polarizing M2 to M1 macrophage was validated by 
gain and loss-of-function analyses in BMDMs. 
 
M2 macrophages  
 
Lymphocytes 
 
The ratio of M1:M2 macrophages is 4:1 in lean adipose tissue (262). Even though M1 and M2 
macrophage activities can exist without T or B cell influence (263), specialized or polarized T 
cells including Th1, Th2 and Tregs do play a role in macrophage polarization (264). 
 
For example, Tregs can induce M2 macrophage differentiation in mice by secretion of IL-10 and 
TGF-β (265). Moreover, in the lean adipose tissue, Tregs are involved in the regulation of tissue 
homeostasis and maintenance of M2 macrophage population, whereas obesity is associated with 
decreased number of Tregs in adipose tissue (228). In addition, the presence of eosinophils and 
Tregs, which secrete cytokines IL-4/IL-13 and IL-10, respectively, together with adiponectin 
secreted by adipocytes, polarize macrophages toward an anti-inflammatory phenotype (M2 like) in 
the adipose tissue. In conclusion, these immune cells and their secretome maintain the positive 
balance of M2 macrophages in the lean AT (266). 
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A novel duo in modulating the polarization has also been identified: ILC2s (innate lymphoid type 
2 cell) and IL-33. ILC2s are a regulatory subtype of ILCs, which are divided into three distinct 
populations, ILCs 1, 2 and 3 (267). With respect to the cytokine profile expression, these 
sub-populations are analogous to CD4+ T helper subsets: Th1, Th2 and Th17, respectively, though 
ILCs do not have T-cell receptors or specifically respond to antigenic signals (268). IL-33 is 
constitutively expressed in specialized populations of epithelial and endothelial cells of human as 
well as mice. Moreover, ST2 (interleukin 1 receptor-like 1, the receptor of IL-33) is highly 
expressed in ILC2s and Th2 lymphocytes and Tregs. Upon binding to ST2, IL-33 induces the 
secretion of anti-inflammatory cytokines including IL-5 and IL-13 by ILC2s in the adipose tissue, 
and the polarization of macrophages to an M2 phenotype (269). Furthermore, Han et al. proved 
that Tregs expressed higher levels of ST2 in adipose tissue of the lean mice, compared with the 
obese control, while IL-33 treatment restored the ST2-positive Treg population and alleviated 
metaflammation in the adipose tissue (270).  
 
IRF/STAT signaling pathways 
 
IL-10 induces the polarization to M2 phenotype by activating STAT3 via receptor (IL-10R). 
IL-10R is a heterodimer composed of IL-10R1 and IL-10R2 (271). Upon binding to IL-10, IL-10R 
undergoes autophosphorylation, thereby activating the transcription factor STAT3 to inhibit the 
expression of pro-inflammatory factors. It has been reported that IL-10 responds to TLR activation 
in the macrophages. The components in IL-10-induced macrophage transcriptome include TLR1, 
TLR8, MARCO (macrophage receptor with collagenous structure) and chemoattractants CXCL13 
and CXCL4 (271). 
 
In addition to IL-10, IL-4 as well as IL-13 induces the polarization to M2 phenotype by activating 
STAT6 of IRF/ STAT signaling pathways in the adipose tissue (272). Binding to IL-4 receptor 
alpha (IL-4Rα), IL-4 and IL-13 activate JAK1 and JAK3 respectively (273), thus to induce STAT6 
activation and translocation. For example, during severe (respiratory syncytial virus) RSV-induced 
bronchiolitis, IL-4Rα/STAT6-dependent polarization to M2 macrophages significantly inhibited 
the inflammation and protected against the epithelial damage in lungs (274). Transcription factors 
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involved in the M2 polarization via IL-4 stimulation were demonstrated by transcriptome analysis, 
include various signaling mediators, such as CISH (cytokine-inducible Src homology 2 containing 
protein), SOCS1 and transcription factors, such as c-myc and IRF4, KLF-4 (Kruppel-like factor 4) 
(275). Moreover, besides being directly induced by TLR signaling, SOCS1 can also be 
up-regulated by IL-4 in concert with TLR, which in turn inhibits the action of STAT1 and STAT3 
(276). In macrophages, SOCS proteins regulate the sensitivity of cells toward cytokines and 
modulate signaling via TLRs by Notch signaling (277). 
 
It is noteworthy that PPARγ together with KLF-4 promote M2 polarization induced by IL-4 or 
IL-13. For example, mice with myeloid-specific deficiency of either PPARγ or KLF-4 resulted in 
the suppressed M2 polarization of macrophages (278). Similarly, IL-4 failed to promote the M2 
polarization and suppress the secretion of IL-6 in macrophages deficient of PPARγ (279). In 
addition, other members of the PPAR family, PPARβ/δ, when stimulated by IL-4 and IL-13, also 
appear to promote the M2 polarization (280). 
 
 
 
1.5. The vitamin D system 
 
1.5.1. Vitamin D metabolism (Figure 1.7) 
 
Vitamin D is a pleiotropic steroid hormone. Besides regulation of calcium homeostasis and bone 
turnover, it has anti-proliferative, pro-differentiation, immuno-modulatory, and anti-inflammatory 
properties in various cells and tissues in the body (281, 282). 
 
Vitamin D (also known as cholecalciferol), is mainly generated in the skin where one of the rings 
of the precursor molecule (7-dehydrocholesterol) is broken by ultraviolet B light (sunlight), but 
can also be ingested from a number of foods, such as egg yolks, red meat and oily fish. Afterwards, 
to achieve the biologically active form 1α,25(OH)2D3  (calcitriol), vitamin D must first be 
hydroxylated at the carbon 25 position by 25-hydroxylase, to generate 25(OH)D3 (calcifediol) in 
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the liver. This hydroxylation is accomplished by several cytochrome P450 (CYP) isoforms 
including mitochondrial CYP27A1, the microsomal CYP2R1 (considered as the high-affinity 
25-hydroxylase), CYP3A4 and CYP2J311 (283). 25(OH)D3 is the most plentiful and stable 
metabolite of vitamin D in human serum, the level of which is the best indicator of vitamin D 
status in body either from subcutaneous synthesis or from diet, as it binds serum vitamin D 
binding protein as well as other albumin super family members in the blood with high affinity 
(284). In general, 25(OH)D3 is not thought to exert much biologic activity in the body and is 
further circulated to the proximal tubule of kidneys, where it is hydroxylated at the 1 position to 
become 1α,25(OH)2D3  (calcitriol), which is the biologically active form of vitamin D (283). 
Interestingly, many other cells, especially macrophages in all tissues are capable of expressing 
1-hydroxylase and synthesizing 1α,25(OH)2D3 locally (285). The hydroxylation is accomplished 
by the enzyme CYP27B1, the activity of which is essentially enhanced by PTH (parathyroid 
hormone) (286). Determination of circulating 1α,25(OH)2D3, at the present stage of the clinical 
knowledge, has very limited clinical utility. For though circulating 1α,25(OH)2D3 is diagnostic for 
several clinical conditions, including vitamin D-dependent rickets types I and II, hypercalcemia 
associated with sarcoidosis, tuberculosis, fungal infections, Hodgkin’s disease, lymphoma, 
Wegener’s granulomatosis and other clinical conditions involving the vitamin D endocrine system, 
including hypoparathyroidism, hyperparathyroidism and chronic renal failure [for which the assay 
of 1,25(OH)2D3 is a confirmatory test], circulating 1α,25(OH)2D3 provides essentially no 
information with respect to the patient’s nutritional vitamin D status (287). 
 
Mediated by vitamin D receptor (VDR), 1α,25(OH)2D3 modulates the genomic or non-genomic 
response of numerous cells and tissues throughout the body, in an endocrine, autocrine or 
paracrine manner (285) (Figure 1.8). 
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Figure 1.7 Vitamin D sources and metabolism. The recommended reference range for 25(OH)D3 
levels is 20-100 ng/ml (50-250 nM). Obtained from (284). 
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Figure 1.8 Pathways for generating biological responses by 1,25(OH)2D3. In the genomic 
pathway (left-hand side), occupancy of the VDR-RXR complex by 1,25(OH)2D3 leads to an up- or 
down regulation of genes subject to hormone-receptor regulation. In the non-genomic pathway 
(right-hand side), occupancy of the VDR membrane receptor by 1,25(OH)2D3 can lead to the 
initiation of rapid responses that are coupled through appropriate second-messenger systems (e.g. 
Ca+2), either directly to the generation of the end biological responses or indirectly through 
modulation of genomic responses. Obtained from (288). 
 
 
 
 
 
1α,25(OH)2D3 
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1.5.2. Vitamin D receptor 
 
The gene for the VDR is located on chromosome 12 (12q13.11), and there is only one isoform 
encoded by this gene in humans and other organisms. Though 14 distinct transcripts of VDR 
(differing in their 5 termini) have been reported to be generated as a result of alternative splicing 
or differential promoter usage and some of them may be associated with the presence and/or 
severity of many rheumatic diseases (289), most of the variant transcripts produce the same 
classical VDR protein, consisting of 427 amino acids (290). 
 
The VDR is a ligand-dependent transcription factor belonging to the super family normally 
referred to as the steroid/thyroid hormone receptors (291) and can be functionally divided into 
three regions with well-characterized functions: an NH2-terminal region contains a 
ligand-independent transactivation function, AF-1 (activation function-1); a central region 
contains the DBD (DNA binding domain), which is composed of two C2-C2 type zinc fingers and 
responsible for targeting the VDR to VDREs (vitamin D response elements); and a C-terminal 
region contains a multi-functional domain consisting of the LBD (ligand binding domain), the 
RXR (retinoid X receptor) heterodimerization motif and a ligand-dependent transactivation 
function, AF-2, which is mainly present in cells of the bones, intestines, kidneys and parathyroid 
gland, and has traditionally been associated with calcemic activities (i.e. calcium and phosphorus 
homeostasis and maintenance of bone content). The presence of VDR in cells other than those 
organs has led to the recognition of non-calcemic actions of VDR ligands, such as 
pro-differentiation, immuno-modulation and anti-inflammation, etc (292). In the absence of ligand 
and serum in cellular systems, most of the VDR is present in the cytoplasm (293). When a VDR 
ligand binds to the LBD of VDR, the VDR forms a heterodimer with RXR, which is a nuclear 
receptor activated by 9-cis retinoic acid (vitamin A) and an obligate partner of VDR in mediating 
the action of VDR ligands (291). The ensuing conformational change enhances the formation of 
VDR-RXR heterodimer (294). Meanwhile the VDR ligand induces the translocation of the 
transcriptional complex (composed of the ligand and heterodimer) into the nucleus (295). 
Importantly, it has already been shown that only 1α,25(OH)2D3 and its synthesized analogues 
(VDR agonists) have high affinity of binding upon the VDR (296). 
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Besides directly inhibiting the expression of some genes by antagonizing the action of certain 
transcription factors [e.g. nuclear factor NF-AT (unclear factor of activated T cells) and NF-κB 
(297, 298)], the transcriptional complex can bind to VDREs [present in the promoter regions of 
vitamin D-responsive genes (299)] and cofactors, thereby positively or negatively regulating the 
gene transcription. Cofactors (which don’t directly bind to DNA) possess the capability of 
modulating gene expression by acting as a bridge between the transcriptional complex and the 
basal Pol II transcription machinery. They consist of two functionally distinct families of proteins, 
namely coactivators and corepressors. Coactivators mediate the induction of transcription 
(positive regulation), whereas corepressors suppress the gene expression (negative regulation) 
(Figure 1.9) (292). 
 
Positive regulation 
 
Positive regulation is mediated by SRC (steroid receptor coactivator) and DRIP (VDR-interacting 
proteins) (300). The SRC family of cofactors includes SRC-1, SRC-2 and SRC-3. These SRC 
family members along with CBP (CREB binding protein)/p300 and pCAF (p300/CBP-associated 
factor), are histone acetyltransferases that destabilize the nucleosomal core by catalyzing the 
acetylation of lysine residues present in the N-terminal tails of histones (301). DRIP is a complex 
approximately 20 proteins and contains mediator factors that are required for the interaction with 
basal transcription factors and polymerase II. The transcriptional complex recruits the complete 
DRIP complex by ligand-mediated interaction with DRIP 205, which is a component of the DRIP 
complex (302). 
 
The first step of the regulation involves the recruitment of the transcriptional complex-SRC or 
-histone acetyltransferase activity complex to a responsive promoter of VDREs, thereby 
facilitating the destabilization of the nucleosomal core to unwind vitamin D responsive genes. And 
then the transcriptional complex-DRIP complex targets the unwound DNA to promote the 
transcription (expression) of the genes (292). 
 
Negative regulation 
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Negative regulation is mediated by three corepressors including (nuclear receptor co-repressor) 
NcoR-1, NcoR-2 and Hairless (301). The transcriptional complex-corepressor complex recruits 
histone deacetylase activities and subsequently deacetylates the lysine residues present in the 
N-terminally located in histone tails, thereby compacting the chromatin to silence of the genes 
(303).  
 
The vitamin D-responsive genes modulated by the transcriptional complex include osteocalcin, 
osteopontin and RANKL (receptor activator of NF-κB ligand), which participate in extracellular 
bone matrix formation and bone remodeling (291); EGF-R (epidermal growth factor receptor), 
c-myc, K16 and PTH, which are involved in cell proliferation and differentiation (304-306); 
cytokines including IL-2, IL-12, TNF-α, IFN-γ and GM-CSF (granulocyte-macrophage 
colony-stimulating factor), which modulate inflammatory response in the tissues (307-310). 
 
In addition, it has been recognized that by binding to VDR on the plasma membrane, 1,25(OH)2D3 
can exert non-genomic actions, such as the rapid intestinal absorption and reabsorption of Ca2+ 
(transcaltachia), opening of voltage-gated Ca2+ and Cl- channels in osteoblasts, migration of 
endothelial cells and secretion of insulin by beta pancreatic cells (288). The signaling molecules 
involved in these processes include sarcoplasmic reticulum Ca2+-ATPase on plasma membranes, 
phospholipase C and phospholipase A2 (PLA2), PI3K, p21ras and a variety of second messengers 
(Ca2+, cyclic AMP, fatty acids and 3-phosphoinositides such as phosphatidylinositol 3,4,5 
triphosphate), accompanied by activation of protein kinases, such as PKA, PKC, MAPKs and 
Ca2+-calmodulin kinase II, etc (311-314). 
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Figure 1.9 The positive (by coactivator) and negative (by corepressor) genomic responses 
mediated by 1α,25(OH)2D3–VDR-RXR complex. Obtained from (315).  
 
 
 
 
 
The expression of VDR in a variety of cell lines and primary cells, together with the increased 
evidence regarding its involvement in the processes of cell proliferation, differentiation, and 
immuno-regulation, has prompted testing of the therapeutic effect of 1α,25(OH)2D3 and other 
VDR agonists (e.g. ZK159222 and ZK191784) in several types of autoimmune diseases and 
cancers. Notably, it has been shown that 1α,25(OH)2D3 has anti-inflammatory properties on 
different human and mouse cells (292). 
 
However, the immuno-modulatory (i.e. anti-inflammatory) properties of 1α,25(OH)2D3 are mostly 
achieved only if very high doses are applied, which can provoke hypercalcemia as a side effect. 
Hence, during recent decades there were many attempts to synthesize other VDR agonists 
[1α,25(OH)2D3 analogues] with the same or even stronger anti-inflammatory efficacy but lower 
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capacity in raising blood calcium levels (316). The development of agonists is mainly based on 
knowledge about the specific interactions of 1α,25(OH)2D3 or its analogues with the ligand 
binding pocket, which is in the LBD of VDR (Figure 1.10) (283). 
 
To compare the efficacies of 1α,25(OH)2D3 with VDR antagonists, the mammalian one-hybrid 
assays (an expression vector for a fusion protein containing the DBD of the yeast transcription 
factor GAL4 and the LBD of the VDR together with a reporter gene construct containing a GAL4 
binding site-driven luciferase gene) performed in HeLa cells demonstrated that 1α,25(OH)2D3 
induced reporter gene activity in a typical dose response [EC50 (half maximal effective 
concentration)-value of 10-9 M], whereas ZK159222 showed very low ligand sensitivity 
(EC50-value of 1.2 x 10-7 M) (317). Similarly, the reporter gene assays [expression vectors for 
VDR and RXR and a reporter gene construct containing (directly repeated arrangements of two 
hexameric binding sites with three spacing nucleotides) DR3-type VDRE- driven luciferase gene] 
in Cos-7 cells exhibited that the EC-value of 1α,25(OH)2D3 is 1.7 x 10-9 M, while the ZK159222 
is 10-8 M) (317). Moreover, the EC50-value was 2.3 x 10-10 M for 1α,25(OH)2D3 and 5.3 x 10-8 M 
for ZK191784, when inducing osteocalcin production (318). 
 
Figure 1.10 The molecular structure of VDR agonists. 
 
 
 
 
 
ZK159222 
 
1α,25(OH)2D3 ZK191784 ZK159222 
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ZK 159222 is the first carboxylic ester analogues of 1α,25(OH)2D3 with a partial agonist profile. It 
has additional cyclopropyl rings and allylic alcohol substructures on its side chain, and an equal 
affinity to the nuclear VDR compared with 1α,25(OH)2D3. Metabolism studies in vitro indicate 
that its ester group is rapidly hydrolyzed in serum, thereby giving rise to the biologically less 
active carboxylic acid (319). Importantly, in rats ZK 159222 reduced the hypercalcemic and 
hypercalciuric activity by approximately 3000 times, when compared with 1α,25(OH)2D3 (320). 
Therefore, it is a promising new compound in vitamin D research. 
 
Moreover, ZK 159222 inhibited lymphocyte proliferation, but induced osteocalcin synthesis in 
ROS 1712.8 cells (320). In HL60 cells (a promyelocytic leukemia cell line), ZK 159222 induced 
only a 10% differentiation (measured by nitroblue tetrazolium and demonstrated by reduction in 
CD14 expression) compared to that by 1α,25(OH)2D3 (320). Interestingly, ZK159222 also appears 
to be a competitive 1α,25(OH)2D3 antagonist. For instance, in MCF7 calls transiently transfected 
with a gene construct [DR3-vitamin D response element (a directly repeated arrangement of the 
hexameric binding sites with three spacing nucleotides, which represents an optimal binding site 
for VDR-RXR heterodimers) (321) and luciferase reporter], ZK 159222 displayed no agonistic but 
a 1α,25(OH)2D3 antagonistic effect with the similar potency as in HL60 cells (320).  
 
Noteworthy, a recent study has shown that ZK159222 (10-8, -6 M) [or ZK191784 (10-8, -6 M), which 
will be discussed next in this section] significantly inhibited the release of pro-inflammatory 
factors including IL-6, IL-8, MCP-1 and RANTES from THP-1-MacCM-stimulated human white 
adipocytes. The anti-inflammatory effects are probably mediated by blocking phosphorylated 
NF-κB in the nucleus or phosphorylated MAPK p38 in the cytoplasm, thereby inhibiting the 
pro-inflammatory gene expression and secretion (24 h) (322). 
 
ZK191784 
 
ZK191784 contains a structurally modified side chain characterized by a 22,23-double bond, 
24R-hydroxy group, 25-cyclopropyl ring and 5-butyloxazole unit, and competitively binds to the 
VDR with a similar affinity as 1α,25(OH)2D3 (323). 
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Nijenhuis et al. reported that ZK191784 normalized the Ca2+ hyperabsorption and the expression 
of intestinal Ca2+ transport proteins in TRPV5-/- mice (a phenotype displaying hypercalciuria, 
hypervitaminosis D, increased intestinal expression of the epithelial Ca2+ channel TRPV6, the 
Ca2+-binding protein calbindin-D9K and intestinal Ca2+ hyperabsorption). Similarly, the 
compound decreased intestinal Ca2+ absorption in WT mice as well as 1α,25(OH)2D3 –dependent 
Ca2+ uptake by Caco-2 cells (318). Therefore, ZK197841 is associated with less hypercalcemic 
side effects compared with 1α,25(OH)2D3 or other analogues currently used in clinical practice. 
 
Importantly, like 1α,25(OH)2D3, ZK191784 exhibited potent immune-suppressive and 
anti-inflammatory activity by inhibiting antigen-induced lymphocyte proliferation and cytokine 
secretion in vitro. Moreover, like ZK15922, it could also exert 1α,25(OH)2D3 -antagonistic effect 
on HL-60 cell differentiation (323, 324). 
 
 
1.5.3. Vitamin D and adipose tissue  
 
Storage 
 
Vitamin D is a fat soluble secosteroid. It has been long shown that adipose tissue is the principal 
storage site for vitamin D and its metabolites, mainly in lipid droplets of adipocytes (325). 
 
In humans, approximately 17% of orally-administered vitamin D dose is stored in adipose tissue 
whilst the rest is metabolized (326). Moreover, adipose tissue accumulates vitamin D 
proportionate to its concentration in plasma (327). Furthermore, the distribution of vitamin D and 
its metabolites in human adipose tissue have been studied by different analytical methods. For 
instance, with sensitivity less than 1 ng/g of tissue, HPLC (high-performance liquid 
chromatography) was used to measure the concentration of vitamin D in the human fat samples, 
which were obtained from autopsy (328). The concentrations were 45.3 ± 22.2 ng/g in the 
perirenal adipose tissue and 115.6 ± 52.4 ng/g in the axillary tissue. Similar results have been 
shown in the obese adults using LC/MS (liquid chromatography mass spectrometry) method (329). 
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Recently, a new technique called TOF-SIMS (time-of-flight secondary ion mass spectrometry) 
was used to the measurement purpose in human adipose tissue. This technique has several 
advantages: though it needs sophisticated sample preparation, the sample volume is relative low 
compared with the above-mentioned techniques; not only measuring vitamin D in different body 
compartments, but also it can specify the sub-cellular localization, by using ultracentrifugation to 
separate cellular components, and demonstrating it is found in adipocyte lipid droplets (325). In 
addition, adipose tissue also releases vitamin D at a much slower rate that is proportionate to its 
storage concentration (327). 
 
Taken together, it has been suggested that adipose tissue functions as a vitamin D buffering system 
that prevents uncontrolled synthesis of 25(OH)D3 in the liver (330). Moreover, under fasting 
conditions, the slow release of vitamin D from adipose tissue may protect against the potential 
toxicity of vitamin D excess (331). 
 
Production 
 
25-hydroxylases including CYP2R1, CYP2J2, CYP27A1 andCYP3A4 [hydroxylating vitamin D 
at the carbon 25 position to generate 25(OH)D3 in the liver] have all been shown to be expressed 
in SAT as well as VAT (332, 333). Moreover, the expression of extra-renal 
25(OH)D3-1α-hydroxylase (CYP27B1) also has been discovered in both rat and human adipose 
tissue. Noteworthy, 3T3-L1 preadipocytes express 1α-hydroxylase and were able to convert 
3H25(OH)D3 to 3H1α,25(OH)2D3 (332, 334). But unlike the kidney, 1α-hydroxylase expressed by 
adipose tissue is not regulated by dietary calcium and vitamin D (335). 
 
Degradation 
 
The degradation of 1α,25(OH)2D3 by adipose tissue has been well established. CYP24A1, which 
catabolizes 25(OH)D3 and 1α,25(OH)2D3 to calcitroic acid and other inactive metabolites (336), is 
expressed in both human SAT and VAT (332). By induction of CYP24A1, 1α,25(OH)2D3 could 
stimulate its own degradation. In addition, it has been shown that over-expression of adipose 
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tissue CYP24A1 is associated with metabolic diseases, but the relevant pathophysiologic 
mechanisms still need further investigation.  
 
Effects on adipogenesis 
 
1α,25(OH)2D3 (10-8 M) stimulated the differentiation of porcine MSCs (mesenchymal stem cells) 
toward adipocytic phenotype in a dose dependent manner. The differentiation was demonstrated 
by increased gene expression of PPARγ, LPL (lipoprotein lipase) and AP2 (adipocyte-binding 
protein2) (12 day) (337). Similarly, Narvaez et al. reported that in the presence of 
1,25(OH)2D3 (10-8 M), hASC (human adipose-derived stem cells) differentiated toward adipocytes 
with an increased expression of adipogenic marker genes [e.g. FABP4 (fatty acid binding protein) 
and PPARγ] and enhanced lipid accumulation (14 day) (338). Similarly, 1,25(OH)2D3 (10-10, -8 M) 
promoted differentiation of already committed human subcutaneous preadipocytes by 
up-regulating the level of adipogenic FABP4 as well as enhancing the gene expression of LPL 
and  PPARγ (334). In addition, the VDR is expressed in the earliest stages of adipocyte 
differentiation (4 h) (339). Knock down of the VDR by siRNA (small interfering RNA), the 
differentiation of 3T3-L1 cells was inhibited (340). 
 
Paradoxically, besides inhibiting lipid droplet formation (7-8 day), 1α,25(OH)2D3 (10-8 M) 
inhibited adipogenesis by suppressing the gene expression of C/EBPα and PPARγ, antagonizing 
the transacting activity of PPARγ, stabilizing the VDR protein (24 h) in 3T3-L1 preadipocytes 
(341). Moreover, 1α,25(OH)2D3 (10-8 M) stimulated the expression of ETO (eight twenty-one, a 
C/EBP β corepressor) (24 h), thereby inhibiting the adipogenesis required transcriptional action of 
any remaining C/EBP β 3T3-L1 preadipocytes (340). In addition, the anti-adipogenic effect of 
1α,25(OH)2D3 mediated by WNT signaling has emerged recently. For instance, 1α,25(OH)2D3 
(10-8 M) inhibits the differentiation of 3T3-L1 preadipocytes by maintaining the expression levels 
of WNT10B and nuclear β-catenin, thereby suppressing the level of PPARγ in 3T3-L1 adipocytes 
(342). Similarly, by suppressing DKK1 (dickkopf1) whilst enhancing the secretion of SFRP2 
(frizzled-related protein 2) via VDR mediated WNT signaling (48 h), 1,25(OH)2D3 (10-8 M) 
inhibited mouse BMSCs differentiation into adipocytes (343).  
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It is obvious that the conflicting results concerning the effects of 1α,25(OH)2D3 and its interactions 
with PPARγ in modulating adipogenesis/lipogenesis, likely reflect not only different models but 
also the end points reported. With respect to different models, some cells produce PPARγ ligands 
upon treatment with adipogenic media endogenously, while others require exogenous 
supplementation with synthetic PPARγ ligands for differentiation, and these uncertainties make it 
difficult to unravel the interactions between PPARγ and VDR activity (338). In addition, single 
cell profiling techniques have shown that changes in adipogenic marker genes do not strictly 
correlate with lipid droplet accumulation (344), not to mention that most of the above-mentioned 
studies, especially those of 1α,25(OH)2D3 exerting potent anti-proliferative effects, did not 
normalize lipid droplets formation by cell density.  
 
Effects on adipocyte apoptosis 
 
By microarray analysis of gene expression, it has been demonstrated that 1α,25(OH)2D3 (10-8 M) 
significantly inhibited adipocyte apoptosis in human SAT in vitro (345). The anti-apoptotic effect 
also has been observed in differentiated 3T3-L1 cells (346). The underlying mechanism of 
anti-apoptosis is probably that physiological (low) doses (<10-7 M) of vitamin D3 could inhibit 
apoptotic gene expression, such as caspase-1 and caspase-2, but stimulate anti-apoptotic gene 
expression, such as BCL-2 (B-cell lymphoma 2) (347).  
 
Paradoxically, an increased intake of vitamin D3 [25 IU per os for 10 weeks] was associated with 
weight loss displayed by induction of apoptosis in WAT of the obese mice on HFD (348). 
Similarly, high dose (10-7 M) of 1α,25(OH)2D3 stimulated the apoptosis of differentiated 3T3-L1 
cells (346). 
 
The apoptosis induced by 1α,25(OH)2D3 (10-7 M) is mediated by Ca2+ signaling (347). In mature 
3T3-L1 adipocytes, 1α,25(OH)2D3 (10-7 M) rapidly stimulates the voltage-dependent as well as 
voltage-insensitive Ca2+ influx and triggers Ca2+ release from ER stores through the (inositol 
1,4,5-trisphosphate receptor) IP3R/Ca2+ release channels and (ryanodine receptor) RyR/Ca2+ 
release channels (day 1). Consequently the sustained increase of intracellular calcium initiates 
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apoptosis by activation of Ca2+-dependent protease calpain and Ca2+/calpain-dependent caspase-12 
(day 3) (349). Noteworthy, the susceptibility of mature adipocytes to 1α,25(OH)2D3 induced-effect 
of increasing intracellular Ca2+, depends upon Ca2+-buffering capacity of these cells (350). 
 
Effects on metaflammation  
 
Though in a randomized controlled trial including fifty-five obese subjects, oral supplementation 
of vitamin D 7000 IU (international unit) per day over 26 weeks neither affected inflammatory 
markers in the circulation nor in the adipose tissue (351), there is a body of evidence suggesting 
that 1α,25(OH)2D3 is anti-inflammatory. In LPS-stimulated 3T3-L1 cells, 1α,25(OH)2D3 (10-7 M) 
significantly reduced the release of IL-6 (24 h) (352). Similar results have also obtained in 
adipocytes from human subcutaneous WAT. For instance, 1,25(OH)2D3 (10-7, -8 M) attenuated 
TNF-α induced MCP-1 secretion (24 h) (353); inhibited THP-1-MacCM-induced gene expression 
of pro-inflammatory factors, such as MCP-1, IL-6 and IL-8 (24 h) (354). In addition, dietary 
supplementation of vitamin D (0.05 mg/kg of diet for 4 weeks) significantly reduced the secretion 
of IL-6 from epididymal adipose tissue of the mice on HFD (352). 
 
It has been demonstrated that the anti-inflammatory effects of 1,25(OH)2D3 (10-8 M) were 
mediated by inhibition of the NF-κB and MAPK signaling pathways (354). The activation of these 
two pathways is essential in the signal transduction of pro-inflammatory factors in adipocytes, 
whereas 1α,25(OH)2D3 (10-8 M) attenuated the activation by inhibiting the phosphorylation of relA 
as well as of p38 (24 h) (355, 356).  
 
Interestingly, 1α,25(OH)2D3 (10-8 M) also inhibited inflammation by enhancing the suppressive 
activity of human Tregs (357, 358). However, the underlying mechanism needs to be understood. 
 
 
 
1.6. Aims and Hypotheses 
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1.6.1. Hypotheses 
 
1. That VDR agonists [including 1α,25(OH)2D3 and its synthesized (pharmacological) 
analogues (ZK159222 and ZK191784)] reduce inflammatory responses in human adipose 
tissue; 
2. These anti-inflammatory effects of VDR agonists on preadipocytes are mediated by 
modulation of multiple intracellular signaling, including the NF-κB, MAPK or unfolded 
protein response (UPR) pathways. 
 
 
1.6.2. Aims 
1. To study the anti-inflammatory effects of VDR agonists on MacCM (macrophage 
conditioned medium) or IL-1β-stimulated human white preadipocytes (an in vitro model of 
metaflammation in adipose tissue). This was achieved by measurement of the reduction of 
gene expression using qPCR (including IL-1β, IL-6, IL-8, MCP-1 and RANTES) or secretion 
using proteome array and ELISA (including IL-1β, IL-6, IL-8, MCP-1 and RANTES) for 
important mediators of inflammation in the model. 
2. To investigate by which signaling molecules VDR agonists exert the anti-inflammatory 
effects. This was achieved by measurement of the reduction of phosphorylated relA of the 
NF-κB pathway, phosphorylated ERK (p42/44) or phosphorylated p38 of the MAPK 
pathways; or increase of methylated relA of the NF-κB pathway; or modulation of XBP-1 or 
phosphorylated eIF-2α of the UPR pathways (using western blotting). 
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2. Materials and Methods 
 
2.1. THP-1-monocytes/macrophages 
 
The THP-1 cell line was originally isolated from the peripheral blood of a 1-year old male patient 
suffering from acute monocytic leukemia (359). This cell line (in the monocyte as well as 
macrophage-like state) has been widely applied to studies regarding immune responses. THP-1 
monocytes can be differentiated into a macrophage-like phenotype using either PMA 
(Phorbol12-myristate13-acetate), 1α,25(OH)2D3 or M-CSF (macrophage colony-stimulating factor) 
(360, 361). (Non-activated) M0 macrophages can develop from THP-1 monocytes by PMA 
stimulation in 48 h, such as adhering to culture plates, altering their morphology into flat and 
amoeboid in shape, with rough ER, large numbers of ribosomes, and well-developed Golgi 
apparatuses in the cytoplasm (362).  
 
The advantages of THP-1 cell line include:  
a) Under growing conditions with RPMI 1640 supplemented with 10% FBS, THP-1 cells can 
quadruple within three and a half days (363);  
b) The cell line is relatively easy and safe to use since there hasn’t been any reported evidence 
for the presence of infectious viruses or toxic products in THP-1 cells (363); 
c) THP-1 cell line can be cultured in vitro up to passage 25 or recovered after being stored for a 
number of years and by following an appropriate protocol, without changes of cell sensitivity 
and activity (363);  
d) The homogeneous genetic background of THP-1 minimizes the degree of variability in the 
cell phenotype, which renders reproducibility of findings (364),  
 
THP-1 cells have been long used as an in vitro model of human monocytes and macrophages in 
mechanistic studies of inflammatory diseases (365, 366). It has been demonstrated that 
macrophage infiltration occurs in MAO (6). In in vitro experiments, the macrophages are often 
described as being in an M1-activated state, which can be obtained by stimulating 
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THP-1-macrophages with LPS (367, 368). The studies have shown that LPS significantly 
up-regulates the expression of the NF-κB transcription factor, which subsequently orchestrates a 
network of gene expression leading to cell proliferation, differentiation, migration, survival, and 
importantly the activation of inflammation, which is mediated through the release of 
pro-inflammatory factors including IL-1β, IL-6, IL-8 and TNF-α (367, 368). 
 
 
 
2.2. Culture of THP-1-monocytes 
 
Strict aseptic techniques are applied to the following protocols. All the procedures (except the 
centrifuging step) are performed under a laminar flow cabinet. 
 
1. Prepare supplies as shown in Table 2.2.1. 
 
Table 2.2.1 Supplies needed for culture of THP-1-monocytes 
 
Supply Catalogue Number Supply Catalogue Number 
THP-1-monocytes - RPMI 1640 medium Sigma R8758-500 ML 
Penicillin-Streptomycin Gibco 15140122 T75 flask Sigma CLS430641U-100EA 
FBS (Fetal bovine serum) Gibco 16000044 Filter (0.22 μm) TPP 99250 
Pipette and Pipette Tip - Glovers - 
10% Virkon (in water) - 70% Ethanol (in water) Sigma51976-500 ML-F 
Incubator - PBS Gibco 10010023 
Hemocytometer Digital Bio 2-7723-23 Microscope - 
1.5 ml Eppendorf tube (sterile) - 250 ml beaker - 
Distilled water - 50 ml centrifuge tube - 
 
2. Prepare MGM (the whole THP-1-monocyte growth medium) and MM (monocyte medium) 
as shown in Table 2.2.2. Filter the medium and apply them to the following experiments. 
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Table 2.2.2 Preparation of MGM and MM 
 
Type Recipe 
MGM 10% FBS in RPMI 1640 Medium,  
1 x penicillin-Streptomycin (10,000 U/ml) 
MM RPMI 1640 Medium,  
1 x penicillin-Streptomycin (10,000 U/ml) 
 
 
 
2.2.1. Culture of THP-1-monocytes 
 
Protocol for cryo-preserved cells 
 
1. Fill T75 flasks with MGM (25 ml/T75 flask). Place the flasks in an incubator (37°C, 5% CO2) 
for 30 min. 
2. Remove a cryovial of THP-1-monocytes [107 cells/vial, kindly provided by Professor Helen 
R Griffiths (Aston University, UK)] from the liquid nitrogen container and immediately place 
it on dry ice. Briefly twist the cap a quarter turn to relieve pressure, and then re-tighten it. 
Immerse the vial into a water bath (37°C) just to the screw cap for 2 min. Ensure that no 
water enters the thread of the screw cap. 
3. Thoroughly rinse the cryovial with 70% ethanol. Aspirate the excess ethanol from the thread 
area of the screw cap. Open the vial and transfer the whole 1 ml of the cells into the T75 flask 
containing the pre-warmed MGM. 
4. Place the flasks in an incubator (37°C, 5% CO2) for cell growing. Replace the medium in 
every 48 h.  
 
Cell counting 
 
Take the flasks out of the incubator and spray the screw caps thoroughly with 70% ethanol and let 
them air dry. Transfer the cell suspension into 50 ml centrifugation tubes [1 flask (25 ml)/tube]. 
Draw out 100 μl as a sample then dilute it 9 times in PBS. Load 10 μl of the diluted sample onto a 
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hemocytometer to measure the cell density (= 100，000#of  squares  cell/ml). 
 
 
2.2.2. Protocol for subculture of THP-1 monocytes 
 
1. Subculture is to be initiated when the density of THP-1 monocytes has reached 1 x 
106/ml·T75 flask (confirmed by cell counting) (Figure 2.1). 
2. Warm MGM for 30 minutes in 37°C water bath. 
3. Transfer the cell suspension into a 50 ml centrifuge tube and centrifuge it at 150 x g for 10 
min. 
4. Resuspend the monocytes in the pre-warmed MGM.  
 
 
 
Figure 2.1 The suspension of THP-1 monocytes (cell density: 1 x 106/ml) 
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2.3. THP-1-monocytes treatments  
 
Strict aseptic techniques are applied to the following protocols. All the procedures (except the 
centrifuging step) are performed under a laminar flow cabinet. 
 
2.3.1. Generation of THP-1-MacCM (THP-1-macrophage conditioned medium) 
 
1. Prepare reagents and supplies as shown in Table 2.3.1, 2. 
 
Table 2.3.1 Reagents needed for preparation of THP-1-MacCM 
 
 Catalog Number Stock Concentration 
PMA(Phorbol12-myristate13-acetate) Sigma P1585-1mg 2 μg/μl [in DMSO(dimethyl sulfoxide)] 
LPS  Sigma L3024-5mg 5 mg/ml (in water) 
ATP (Adenosine 5 ′-triphosphate) Sigma FLAAS-1VL - 
 
 
Table 2.3.2 Supplies needed for preparation of THP-1-MacCM 
 
Supply Catalogue Number Supply Catalogue Number 
RPMI 1640 medium Sigma R8758-500 ML FBS (Fetal Bovine Serum) Gibco 16000044 
Penicillin-Streptomycin Gibco 15140122 Dnase-free water ThermoFisher 10977015 
Filter (0.22 μm) TPP 99722 Pipette and Pipette Tip - 
Incubator - Glovers - 
10% Virkon (in water) - 70% Ethanol (in water) Sigma 51976-500 ML-F 
Microscope - Paper towel - 
1.5 ml Eppendorf tube - 15 ml and 50 ml centrifuge tube - 
Centrifuge - 250 ml beaker - 
Distilled water - Marker (pen) - 
Syringe (20 ml) -   
 
2. When the density of THP-1 monocytes has reached 1 x 106/ml·T75 flask, transfer the cell 
suspension into a 50 ml centrifuge tube and centrifuge it at 150 x g for 10 min. 
3. Resuspend the cells in 100 nM PMA (diluted in MGM, 25 ml/T75 flask) to induce the 
differentiation for 48 h (Figure 2.2.).  
4. Replace the differentiation medium with 1 μg/ml LPS, 1 mM ATP (diluted in MM, 25 ml/T75 
flask) to activate the THP-1-macrophages for 24 h. 
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5. Collect the THP-1-MacCM, filter and store it at -80°C for further use. 
 
 
2.3.2. THP-1-macrophage treatments  
 
1. Prepare reagents and supplies as shown in Table 2.3.3, 4. 
 
Table 2.3.3 Reagents needed for treatments of THP-1-macrophages 
 
 Catalog Number Stock Concentration  
PMA Sigma P1585-1mg 2 μg/μl (in DMSO) 
LPS  Sigma L3024-5mg 5 mg/ml (in water) 
ATP  Sigma FLAAS-1VL - 
1α,25(OH)2D3 EnzoB ML-DM2000-0050 10 μg/ml (in DMSO) 
ZK159222 Bayer 1 μg/μl 
ZK191784 Bayer 1 μg/μl 
 
Table 2.3.4 Supplies needed for treatments of THP-1-macrophages 
 
Supply Catalogue Number Supply Catalogue Number 
RPMI 1640 medium Sigma R8758-500 ML FBS (Fetal Bovine Serum) Gibco 16000044 
Penicillin-Streptomycin Gibco 15140122 Dnase-free water ThermoFisher 10977015 
Syringe filter TPP 99722 Pipette and Pipette Tip - 
Incubator - Glovers - 
10% Virkon (in water) - 70% Ethanol (in water) Sigma 51976-500 ML-F 
Microscope - Paper towel - 
1.5 ml Eppendorf tube - 15 ml and 50 ml centrifuge tube - 
Centrifuge - 250 ml beaker - 
Distilled water - Marker - 
 
2. When the density of THP-1 monocytes has reached 1 x 106/ml·T75 flask (confirmed by cell 
counting), transfer the cell suspension into a 50 ml centrifuge tube and centrifuge it at 150 x g 
for 10 min. 
3. Resuspend the cells in 100 nM PMA (diluted in MGM, 25 ml/T75 flask) to induce the 
differentiation for 48 h.  
4. Replace the differentiation medium with 1 μg/ml LPS, 1 mM ATP to stimulate the 
THP-1-macrophages (diluted in GM, 25 ml/T75 flask), or at the same time treating the 
stimulated THP-1-macrophages with VDR agonists for 24 h, as shown in Table 2.3.5. 
5. Collect the untreated and treated THP-1-MacCMs, filter and store them at -80°C for further 
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use. 
 
 
Table 2.3.5 Treatment plan for THP-1-macrophages 
 
 Treatment (in GM, 25 ml/T75 flask) 
THP-1-MacCM 1 μg/ml LPS, 1 mM ATP 
ZK159222(10nM)-MacCM 1 μg/ml LPS, 1 mM ATP, 10 nM ZK159222 
ZK159222(1μM)-MacCM 1 μg/ml LPS, 1 mM ATP, 1 μM ZK159222 
ZK191784(10nM)-MacCM 1 μg/ml LPS, 1 mM ATP, 10 nM ZK191784 
ZK191784(1μM)-MacCM 1 μg/ml LPS, 1 mM ATP, 1 μM ZK191784 
1α,25(OH)2D3(10nM)-MacCM 1 μg/ml LPS, 1 mM ATP, 10 nM 1α,25(OH)2D3 
 
 
 
Figure 2.2 THP-1-macrophages (adhering to culture plates, adopting flat and amoeboid shape, at 
48 h after induction of differentiation) 
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2.4. Human white preadipocytes 
 
WAT consists of approximately one third of mature adipocytes. This not only serves as a storage 
depot of lipids, it is also a remarkable endocrine organ secreting a large number of adipokines, 
whose primary role is the integration of multiple functions, such as energy balance, food intake 
and appetite, immunity, insulin sensitivity, blood pressure, and reproduction (369). Dysfunctional 
secretion of adipokines accompanied by a dysregulated disposal of glucose and lipids, are crucial 
pathogenetic factors contributing to the development of several metabolic disorders, particularly 
metaflammation and insulin-resistance state of obesity (370).  
 
The remaining two thirds are a combination of small blood vessels, nerve tissue, fibroblasts and 
preadipocytes in various stages of development (371). Noteworthy, preadipocytes have the 
capability of proliferating and differentiating into mature adipocytes, which confers adipose tissue 
a constant functional plasticity to expand throughout the entire lifespan (372). Human primary 
preadipocytes can be isolated and cultured from fat tissue explants. In particular culture conditions 
(i.e. IL-1β and THP-1-MacCM), adipokine secretion (i.e. pro-inflammatory factors) from 
preadipocytes can be induced and investigated in vitro (355). However, the major drawbacks of 
primary preadipocyte culture cannot be ignored, which include technical difficulties when trying 
to isolate preadipocytes from other fibroblast-like cells, the relative small proportion of isolated 
preadipocytes to the total fat tissue required, and the limited life span of primary culture (371). 
 
 
 
2.5. Culture and Subculture of preadipocytes 
 
Strict aseptic techniques are applied to the following protocols. All the procedures (except the 
centrifuging step) are performed under a laminar flow cabinet. 
 
1. Prepare supplies as shown in Table 2.5.1. 
2. Prepare PGM (the whole preadipocytes growth medium) as shown in Table 2.5.2. Filter the 
medium and apply it to the following experiments. 
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3. Fill the flasks with PGM (7 ml/T25 flask). Place the flasks in an incubator (37°C, 5% CO2) 
for 30 min. 
 
Table 2.5.1 Supplies needed for subculture and culture of preadipocytes 
 
Supply Catalogue Number Supply Catalogue Number 
Human white preadipocytes PromoCell C-12730 Preadipocyte growth medium PromoCell C27410 
SupplementMix PromoCell C39425 100 x Antibiotic-Antimycotic ThermoFisher 15240062 
T25 flask Sigma CLS430639U-20EA 12-wells plate Sigma CLS3513-50EA 
Filter TPP 99250 Paper towel - 
Pipette and Pipette Tip - Glovers - 
10% Virkon (in water) - 70% Ethanol (in water) Sigma 51976-500 ML-F 
Trypsin ThermoFisher 25200056 PBS Gibco 10010023 
Hemocytometer Digital Bio 2-7723-23 Microscope - 
50 ml centrifuge tube - Incubator - 
1.5 ml Eppendorf tube - 250 ml beaker - 
Distilled water -   
 
 
Table 2.5.2 Preparation of PGM 
 
Type Recipe 
PGM 500 ml Preadipocyte Growth Medium,  
A vial Preadipocyte Growth Medium SupplementMix  
[Final supplementation concentrations after addition to the growth medium: 
fetal calf serum (0.05 ml/ml), endothelial cell growth supplement (0.004 ml/ml), 
epidermal growth factor (recombinant human) (10 ng/ml), hydrocortisone (1 μg/ml), Heparin (90 μg/ml)]  
5 ml 100 x Antibiotic-Antimycotic (10,000 U/ml penicillin, 10,000 μg/ml streptomycin, and 25μg/ml amphotericin B)  
 
 
2.5.1. Culture of preadipocytes  
 
Protocol for cryo-preserved cells 
 
1. Thoroughly rinse the cryovial of primary human white preadipocytes [derived from 
subcutaneous adipose tissue of a female Caucasian subject (BMI: 21; age: 44 years), 
PromoCell, Germany] with 70% ethanol. Aspirate the excess ethanol from the thread area of 
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the screw cap. Open the vial and transfer the cells into flasks containing the pre-warmed 
PGM (0.25 ml/flask). 
2. Place the flasks in an incubator (37°C, 5% CO2) for cell attachment. Replace the medium in 
every 48 h.  
 
Protocol for proliferating cells 
 
1. Warm PGM for 30 min in 37°C water bath.  
2. Take the flasks out of the incubator and spray the screw caps thoroughly with 70% ethanol 
and let them air dry. Aspirate the old PGM from the flasks and replace with the pre-warmed 
growth medium. 
3. Check the cell density under a microscope (Figure 2.3.). The cells are sub-cultured once they 
have reached 90% confluence (Figure 2.4.). 
 
 
2.5.2. Subculture of preadipocytes  
 
1. Place the trypsin, PBS and growth medium in the 37°C water bath for 30 min. Carefully 
aspirate the old growth medium from the culture flasks. Add pre-warmed PBS (7 ml/flask) to 
the non-cell attaching side of the flasks, slowly reverse the flasks to prevent the cells from 
flushing away, and wash the cells by gently agitating the flasks for 15 sec. Carefully aspirate 
the PBS from the flasks. Repeat the washing procedure once. 
2. Add trypsin (1 X) (1.5 ml/flask) into the flasks and detach the cells at room temperature. 
Close the flasks and examine the cells under a microscope. When the cells start to detach, 
gently tap the side of the flasks to loosen the remaining cells. 
3. When most of the cells are detached, add PGM (1.5 ml/flask) and gently agitate. Carefully 
aspirate the cell suspension from the flasks and transfer them into centrifugation tubes (1 
flask/tube). Spin down the cells for 3 min at 220 x g. 
4. Discard the supernatant. Add 48-60 ml of PGM to each of the tubes to re-suspend the cells.  
5. Seed the preadipocytes into 12-wells plates (2 ml/well, seeding density: approximately 5000 
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cells per cm2). Place the plates in an incubator (37°C, 5% CO2) for cell attachment. Replace 
the medium in every 48 h.  
6. The cells are to be pre-treated once they have reached 90% confluence. 
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Figure 2.3 Human white preadipocytes (initial culture) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Human white preadipocytes (90% confluent) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 
 
2.6. Preadipocyte pre-and treatments 
 
Strict aseptic techniques are applied to the following protocols. All the procedures are performed 
under a laminar flow cabinet. 
 
1. Prepare reagents and supplies as shown in Table 2.6.1, 2. 
 
Table 2.6.1 Reagents needed for pre- and treatments of preadipocytes 
 
 Catalog Number Stock Concentration  
IL-1β Sigma 19401-5UG 0.1 μg/μl (in water) 
IL-1β neutralizing antibody R&D Systems MAB601R-01M 1 mg/ml (in water) 
IL-6 neutralizing antibody R&D Systems AF-206-NA 1.474 mg/ml 
1α,25(OH)2D3 EnzoB ML-DM2000-0050 10 μg/ml (in DMSO) 
ZK159222 Bayer 1 μg/μl (in DMSO) 
ZK191784 Bayer 1 μg/μl (in DMSO) 
 
 
Table 2.6.2 Supplies needed for pre- and treatments of preadipocytes 
 
Supply Catalogue Number Supply Catalogue Number 
Human white preadipocytes PromoCell C-12730 Preadipocyte growth medium PromoCell C27410 
SupplementMix PromoCell C39425 100 x Antibiotic-Antimycotic ThermoFisher 15240062 
Pipette and Pipette Tip - Glovers - 
10% Virkon (in water) - 70% Ethanol (in water) Sigma 51976-500 ML-F 
Untreated and treated MacCM  - RPMI 1640 medium Sigma R8758-500 ML 
Microscope - Incubator - 
50 ml centrifuge tube - Tube rack - 
1.5 and 2 ml Eppendorf tube - 250 ml beaker - 
Distilled water - Paper towel - 
Ice  - Universal tube - 
PBS Gibco 10010023 Trizol ThermoFisher 15596026 
Trizma base Sigma T1503-500G SDS Sigma L3771-100G 
HCl (hydrochloric acid) Sigma H1758-500 ML Glycerol Sigma G5516-100 ML 
protease inhibitor cocktail Sigma P8340-1 ML phosphatase inhibitor cocktail Sigma P2850-1 ML 
PH meter -   
 
2. Culture the preadipocytes alone, or treat them with IL-1β or THP-1-MacCM, or in the 
presence of cytokine neutralizing antibody for 24 h. Pretreat further groups of the 
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preadipocytes with VDR agonists [1α,25(OH)2D3, ZK159222 and ZK191784] for 24 or 48 h, 
followed by (medium replacement) treatments with IL-1β or THP-1-MacCM in the presence 
of VDR agonists (as show in Table 2.6.3-6) before culture medium or lysate collection (n = 6 
well/ pre- and treatment, all the reagents diluted in PGM). 
 
 
 
Table2.6.3 Pre- and treatment plan of Chapter 3 
 
 Pretreatment (24 h) (in PGM) Treatment (24 h) (in PGM) 
control - (25%) RPMI1640 
THP-MacCM(25%) - (25%) THP-MacCM 
IL-1βAb(15μg/ml) +MacCM(25%) - (25%) THP-MacCM, 15 μg/ml IL-1β antibody 
IL-6Ab(300ng/ml)+ MacCM(25%) - (25%) THP-MacCM, 300 ng/ml IL-6 antibody 
VD(0.01nM)+MacCM(25%) 0.01 nM 1α,25(OH)2D3 (25%) THP-MacCM, 0.01 nM 1α,25(OH)2D3 
VD(0.01nM)+MacCM(25%) 0.1 nM 1α,25(OH)2D3 (25%) THP-MacCM, 0.1 nM 1α,25(OH)2D3 
VD(0.01nM)+MacCM(25%) 1 nM 1α,25(OH)2D3 (25%) THP-MacCM, 1 nM 1α,25(OH)2D3 
VD(10 nM)+MacCM(25%) 10 nM 1α,25(OH)2D3 (25%) THP-MacCM, 10 nM 1α,25(OH)2D3 
 
 
Table 2.6.4 Pre- and treatment plan of Chapter 4 
 
 Pretreatment (24 h) (in PGM) Treatment (24 h) (in PGM) 
control - - 
IL-1β(0.5ng/ml) - 0.5 ng/ml IL-1β 
IL-1β(2ng/ml) - 2 ng/ml IL-1β 
VD(0.01nM)+IL-1β(0.5ng/ml) 0.01 nM 1α,25(OH)2D3 0.5 ng/ml IL-1β, 0.01 nM 1α,25(OH)2D3 
VD (0.1nM)+IL-1β(0.5ng/ml)  0.1 nM 1α,25(OH)2D3 0.5 ng/ml IL-1β, 0.1 nM 1α,25(OH)2D3 
VD(1nM)+IL-1β(0.5ng/ml)  1 nM 1α,25(OH)2D3 0.5 ng/ml IL-1β, 1 nM 1α,25(OH)2D3 
VD(10nM)+IL-1β(0.5ng/ml)  10 nM 1α,25(OH)2D3 0.5 ng/ml IL-1β, 10 nM 1α,25(OH)2D3 
VD(0.01nM)+IL-1β(2ng/ml)  0.01 nM 1α,25(OH)2D3 2 ng/ml IL-1β, 0.01 nM 1α,25(OH)2D3 
VD (0.1nM)+IL-1β(2ng/ml)  0.1 nM 1α,25(OH)2D3 2 ng/ml IL-1β, 0.1 nM 1α,25(OH)2D3 
VD(1nM)+IL-1β(2ng/ml)  1 nM 1α,25(OH)2D3 2 ng/ml IL-1β, 1 nM 1α,25(OH)2D3 
VD (10nM)+IL-1β(2ng/ml)  10 nM 1α,25(OH)2D3 2 ng/ml IL-1β, 10 nM 1α,25(OH)2D3 
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Table 2.6.5 Pre- and treatment plan of Chapter 5 
 
 Pretreatment (48h) (in PGM) Treatment (24 h) (in PGM) 
control - - 
IL-1β(0.5ng/ml) - 0.5 ng/ml IL-1β 
ZK159222(10nM)+IL-1β(0.5ng/ml) 10 nM ZK159222 0.5 ng/ml IL-1β, 10 nM ZK159222 
ZK159222(1μM)+IL-1β(0.5ng/ml) 1 μM ZK159222 0.5 ng/ml IL-1β, 1 μM ZK159222 
ZK191784(10nM)+IL-1β(0.5ng/ml) 10 nM ZK191784 0.5 ng/ml IL-1β, 10 nM ZK191784 
ZK191784(1μM)+IL-1β(0.5ng/ml) 1 μM ZK191784 0.5 ng/ml IL-1β, 1 μM ZK191784 
VD(10nM)+IL-1β(0.5ng/ml) 10 nM 1α,25(OH)2D3 0.5 ng/ml IL-1β, 10 nM 1α,25(OH)2D3 
 
 
Table 2.6.6 Pre- and treatment plan of Chapter 6 
 
 Pretreatment (48h) (in PGM) Treatment (24 h) (in PGM) 
control - (25%) RPMI1640 
THP-1-MacCM[25%] - (25%) THP-1-macrophages (shown in Table 2.3.5) 
ZK159222(10nM)-MacCM[25%] 10 nM ZK159222 (25%) ZK159222 (10 nM)-MacCM (shown in Table 2.3.5) 
ZK159222(1μM)-MacCM[25%] 1 μM ZK159222 (25%) ZK159222 (1 μM )-MacCM (shown in Table 2.3.5) 
ZK191784(10nM)-MacCM[25%] 10 nM ZK191784 (25%) ZK191784 (10 nM)-MacCM (shown in Table 2.3.5) 
ZK191784(1μM)-MacCM[25%] 1 μM ZK191784 (25%) ZK191784 (1 μM )-MacCM (shown in Table 2.3.5) 
VD(10nM)-MacCM[25%] 10 nM 1α,25(OH)2D3 (25%) 1α,25(OH)2D3 (10 nM)-MacCM (shown in Table 2.3.5) 
 
 
 
3. Directly collect the culture media (n = 6), store them at -80°C for cytokine array and ELISA. 
4. Rinse the treated preadipocytes twice in ice-cold PBS and lyse them with Trizol (n = 6, 250 
μl/well), the lysate is then stored at -80°C before analysis. 
5. Rinse the treated preadipocytes twice in ice-cold PBS and scrape them into a freshly prepared 
lysis buffer (n = 6, 100 μl/well) as shown in Table 2.6.7, stored the lysate at -80°C for BCA 
assay. 
 
Table 2.6.7 Preparation of the lysis buffer 
 
Type Recipe 
Lysis Buffer 50 mM Tris-HCl pH 6.7, 10% Glycerol,  
4% SDS (sodium dodecyl sulfate) 
protease inhibitor cocktail (1 ml/10 ml of the lysis buffer), 
phosphatase inhibitor cocktail (1 ml/100 ml of the lysis buffer) 
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2.7. Cytokine array  
 
2.7.1. Principle 
 
Proteome arrays are often used for detecting protein expression from various samples including 
serum, plasma, cell, tissue lysates or supernatants (373, 374). 
 
In this technology, firstly, sample (pro-inflammatory factors in our studies) detection requires the 
binding of 2 distinct antibodies [a capture antibody spotted and fixed on a nitrocellulose 
membrane and a detection antibody, each binding to a unique epitope of the same sample. 
Secondly, a (HRP) horseradish peroxidase-linked secondary antibody is added to bind to the 
detection antibody’s Fc region (nonspecific). The binding emits a chemiluminescent signal when 
reacting with an enhanced chemiluminescent substrate, consequently the signals detected and 
measured by an X-ray scanner. Reference peptides are printed on the corners of the array to allow 
for protein relative quantification of the samples (Figure 2.5).  
 
The sandwich-based antibody arrays are rapid, automated, economical, and highly sensitive, 
consuming small quantities of samples and reagents (375). Their reproducibility also enables 
quantitative analysis, which confers greater specificity and lower background signal, to be 
performed (376). 
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Figure 2.5 The mechanism of cytokine array (obtained from R&D systems) 
 
 
 
 
 
2.7.2. General protocol 
 
1. Prepare reagents and supplies as shown in Table 2.7.1, 2. 
2. Pipette 2 ml of array buffer 6 (serving as a block buffer) into each well of the 4-well 
multi-dish. 
3. Place array in the dish. The number on the array should be facing upward (upon contact with 
array buffer 6, the blue dye from the spot will disappear). 
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Table 2.7.1 Preparation of the reagents for the cytokine arrays 
 
Reagent Preparation  Catalogue Number 
Human cytokine 
array 
Immediately before use, remove each membrane to be used from between the protective 
sheets with a flat-tipped tweezers. Handle the membranes with gloved hands and 
flat-tipped tweezers only. 
R&D Systems, 
ARY005 
R&D 
Systems,ARY022 Detection antibody 
cocktail 
Before use, reconstitute the detection antibody cocktail in 200μL of deionized or distilled 
water. 
1 x Array buffer 4/6 Array buffer 4 may contain a precipitate. Mix well before and during use. Add 4 ml of 
array buffer 4 to 8 ml of array buffer 6. Prepare fresh for each use. 
1 x Wash buffer If crystals have formed in the concentrate, warm the bottles to room temperature and mix 
gently until the crystals have completely dissolved. Add 40 ml of wash buffer 
concentrate to 960 ml of distilled water. 
Chemi reagent mix Chemi reagent 1 and 2 should be mixed in equal volumes in 15 minutes of use. Protect 
from light. 1 ml of the resultant mixtures is required per membrane. 
1 x 
Streptavidin-HRP 
Immediately before use, dilute the Streptavidin-HRP in Array buffer 6. See via label for 
dilution factor. 
Note: Bring all reagents to room temperature before use. 
 
Table 2.7.2 Supplies needed for the cytokine arrays 
 
Supply Catalogue Number Supply Catalogue Number 
4-Well multi dish R&D Systems, ARY005 
R&D Systems,ARY022 
Transparent overlay template R&D Systems, ARY005 
R&D Systems,ARY022 
Pipette and pipette tip - Glovers - 
Dnase-free water ThermoFisher 10977015 Distilled water - 
Rocking platform shaker - 500 ml Bottle - 
Paper towel - Flat-tipped Tweezers - 
Plastic sheet protector - Plastic container - 
ChemiDoc - Universal tube - 
Marker -   
 
 
4. Incubate the array for 1 h on a rocking shaker. Orient the dish so that each array rocks end to 
end in its well. 
5. While the arrays are blocking, prepare samples by mixing 1 ml of Array Buffer 6 and 0.6 ml 
of the pooled cell culture supernatant together [100 μl of each of the collected media from the 
treated preadipocytes (n = 6, per treatment)]. Aspirate array buffer 6 from the wells of the 
dish and add the prepared samples. Place the lid on the dish. 
6. Incubate the array overnight at 4 °C on a rocking platform shaker 
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7. Carefully remove the array and place them into individual containers with 20 ml of 1 X wash 
buffer. Rinse the dish with distilled water and dry thoroughly. 
8. Wash each array 3 times with 1 x wash buffer for 10 min on a rocking platform shaker. 
9. For each array, add 30 μl of detection antibody cocktail to 1.5 ml of 1 x Array Buffer 4/6. 
Pipette 1.5 ml per well of the diluted detection antibody cocktail into the dish. 
10. Carefully remove each array from its wash container. Allow excess wash buffer to drain from 
the array. Return the array to the 4 well-dish containing the diluted detection antibody 
cocktail, and cover the dish with the lid. 
11. Incubate the array for 1 h on a rocking platform shaker. 
12. Wash the array as described in step 8 and 9. 
13. Pipette 2 ml of 1 X streptavidin-HRP into each well of the 4-well multi-dish. 
14. Carefully remove each array from its wash container. Allow excess wash buffer to drain from 
the array. Return the array to the 4-well multi-dish containing the 1 X streptavidin-HRP. 
Cover the wells with the lid. 
15. Incubate the array for 30 min at room temperature on a rocking platform shaker. 
16. Wash the array as described in steps 8 and 9. 
17. Carefully remove the array from the dish. Allow excess wash buffer to drain from the array 
by blotting the lower edge onto paper towels. Return the array to the 4 well multi-dish and 
pipette 1 ml of the prepared chemi reagent mix evenly onto each array, and cover the lid. 
Incubate them for 1 min. 
18. Carefully remove each array from the dish and allow excess wash buffer to drain from the 
membrane by blotting the lower edge onto paper towels. Place each array on a plastic sheet 
protector (the number on the array should be facing upward), then cover it with a transparent 
overlay template and take care to gently smooth out any air bubbles. 
19. Place the array assemblies into the chamber of ChemiDoc for detection. 
20. Present results as pixel density relative to the reference controls on the array. 
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2.8. ELISA  
 
2.8.1. Principle 
 
Like the proteome array, a ‘sandwich’ ELISA (enzyme-linked immunosorbent assay) is used to 
detect sample (cell culture media) antigen (pro-inflammatory factors in our studies).  
 
Firstly, a 96-well ELISA microplate is coated with a known quantity of capture antibody that binds 
to a specific epitope of the antigen, any nonspecific binding sites are blocked with the reagent 
diluents; secondly, the antigen-containing sample is added to the plate for the capture antibody 
binding; thirdly, a detection antibody is added to bind to another epitope of the same antigen; 
finally, a HRP-linked secondary antibodies is added to nonspecifically binds to the detection 
antibody’s Fc region. The plate is washed to remove any unbound antigen, detection antibody and 
secondary antibody after each binding step (377). 
 
Subsequently a substrate is added to be converted by HRP into a colormetric signal, the 
absorbance of which is measured to determine the presence and quantity of antigen (377). 
 
 
2.8.2. General protocol 
 
Before formal assays, several of the samples need to be diluted properly according to the results 
from the preliminary assays. 
 
1. Prepare reagents and supplies as shown in Table 2.8.1, 2. 
 
Table 2.8.1 Preparation of the reagents for the ELISAs 
 
Reagent Preparation Catalogue 
Number 
Human IL-1β capture 
antibody 
Reconstitute each vial (240 μg) with 0.5 ml of PBS, dilute in PBS to the working 
concentration (4 μg/ml) before assay. 
R&D Systems, 
DY201-05 
Human IL-1β detection 
antibody 
Reconstitute each vial (12 μg) with 1 ml of reagent diluent, dilute in reagent diluent to 
the working concentration (200 ng/ml) before assay. 
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Human IL-1β standard Reconstitute each vial (55 ng) with 0.5 ml of deionized water. A seven point standard 
curve using 2-fold serial dilutions in reagent diluent and a high standard of 250 pg/ml is 
recommended.  
Human IL-6 capture 
antibody 
Reconstitute each vial (120 μg) with 0.5 ml of PBS, dilute in PBS to the working 
concentration (2 μg/ml) before assay. 
R&D Systems, 
DY206-05 
Human IL-6 detection 
antibody 
Reconstitute each vial (3 μg) with 1 ml of reagent diluent, dilute in reagent diluent to the 
working concentration (50 ng/ml) before assay. 
Human IL-6 standard Reconstitute each vial (65 ng) with 0.5 ml of deionized water. A seven point standard 
curve using 2-fold serial dilutions in reagent diluent and a high standard of 600 pg/ml is 
recommended. 
Human IL-8 capture 
antibody 
Reconstitute each vial (240 μg) with 0.5 ml of PBS, dilute in PBS to the working 
concentration (4 μg/ml) before assay. 
R&D Systems, 
DY208-05 
Human IL-8 detection 
antibody 
Reconstitute each vial (1.2 μg) with 1 ml of reagent diluent, dilute in reagent diluent to 
the working concentration (20 ng/ml) before assay. 
Human IL-8 standard Reconstitute each vial (40 ng) with 0.5 ml of deionized water. A seven point standard 
curve using 2-fold serial dilutions in reagent diluent and a high standard of 2000 pg/ml 
is recommended. 
Human CCL-2/MCP-1 
capture antibody 
Reconstitute each vial (60 μg) with 0.5 ml of PBS, dilute in PBS to the working 
concentration (1 μg/ml) before assay. 
R&D Systems, 
DY279-05 
Human CCL-2/MCP-1 
detection antibody 
Reconstitute each vial (3 μg) with 1 ml of reagent diluent, dilute in reagent diluent to the 
working concentration (50 ng/ml) before assay. 
Human CCL-2/MCP-1  
standard 
Reconstitute each vial (70 ng) with 0.5 ml of deionized water. A seven point standard 
curve using 2-fold serial dilutions in reagent diluent and a high standard of 1000 pg/ml 
is recommended. 
Human 
CCL-5/RANTES 
capture antibody 
Reconstitute each vial (60 μg) with 0.5 ml of PBS, dilute in PBS to the working 
concentration (1 μg/ml) before assay. 
R&D Systems, 
DY278-05 
Human 
CCL-5/RANTES 
detection antibody 
Reconstitute each vial (1.2 μg) with 1 ml of reagent diluent, dilute in reagent diluent to 
the working concentration (20 ng/ml) before assay. 
Human 
CCL-5/RANTES 
standard 
Reconstitute each vial (60 ng) with 0.5 ml of deionized Water. A seven point standard 
curve using 2-fold serial dilutions in reagent diluent and a high standard of 1000 pg/ml 
is recommended. 
Streptavidin-HRP Dilute in reagent diluent according to the factor on the label Within the kits 
Wash Buffer Dilute 25 times in distilled water R&D Systems, 
WA126 
Substrate Solution  Mix substrate A and substrate B at 1:1 (100 μl of the mixture per sample) R&D Systems, 
DY999 
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Table 2.8.2 Supplies needed for the ELISAs 
 
Supply Catalog # Supply Catalogue Number 
96 Well microplate R&D Systems, DY990 Pipette and pipette tip - 
Plate sealer R&D Systems, DY992 Glovers - 
Dnase-free water ThermoFisher 10977015 Distilled water - 
PBS R&D Systems, DY006 Reagent diluent R&D systems, DY995 
Paper towel - 500 ml Bottle - 
Trough - 15 ml Centrifugation tube - 
25 ml Centrifugation tube - Universal tube - 
Stop solution R&D systems, DY995 Microplate reader SPECTROstar Nano 
 
 
Plate preparation 
 
1. Coat a 96-well microplate with 100 μl per well of the working dilution of Capture Antibody. 
Seal the plate and incubate overnight at room temperature. 
2. Aspirate each well and wash it with Wash Buffer 3 times by filling each-well with wash 
buffer (200 μl) using a multi-channel pipette (complete removal of liquid at each step is 
essential for good performance). After the last wash, remove any remaining wash buffer by 
inverting the plate and blotting it against clean paper towels. 
3. Block the plate by adding 200 μl of Reagent Diluent to each well. Incubate it at room 
temperature for 1 h. 
4. Repeat the aspiration/wash as in step 2. The plate is now ready for sample addition.   
 
Assay procedure 
 
1. Add 100 μl of sample or the working dilutions of standards (as shown in Table 2.6.3.) or 
Blank (Reagent Diluent) per well. Cover the pate with plate sealer and incubate it for 2 h at 
room temperature. 
2. Repeat the aspiration/wash as in step 2 of plate preparation. 
3. Add 100 μl of the working dilution of Detection Antibody to each well. Cover the plated with 
a new plate sealer and incubate it for 2 h at room temperature. 
4. Repeat the aspiration/wash as in step 2 of plate preparation. 
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5. Add 100 μl of the working dilution of detection streptavidin-HRP to each well. Cover the 
plate with a new plate sealer and incubate it for 20 min at room temperature. Avoid placing 
the plate in direct light. 
6. Repeat the aspiration/wash as in step 2 of plate preparation. 
7. Add 100 μl of substrate solution to each well. Cover the plate with a new plate sealer and 
incubate it for 20 min at room temperature. Avoid placing the plate in direct light. 
8. Add 50 μl of stop solution to each well immediately, using a microplate reader to subtract 
readings at 540 nm from the readings at 450 nm.  
 
Data analysis 
 
1. Average the duplicate readings for each standard control and sample. Subtract the average 
optical density (O.D) of Blank. 
2. Create a standard curve (the standard concentrations are shown in Table 2.8.3) by using 
computer software to generate a four parameter logistic (4-PL) curve-fit (if samples have 
been diluted, the concentration read from the standard curve must be multiplied by the 
dilution factor), as shown in Figure 2.6 - 10. 
 
 
 
Table 2.8.3 The standard concentrations of the ELISAs 
 
Type Concentration range ( pg/ml) 
IL-1β 250 125 62.5 31.3 15.6 7.8 3.9 
IL-6 600 300 150 75 37.5 18.8 9.4 
IL-8 2000 1000 500 250 125 62.5 31.3 
MCP-1 1000 500 250 125 62.5 31.3 15.6 
RANTES 1000 500 250 125 62.5 31.3 15.6 
81 
 
Figure 2.6 The standard curve of IL-1β (4-PL curve fit) 
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Figure 2.7 The standard curve of IL-6 (4-PL curve fit) 
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Figure 2.8 The standard curve of IL-8 (4-PL curve fit) 
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Figure 2.9 The standard curve of MCP-1 (4-PL curve fit) 
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Figure 2.10 The standard curve of RANTES (4-PL curve fit) 
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2.9. Total RNA isolation and Quantification  
 
2.9.1. Principle 
 
Trizol is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary 
components which facilitate the isolation of a variety of RNA species of large or small molecular 
size, and maintains the integrity of RNA due to the highly effective inhibition of RNase activity 
while disrupting cells and dissolving cell components (378). 
 
Chloroform is added to Trizol-dissolved samples (the treated preadipocytes in our studies), and the 
homogenate is allowed to separate into a clear upper aqueous layer (containing RNA), an 
interphase, and a red lower organic layer (containing the DNA and proteins), and then RNA is 
precipitated from the aqueous layer with isopropanol. The precipitated RNA is washed with 
ethanol to remove impurities, and then resuspended in DNase-free water for purity determination 
and quantification. 
 
 
2.9.2. Supply preparation 
 
Prepare supplies as shown in Table 2.9.1. 
 
Table 2.9.1 Supplies required for total RNA isolation and quantification 
 
Supply Catalogue Number Supply Catalogue Number 
1.5 ml EP tube - Pipette and pipette tip - 
Glovers - Fume hood - 
goggles - Distilled water - 
Centrifuge  - mixer - 
ice - container - 
chloroform Sigma 288306-100 ML isopropanol Sigma 19516-500 ML 
75% ethanol (in water) Sigma 51976-500 ML-F DNase-free water ThermoFisher 10977015 
NanoDrop Thermo Scientific Tube rack - 
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2.9.3. Total RNA isolation 
 
The following procedures are operated in a fume cupboard. Always use the appropriate 
precautions to avoid RNase contamination when preparing and handling RNA. 
 
Phase separation 
 
1. Incubate the frozen (-80°C) Trizol-dissolved cell sample (250 μl) for 5 min at room 
temperature to permit the complete dissociation of the nucleoprotein complex. 
2. Add 100 μl of chloroform into each of the samples. 
3. Shake the mixture of chloroform and sample vigorously for 15 min. 
4. Centrifuge the mixture at 14,000 rpm for 15 minutes at 4°C to create the three phases, the 
aqueous layer of which contains RNA. 
5. Transfer the aqueous layer to a new 1.5 ml tube by angling the tube at 45º and pipetting the 
solution out (approximately 50 – 100 μl). Avoid drawing any of the interphase or organic 
layer into the pipette when removing the aqueous layer. 
 
RNA precipitation 
 
1. Add 25 μl of isopropanol into each of the aqueous samples and vortex the mixture 
thoroughly. 
2. Stand the mixture for 10 min at room temperature. 
3. Centrifuge the mixture at 14,000 rpm for 10 min at 4°C to wash off any DNA contamination. 
4. Remove the supernatant to a new 1.5 ml tube. 
5. Add 225 μl of isopropanol into each of the supernatants and vortex the mixture thoroughly. 
The RNA is often invisible at this stage and forms a gel-like pellet on the side and bottom of 
the tube. 
6. Stand the mixture for 10 min at room temperature then centrifuge it at 14,000 rmp for 10 min 
at 4°C. 
7. Remove the supernatant from the tube, leaving only the RNA pellet. 
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RNA wash 
 
1. Add 100 μl of 75% ethanol onto the pellet and centrifuge the mixture at 14,000 rpm for 10 
min at 4°C. 
2. Remove the supernatant from the tube, and air dry the RNA pellet for 5-10 min. Do not allow 
the RNA to dry completely, because the pellet can lose solubility. 
 
RNA resuspension 
 
1. Dissolve the RNA pellet in 10 μl RNase-free water by passing the solution up and down 
several times through a pipette tip.  
2. Proceed to downstream applications, or store at -80°C. 
 
 
2.9.4. RNA quantification  
 
Making RNA measurement 
 
1. Bring the samples of isolated RNA to be quantified out of -80°C freezer and chill them in an 
ice-box. 
2. Select the Nucleic Acid application from the main menu of the analytic software of the 
NanoDrop spectrophotometer. If the wavelength verification window appears, ensure the arm 
is down and click OK. 
3. Select RNA-40 from the Type drop-down list and choose μg/μl as the concentration unit 
from the drop-down list adjacent to the color codes concentration box. 
4. Select Add to report to automatically include all measurements in the current report. The 
Add to report checkbox must be selected prior to a measurement to save the same data to a 
workbook. 
5. Select Overlay spectra to display multiple spectra at a time. 
6. Pipette 1μl of DNase water as blanking solution onto the bottom pedestal, lower the arm and 
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click the Blank button. The arm must be down for all measurements. 
7. Enter a Sample ID in the appropriate filed, load the first sample as described for the blank 
calibration above and click Measure. ~2.0 (the ratio of A260/280) is generally accepted as 
“pure” for RNA. Abnormal 260/280 ratios usually indicate that the sample is either 
contaminated by protein or a reagent such as phenol or that there was an issue with the 
measurement. A lower A260/A280 ratio may be caused by: residual phenol or other reagent 
associated with the RNA isolation protocol; a very low concentration (<10 ng/μl) of nucleic 
acid. Whereas a high 260/280 ratio indicates RNA degradation. In addition, the 260/230 
values for “pure” nucleic acid are commonly in the range of 2.0-2.2. 
 
After the measurement 
 
1. Simply wipe the upper and lower pedestals using a dry laboratory wipe and the instrument is 
ready to measure the next sample. 
2. Export the report as saving it as Report, Excel X ML Spreadsheet (*x ml) until the last 
sample has been measured, as shown in Figure 2.11. 
3. Print the report out and dilute part of the sample to 0.1 μg/μl according to its yield and purity 
(the volume of the diluted sample should be higher than 5 μl), then proceed to reverse 
transcription, or store the un-diluted and diluted samples in the -80°C freezer.
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Figure 2.11 A report exported by NanoDrop in Excel spreadsheet 
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2.10. Reverse transcription and qPCR 
 
2.10.1. Principle 
 
The RNA template is first converted into a cDNA (complementary DNA) using a reverse 
transcriptase. The cDNA is then used as a template for exponential amplification using TaqMan 
qPCR (quantitative real-time polymerase chain reaction) (379).  
 
The TaqMan probe consist of a fluorophore (FAM, 6-carboxy fluorescein) covalently attached to 
the 5’-end of the oligonucleotide probe and a quencher at the 3’-end (380). When the fluorophore 
and the quencher are in proximity, quenching inhibits any fluorescence signals (380). 
As Taq polymerase extends a specific set of primers and synthesizes nascent strands, the 5’ to 3’ 
exonuclease activity of the Taq polymerase degrades the probe that has annealed within the DNA 
region amplified by the set of primers. The degradation of probe releases the fluorophore from 
itself and breaks the close proximity to the quencher, thereby relieving the quenching effect and 
allowing the fluorescence emitted by the fluorophore when excited by the cycler’s light source 
via Förster Resonance Energy Transfer (381). 
 
Hence, the fluorescence detected in the quantitative PCR thermal cycler is directly proportional to 
the fluorophore released and the amount of cDNA template present in the qPCR. 
 
In addition, a good internal control (with consistent expression levels under experimental 
conditions) is critical in all quantitative analyses of gene expression, and serial analysis of gene 
expression on various human samples (brain, breast, colon, pancreas and prostate) has shown that 
PPIA (peptidylprolyl isomerase A) is a better internal control than β-actin or GAPDH (382) 
(Figure 2.12). 
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Figure 2.12 The consistent expression levels of PPIA 
(A) Chapter 3, (B) Chapter 4, (C) Chapter 5, (D) Chapter 6. Data are means ± SEM for groups of 
6. The results were determined using one-way ANOVA with Tukey’s post hoc test and confirmed 
by two independent experiments. 
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2.10.2. Supply preparation 
 
Prepare supplies as shown in Table 2.10.1, 2. 
 
Table 2.10.1 The sequences of primer sets and probes of the TaqMan assays 
 
Gene name Forward primer Reverse primer Probe 
PPIA ACGGCGAGCCCTTGG TTTCTGCTGTCTTTGGGACCT CGCGTCTCCTTTGAGCTGTTTGCA 
IL-1β CGGCCACATTTGGTTCTAAGA AGGGAAGCGGTTGCTCATC ACCCTCTGTCATTCG 
IL-6 CCTGAACCTTCCAAAGATGG ACCAGGCAAGTCTCCTCATT CCAGATTGGAAGCATCCATCTTTTTCA 
IL-8 TGAGAGTGGACCACACTGCG GCACCCAGTTTTCCTTGGGG CCAGACAGAGCTCTCTTCCATCAGAAAG 
MCP-1 CGCCTCCAGCATGAAAGTCT GGAATGAAGGTGGCTGCTATG TGCCGCCCTTCTGTGCCTGC 
RANTES TGCATCTGCCTCCCCATATT AGTGGGCGGGCAATGTAG CTCGGACACCACACCCTGCTGCT 
 
 
Table 2.10.2 Supplies required for reverse transcription and qPCR 
 
Supply Catalogue Number Supply Catalogue Number 
1.5 ml EP tubes - Pipette and pipette tip - 
Glovers - Fume hood - 
goggles - Distilled water - 
Centrifuge - Dnase-free water ThermoFisher 10977015 
ice - 0.2 ml PCR tube - 
96-wells PCR plate Star Lab l1402-9700 Sealing film Star Lab E2796-3020 
Timer - Universal tube - 
qPCR machine (Mx3000P) Agilent Technologies  PCR machine Bio-Rad T100 Thermo Cycler  
cDNA synthesis kit Bio-Rad #1708890EDU qPCR core kit Eurogentec RT-QP73-05 
IL-1β TaqMan assay Applied Biosystems IL-6 TaqMan assay Applied Biosystems 
IL-8 TaqMan assay Applied Biosystems MCP-1 TaqMan assay Applied Biosystems 
RANTES TaqMan assay Applied Biosystems PPIA TaqMan assay Applied Biosystems 
 
 
 
2.10.3. Reverse transcription  
 
1. Add the following to 0.2 ml tubes to make master mix shown in Table 2.10.3. 
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Table 2.10.3 Preparation of the master mix of for the reverse transcription 
 
Component Volume (n = samples) 
Dnase-free water 2.5 μl x n 
5X Buffer 2 μl x n 
iScript enzyme 0.5 μl x n 
Total volume 5 μl x n 
 
2. Add 0.5 μl of RNA sample (0.1 μg/μl) to the master mix to be reverse-transcribed. 
3. Add 0.5μl of Dnase-free water to set up the negative control. 
4. Vortex and pulse down the tubes containing the reaction mixture. 
5. Heat the tubes at 25°C for 5 min. 
6. Heat the tubes at 42°C for 30 min. 
7. Heat the tubes at 85°C for 5 min. 
8. Freeze the tubes at -20°C for storage, or proceed to qPCR. 
 
 
2.10.4. qPCR  
 
1. Add the following to a 1.5 ml tube to make master mix shown in Table 2.10.4. 
 
Table 2.10.4 Preparation of the master mix of for the qPCR assays 
 
Component Volume (n = samples) 
Dnase-free water 7.8125 μl x n 
10X Buffer 1.25 μl x n 
MgCl2 1.25 μl x n 
dNTP 0.5 μl x n 
20X TaqMan mix  
(probes and primers) 
0.625 μl x n 
GoldStar enzyme 0.0625 μl x n 
Total volume 11.5 μl x n 
 
2. Add the master mix to a 96-well PCR plate (one reaction per well) 
3. Add 1 μl of cDNA sample (in duplicate, including the negative control) to the master mix. 
4. Add 1 μl of Dnase-free water to set up the non-template control. 
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5. Seal the plate and pulse down. 
6. Load the plate into a PCR machine and start MxPro program using the thermo profile as 
95°C 10min; 95°C 15 sec, 60°C 1 min (40 cycles). 
7. After the PCR run, select Analysis on the top panel of the plate document page and choose 
the Analysis Selection/Setup page. 
8. Select the Results page to define the Threshold Value. Use Log View (Y-Axis) of the 
amplification plots. Place the threshold line above the background signal but in the half of 
the linear phase of the amplification plot, as shown in Figure 2.13. 
9. Select Text Report in Area to analyze to display the results including the Column for Well, 
Well type, Threshold, Ct for each well. Export the Text Report to Excel and save it as an 
Excel file. 
 
Data analysis 
 
1. All samples are normalized to the values of PPIA (internal control) (383) and the results are 
presented as fold changes of Ct value relative to controls using the 2−ΔΔct formula (384).  
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Figure 2.13 The log view (y-axis) of IL-1β amplification plot 
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2.11. BCA protein assay  
 
2.11.1. Principle 
 
The (bicinchoninic acid) BCA protein assay is a biochemical assay for determining the total 
concentration (0.5 μg/ml to 1.5 mg/ml) of protein in a sample (cell lysates in our studies). Firstly, 
the peptide bonds in protein reduce Cu2+ ions from the copper (II) sulfate to Cu+ (a temperature 
dependent reaction). The amount of Cu2+ reduced is proportional to the amount of protein present 
in the solution. Secondly, two molecules of bicinchoninic acid chelate with each Cu+ ion, forming 
a purple-colored complex that strongly absorbs light at a wavelength of 562 nm. The 
concentration of protein present in the sample can be quantified by measuring the absorption 
spectra and comparing with protein solutions of known concentration (385). 
 
 
2.11.2. General protocol 
 
1. Prepare supplies as shown in Table 2.11.1. 
 
Table 2.11.1 Supplies required for BCA protein assay 
 
Supply Catalogue Number Supply Catalogue Number 
BCA protein assay kit ThermoFisher 23227 Pipettes and pipette tips - 
Glovers - Fume hood - 
Dnase-free water ThermoFisher 10977015 1.5 ml tube - 
Centrifuge - mixer - 
Tube rack - container - 
Sealing film Star Lab E2796-3020 96-well microplate ThermoFisher 15045 
Microplate reader - Ice   
 
Preparation of standards  
 
1. Prepare a set of protein standards as shown in Table 2.11.2. Dilute the contents of one BSA 
(bovine serum albumin) ampoule (concentration: 2,000 µg/ml) into several clean vials (using 
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Dnase-free water as the diluent). 
 
Table2.11.2 The preparation of BSA standards 
 
Dilution Scheme (Working Range = 20-2,000 µg/ml) 
Vial Volume of diluent original (µl) Volume and source of BSA (µl) BSA concentration (µl) 
 
A 0 300 of Stock 2000 
B 125 375 of Stock 1500 
C 325 325 of Stock 1000 
D 175 175 of vial B dilution 750 
E 325 325 of vial C dilution 500 
F 325 325 of vial E dilution 250 
G 325 325 of vial F dilution 125 
H 400 100 of vial G dilution 25 
I 400 0 0 = Blank 
 
Preparation of the BCA WR (working reagent) 
 
1. Use the following formula to determine the total volume of WR required 
(# standards +  # unknowns) × (2) × (200 µl) = total volume WR required. 
2. Prepare WR by mixing 50 parts of BCA Reagent A with 1 part of BCA Reagent B. Note:  
When Reagent B is first added to Reagent A, turbidity is observed that quickly disappears 
upon mixing to yield a clear, green WR. Prepare sufficient volume of WR based on the 
number of samples to be assayed.  
 
Microplate procedure  
 
1. Pipette 10 µl of each standard or unknown sample replicate into a 96-well plate (working 
range = 125-2000 µg/ml)  
2. Add 200 µl of the WR to each well and mix the plate thoroughly on a plate shaker for 30 sec.  
3. Cover the plate and incubate it at 37°C for 30 min. 
4. Cool the plate to room temperature. Measure the absorbance at 562 nm on a spectrometer. 
5. Subtract the average 562 nm absorbance measurement of the Blank standard replicates from 
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the 562 nm measurements of all other individual standard and unknown sample replicates.  
6. Prepare a standard curve by plotting the average Blank-corrected 562 nm measurement for 
each BSA standard vs. its concentration in µg/ml. Use the standard curve to determine the 
protein concentration of each unknown sample. Note: linear curve-fitting is used to plot the 
standard curve, as shown in Figure 2.14. 
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Figure 2.14 The standard curve for BCA (linear fit curve) 
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2.12. Western blotting  
 
2.12.1. Principle 
 
Western blotting is a widely accepted analytical technique used to detect specific proteins in a 
given sample (denatured cell lysates in our studies). It could detect target protein which is as low 
as 1 ng due to the high resolution of gel electrophoresis and strong specificity and high sensitivity 
of immunoassay (386).  
 
Firstly, SDS-PAGE (sodium dodecyl sulfate–polyacrylamide gel electrophoresis) is applied to 
separate various proteins contained in the given sample by the length of the polypeptide. Secondly, 
the separated proteins are transferred onto a nitrocellulose membrane, where they are probed with 
the primary antibodies, and then the HRP-linked secondary antibodies. The binding between the 
primary and secondary antibodies emits a chemiluminescent signal (protein band) when reacting 
with an enhanced chemiluminescent substrate, which can be detected and measured by an X-ray 
scanner. By analyzing location and intensity of the signals, expression details of the target proteins 
in the given samples could be obtained (386).  
 
 
2.12.2. Supply preparation 
 
Prepare supplies as shown in Table 2.12.1. 
 
Table 2.12.1 Supplies required for western blotting 
 
Supply Catalogue Number Supply Catalogue Number 
Pipette and pipette tip - Universal tube - 
1.5 ml tube - Fume hood - 
gloves - Dnase-free water ThermoFisher 10977015 
Centrifuge  - mixer - 
Acrylamide kit Bio-Rad 1610173 10% APS (in water) Bio-Rad 1610700 
TEMED Bio-Rad 1610800 Short plate Bio-Rad 1653308 
1.5 mm spacer plate Bio-Rad 1653312 Casting stand and clamps Bio-Rad 1658050 
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Combs, 15-wells, 1.5 mm Bio-Rad 1653366 Electrophoresis cell Bio-Rad 1658004 
PowerPac Bio-Rad 1645050 Gel releaser Bio-Rad 1653320 
Transfer pack Bio-Rad 1704159 Roller Bio-Rad 1651279 
Transfer system Bio-Rad 1704150 Tweezers - 
Plastic containers - 500 ml bottles - 
Shaker - Paper towel - 
Protein marker Bio-Rad 1610374 Trizma base Sigma T1503-500G 
Tricine Sigma T0377-100G SDS Sigma L3771-100G 
HCl Sigma H1785-500 ML Glycerol Sigma G5516-100 ML 
Beta-mercaptoethanol Sigma 465348-5G Bromophenol Blue Sigma B0126-25G 
NaCl (sodium chloride) SigmaS3014-5KG Tween-20 Sigma P9416-50 ML 
BSA Sigma 2153-50G Chemiluminescent substrate Thermo scientific 2161465 
ChemiDoc - PH meter - 
Plastic wrap - 250 ml beaker - 
Seal bag - Marker - 
Heating block    
 
 
 
2.12.3. Preparation of gel  
 
1. Prepare resolving gel acrylamide solution by combining equal volumes of resolver A and B 
solutions in a clean tube (see Table 2.12.2).  
2. Hold Mini-PROTEAN plastic cassettes vertically for gel casting. Use a single-row AnyGel™ 
casting stand to stabilize the cassette during casting. For Bio-Rad handcast glass plates, use a 
Mini-PROTEAN Tetra cell casting stand to stabilize the plates during casting.  
3. Add the required volume of TEMED (tetramethylethylenediamine) and freshly made 10% 
APS (ammonium persulfate) to the combined resolver solution and mix well. Use 1 ml 
pipette tip to steadily dispense the solution into the cassette. Do not let bubbles form or 
solution mix with air. Fill the cassette to 0.5–1 cm below the bottom of the teeth of the comb. 
Immediately prepare and pour the stacking solution as directed in the next steps.  
4. Prepare stacking gel acrylamide solution by combining equal volumes of stacker A and B 
solutions in a clean tube (see Table 2.12.2).  
5. Add required volume of TEMED and freshly made 10% APS to the combined stacker 
solution and mix well. Pipette solution down the middle of the cassette, filling to the top of 
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the short plates. Apply slowly and steadily to prevent mixing with the resolving solution. 
Align and insert the comb in the cassette carefully to prevent air from being trapped under the 
comb teeth. Allow the gel to polymerize for 30–45 min before electrophoresis.  
 
Table2.12.2. Preparation of acrylamide gels 
 
 1.5 mm Bio-Rad glass plate (n = gels) 
 Stacker Resolver 
Resolver A - 4 ml x n 
Resolver B - 4 ml x n 
Stacker A 1.5 ml x n - 
Stacker B 1.5 ml x n - 
Total Volume 3 ml x n 8 ml x n 
   
TEMED 3 µl x n 4 µl x n 
10% APS 15 µl x n 40 µl x n 
 
 
 
2.12.4. Electrophoresis 
 
1. Prepare the buffers shown in table 2.12.3. 
 
Table 2.12.3 Preparation of the buffers for electrophoresis 
 
Type Recipe 
1 x Cathode buffer 100 mM Tris, 100 mM Tricine, 0.1% SDS 
1 x Anode buffer 100 mM Tris-HCl, pH 8.9 
5 x Sample loading buffer 5% SDS, 50% Glycerol, 0.1% Bromophenol blue, 
5% beta-mercaptoethanol, 250 mM Tris-HCl, pH 6.8 
 
2. Once the gel is finished polymerization, pluck the comb out carefully and take the glass 
plates (containing the gel) out of the stands. 
3. Place the glass plate into the electrode assembly to make an electrophoresis module. Top up 
the module (covering all the wells) with cathode buffer, and then load denatured samples 
(containing 1 x loading buffer, pre-heated at 100°C for 3 min) with equal amount (15-40 
μg/lane) into the wells. Load 10 μl of the ladder in the first and last well of each gel. 
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4. Carefully place the loaded module into the electrophoresis tank, and then fill the outside tank 
with anode buffer to the mark on the tank wall. Place the lid on the tank, and make sure to 
match up the black and red leads. 
5. Run the samples at 45 V for 30 min followed by 85 V till the samples have run to the bottom 
of the gel.  
6. Turn off the PowerPac and drain the module. Take the glass plates out of the module, then 
carefully pry the plates open and retrieve the gel. Immediately proceed to the Assembly 
procedure. 
 
 
2.12.5. Transfer procedure  
 
1. After gel electrophoresis, open the transfer pack and assemble the components on the cassette 
in order according to the instruction. Use a roller to remove any air trapped between layers. 
Two mini format gels should be placed on a Midi stack with the foot of each gel toward the 
center. 
2. Place the lid on the cassette and insert it into either bay of the instrument. Lock the cassette 
by turning the knob clockwise. The upper bay is designated as bay A and the lower is 
designated as bay B. If running 2 cassettes simultaneously, refer to Table 2.12.4 for 
acceptable transfer combinations. 
 
 
Table 2.12.4 Acceptable transfer combinations 
 
 Acceptable 
Combination 1 2 
Upper Bay A 1 mini gel 2 mini gel 
or 1 midi gel 
Lower Bay B 1 mini gel 2 mini gel 
or 1 midi gel 
 
3. Press Turbo and select the gel type. Press List to select the protocol shown in Table 2.12.5. 
Press A: Run or B: Run to start the transfer. 
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Table 2.12.5 Protocol for transfer 
 
Protocol name MW, kD Time, min 
1.5 MM Gel Any 10 
 
4. Pull the cassette straight out of slot (caution: maybe warm) when RUN COMPLETE is 
displayed on the screen. 
5. Disassemble the blotting sandwich and extract the membrane, which is ready for antibody 
probing or storage in plastic seal bag at -20°C. Discard the remaining transfer pack materials. 
 
 
2.12.6. Antibody detection  
 
Vinculin is the last antibody to be detected with each membrane. 
 
1. Prepare the buffers shown in Table 2.12.6. 
 
Table 2.12.6 Preparation of the buffers for antibody detection 
 
Type Recipe 
1 x Washing buffer 150 mM NaCl, 0.1% Tween 20, 20 mM Tris, pH 7.5 
1 x Blocking buffer 5% BSA (bovine serum albumin) in 1 x Washing Buffer 
1 x Stripping buffer 20 ml 10% SDS, 67.5 ml distilled water, 
0.8 ml Beta-mercaptoethanol, 12.5 ml 0.5M Tris-HCl, pH 6.8 
 
2. Place the membrane (the blotted side facing upwards always) in a clean plastic container with 
a pair of tweezers. Wash the membrane with 1 x washing buffer once then drain the container. 
3. Block the membrane with primary antibody (ratios shown in Table 2.12.7) in blocking buffer 
(5 ml/membrane) on a shaker overnight at 4°C. 
4. Wash the membrane in washing buffer 4 x 10 min on a shaker at room temperature. 
5. Incubate the membrane with secondary antibody (ratio shown in Table 2.12.8) in blocking 
buffer (5 ml/membrane) on a shaker for 1 h at room temperature. 
6. Wash the membrane in washing buffer 4 x 10 min on a shaker at room temperature. 
7. Develop the membrane in pre-mixed chemiluminescent substrate [(1 ml stable peroxide 
solution + 1 ml enhancer solution)/membrane] for 5 min. 
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Table 2.12.7 Primary antibodies for detection 
 
Antibody Catalog number Ratio 
Phosphorylated relA CST3033S 1:2000 
Methylated relA CST13188S 1:1000 
Phosphorylated ERK CST4377S 1:2000 
Phosphorylated p38 CST4511S 1:2000 
Phosphorylated eIF-2α CST3597S 1:1000 
XBP1 Abcam ab129002 2μg/ml 
Vinculin Abcam ab37152 1:10000 
 
 
Table 2.12.8 Secondary antibody for detection 
 
Antibody Catalogue number Ratio 
Anti-rabbit IgG (HRP-linked) CST7074S 1:2000 
 
 
2.12.7. Signal detection 
 
1. Wrap the membrane in clean plastic sheets and place it in the chamber of ChemiDoc. 
2. Select colormetric and switch to filter 1, capture the image with the ladder. 
3. Select chemi and switch to no filter, set the program (20 sec, 2000 sec, 100 image) then 
capture the image with the protein bands. 
4. Merge the colormetric and chemi image then measure pixel densities of the bands. 
5. For probing with another antibody, the membrane was incubated with 10 ml of stripping 
buffer for 10 min followed by washing with PBS and 1 x washing buffer at room temperature 
on a shaker. Vinculin was the last antibody being probed with each membrane. All samples 
are normalized to the values of vinculin [it is one of the major components for cell-cell and 
cell-cell-matrix junctions, and has been used as a loading control in studies regarding the 
anti-inflammatory effects of VDR agonists on THP-1-MacCM-stimulated human adipocytes 
(322, 354)]. 
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2.13. Statistical analysis  
 
Data was analyzed using GraphPad Prism 5 (GraphPad Software, USA). Results were presented 
as means ± SEM. The statistical tests used were one-way-ANOVA coupled with Tukey’s post hoc 
test. A value of P<0.05 is considered as statistically significant. 
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3. The effects of 1α,25(OH)2D3 on THP-1-MacCM-stimulated 
human white preadipocytes 
 
3.1. Introduction 
 
WAT consists of mature white adipocytes and a SVF including fibroblasts, endothelial cells, 
immune cells (i.e. macrophages) and preadipocytes (94). Accumulated energy storage in WAT 
leads to obesity, which could subsequently induce metaflammation characterized by infiltration of 
macrophages and secretion of pro-inflammatory factors, and further contribute to a series of 
metabolical disorders, importantly insulin resistance (76). SAT has a higher expandability 
compared with VAT, for it has a higher angiogenic growth capacity and therefore can more easily 
expand its capillary network (81). Enhanced subcutaneous lipids storage is mediated by 
stimulation of adipogenesis, rather than hypertrophy, which might protect against early 
manifestation of obesity-associated metabolic diseases. For example, MHO individuals are more 
insulin sensitive, and have smaller adipocytes in SAT, than those adipocytes of MAO individuals 
that may be able to expand more easily by proliferation (44). However, the protection is relative 
and when adipogenesis is impaired, hypertrophic SAT subsequently participates in the 
pathogenesis of obesity associated metabolic disorders (21, 84). In addition, in severely obese 
patients undergoing bariatric surgery, metaflammation is present in both visceral and subcutaneous 
tissues, as assessed by the presence of macrophage crown-like structures (88).   
 
It has long been known that macrophages play a key role in influencing the proliferation, survival 
and differentiation of preadipocytes (For the specific details, please refer to Introduction Page 
21-23). Several macrophage-secreted factors have been shown to contribute to the 
anti-differentiation/adipogenic ability of MacCM, especially IL-1β. For instance, the impaired 
differentiation was significantly associated with the up-regulated expression of IL-1β in the 
J774-MacCM-treated preadipocytes (144). The anti-adipogenic effect of human THP-1-MacCM 
on human adipose progenitor cells was exerted via IKKβ phosphorylation and activation of NF-κB, 
whereas the IKKβ inhibitor (sc-514) could totally abrogate the anti-adipogenic ability of 
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THP-1-MacCM to promote the differentiation of human preadipocytes (146).   
 
Vitamin D is a fat soluble secosteroid. It has been long proved that adipose tissue is the principal 
storage site for it and its metabolites, which are mainly encountered in lipid droplets of adipocytes 
(325). The major circulating form of vitamin D is 25(OH)D3, which is also used by clinicians to 
determine vitamin D status. Serum is the preferred initial test for assessing vitamin D status. 
Although most laboratories report the normal range to be 50 to 250 nM, the preferred range is 75 
to 150 nM (284). However, this form of vitamin D is biologically inactive and must be converted 
in the kidneys by 1-OHase to the most biologically active form - 1α,25(OH)2D3 (284). The 
reference value of 1α,25(OH)2D3 is: in males <16 years: 24-86 pg/ml (0.06-0.21 nM), > or =16 
years: 18-64 pg/ml (0.04-0.15 nM); in females <16 years: 24-86 pg/ml (0.06-0.21 nM), > or =16 
years: 18-78 pg/ml (0.04-0.19 nM) (387). Noteworthy, macrophages in all tissues are capable of 
expressing 1-hydroxylase and synthesizing 1α,25(OH)2D3 locally (285). Upon extracellular 
stimuli, 1α,25(OH)2D3 binds to VDR to modulate genomic response of numerous cells and tissues 
throughout the body in an endocrine, autocrine or paracrine manner (285).  
 
Several in vitro studies have demonstrated that 1α,25(OH)2D3 could exert an anti-inflammatory 
action on adipocytes. For instance, 1α,25(OH)2D3 (10-7 M) significantly reduced the release of 
IL-6 compared with the LPS-stimulated 3T3-L1 cells (24 h) (352). Similarly, 1α,25(OH)2D3 (10-7, 
-8 M) inhibited THP-1-MacCM induced expression of the inflammatory genes of MCP-1, IL-6 and 
IL-8 in human white adipocytes (24 h) (354). In addition, it has been demonstrated that the 
anti-inflammatory effects of 1α,25(OH)2D3 (10-8 M) were mediated by inhibition of the NF-κB and 
MAPK signaling pathways (24 h) (354). However, the anti-inflammatory effects of 1α,25(OH)2D3 
on human white subcutaneous preadipocytes remains to be characterized in detail. 
 
 
 
3.2. Aims 
 
The aim of the work described in this chapter was to investigate the anti-inflammatory effects of 
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1α,25(OH)2D3 on macrophage-stimulated inflammatory response in human white preadipocytes 
and the signaling pathways involved. A series of experiments were set up to examine whether:  
1. LPS could stimulate THP-1-macrophages to secrete a variety of cytokines, particularly 
pro-inflammatory factors;  
2. THP-1-MacCM could enhance the gene expression of IL-1β, IL-8, IL-6, MCP-1, and 
RANTES in human white preadipocytes;  
3. THP-1-MacCM could enhance the secretion of the pro-inflammatory factors from human 
white preadipocytes;  
4. IL-1β or IL-6 is critical in maintaining the inflammatory response induced by 
THP-1-MacCM;  
5. 1α,25(OH)2D3 could inhibit the secretion or gene expression of the pro-inflammatory factors 
in THP-1-MacCM-stimulated preadipocytes;  
6. THP-1-MacCM could increase the level of phosphorylated relA of the NF-κB pathway as 
well as phosphorylated ERK or p38 of the MAPK pathways in preadipocytes;  
7. 1α,25(OH)2D3 could also modulate the level of phosphorylated eIF-2α of the UPR pathway to 
exert the anti-inflammatory effects on THP-1-MacCM-stimulated preadipocytes. 
 
 
 
3.3. Materials and Methods 
 
Culture of human preadipocytes  
 
Preadipocytes were cultured in T25 flasks, and then sub-cultured into 12-well plates (seeding 
density: 5000 cells per cm2) in PGM (Table 2.5.2) (PromoCell, Germany), and incubated at 37 °C 
in 95% air and 5% CO2. The pretreatment was initiated when the sub-cultured preadipocytes 
reached 90% confluence. 
 
Generation of THP-1-MacCM (macrophage conditioned medium) 
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THP-1 monocytes were cultured in T75 flasks in MGM (Table 2.2.2) (Sigma-Aldrich, UK), and 
incubated at 37 °C in 95% air and 5% CO2. When the monocytes density reached 1×106 cells/ml 
(optimal), the differentiation to macrophages was inducted by 100 nM PMA (Sigma-Aldrich, UK) 
in MGM for 48 h. Then the THP-1-macrophages were activated by 1 μg/ml LPS and 1mM ATP 
(Sigma-Aldrich, UK) in MM (Table 2.2.2) for a further 24 h before medium collection. The 
THP-1-MacCM was filtered through a 0.22 μm filter and stored at −80 °C for preadipocyte 
treatment. 
 
Preadipocyte pretreatment and treatment  
 
To investigate effects of 1α,25(OH)2D3 on THP-1-MacCM-stimulated preadipocytes, 
preadipocytes were either cultured alone (control); with (25%) THP-1-MacCM alone [the 
established protocol (355)], or in the presence of IL-1β neutralizing antibody (15 μg/ml, R&D 
Systems) [the established protocol (355)] or IL-6 neutralizing antibody (300 ng/ml, R&D Systems) 
(established by the preliminary work, and the data shown in Appendix 9.2, 3) for 24 h. Further 
groups of cells were pretreated with 1α,25(OH)2D3 (0.01-10 nM, ENZO Life Sciences, USA) for 
24 h [the established protocol (354, 355)], followed by treatments with (25%) THP-1-MacCM and 
1α,25(OH)2D3 (0.01-10 nM) for a further 24 h [the established protocol (354, 355)] at 37 °C in 95% 
air and 5% CO2. When the experiment was completed, cell media were collected for cytokine 
array and ELISA; preadipocytes were lysed with Trizol for qPCR or lysed with a lysis buffer for 
western blotting. All samples were stored at -80 °C. 
 
Cytokine array  
 
Secreted cytokines from the treated-preadipocytes or THP-1-macrophages were screened using 
Human Cytokine Array Panel A (R&D Systems) following the manufacturer’s instructions. Before 
the assays, 100 μl of each of the collected media from the treated-preadipocytes were pooled (n = 
6, per group) as the samples to be measured. In addition, 600 μl of (25%) THP-1-MacCM was 
directly applied unto the array to be screened for cytokines secreted by THP-1-macrophages. The 
cytokine signals were captured by Molecular Imager ChemiDoc XRS+ System (Bio-Rad, 
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Hertfordshire, UK), and the results were presented as pixel density relative to the reference 
controls on the arrays.  
 
ELISA 
 
The secretion levels of pro-inflammatory factors including IL-1β, IL-6, IL-8, MCP-1 and 
RANTES were measured using human ELISA kits (R&D Systems, UK) following the 
manufacturer’s instructions and SPECTROstar Nano Microplate Reader (BMG LABTECH, 
Germany). According to the results obtained from the preliminary assays, the collected media 
from the treated-preadipocytes needed to be diluted properly before applying to these ELISAs. 
The ELISA result was corrected for total cell protein content [which was measured by Thermo 
Scientific Pierce BCA Protein Assay Kit) and presented pg(cytokine)/μg(cell protein)].   
 
Real-time PCR  
 
The treated-preadipocytes were rinsed twice in ice-cold PBS, lysed with Trizol and stored at -80°C 
(Invitrogen, UK). The total RNA was subsequently precipitated from the lysates with isopropanol 
(Sigma-Aldrich, UK) and re-dissolved in UltraPureDNase/RNase-Free Distilled Water (Thermo 
Scientific, UK). The RNA concentration was measured by NanoDrop 2000 and the purity was 
determined by ratio of absorbance at 260 and 280 nm (Thermo Scientific, UK). The first-strand 
cDNA was synthesized from 0.5μg of the total RNA with iScript cDNA synthesis kit (Bio-Rad, 
UK) in a final volume of 10 μl (per reaction). Real-time quantitative PCR was performed with a 
Stratagene Mx3005P instrument system. The gene expression levels of pro-inflammatory factors 
including IL-1β, IL-6, IL-8, MCP-1, RANTES and internal reference PPIA were measured using 
TaqMan gene expression assays (Applied Biosystems, UK) and qPCR core kit (Eurogentec, 
Seraing, Belgium). Each TaqMan reaction contained 10 ng of sample cDNA in a total volume of 
12.5 μl (per reaction). The assays were performed in duplicate and the thermo cycling program 
was set as follows: 95 °C for 10 min followed by 40 cycles (95 °C for 15 sec, 60°C for 1 min). 
Blank controls without cDNA were run in parallel. All samples were normalized to the values of 
PPIA and the results were presented as fold changes of Ct value relative to controls using the 
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2−ΔΔct formula (384). 
 
Western blotting  
 
The treated-preadipocytes were rinsed twice in ice-cold PBS and scraped into a freshly prepared 
lysis buffer [50 mM Tris-HCl pH 6.7, 10% Glycerol, 4% SDS protease inhibitor cocktail, 
phosphatase inhibitor cocktail (Sigma-Aldrich, UK)]. The concentration of the lysate (protein) 
were measured by Thermo Scientific Pierce BCA Protein Assay Kit and stored at -80°C. Equal 
amounts of the protein samples (20-30 μg/lane) were separated by SDS-PAGE (Mini Protean Tetra, 
TGX FastCast premixed acrylamide solutions, Bio-Rad, UK), and transferred to nitrocellulose 
membranes (Trans-Blot Turbo Midi Nitrocellulose Transfer Packs, Bio-Rad, UK) by Trans-Blot 
Turbo Transfer System (Bio-Rad, UK) for 10 min (protocol name: 1.5mm gel). For 
immunodetection, the membranes were respectively blocked for 1 h at room temperature with the 
blocking buffer [TBS, 0.1% Tween 20, 5% BSA (Sigma-Aldrich, UK)], firstly incubated overnight 
in the blocking buffer at 4 °C with primary antibodies including phosphorylated relA of the NF-κB 
signaling pathway, phosphorylated ERK, phosphorylated p38 of the MAPK signaling pathways 
(New England BioLab, UK) at 1:2000 dilution; phosphorylated (eukaryotic translation initiation 
factor) eIF-2α in the PERK induced arm of the UPR (New England BioLab, UK) at 1:1000 
dilution, and then with a secondary anti-rabbit antibody (New England BioLab, UK) at 1:2000 
dilution. Eventually the membranes were probed with vinculin antibody (Abcam, UK) as a 
loading control. The signals were stained by chemiluminescence (West Pico kit, Pierce, 
Loughborough, UK), captured and measured by Molecular Imager ChemiDoc XRS+ System 
(Bio-Rad). The molecular weight of the detected signaling bands was estimated with PageRuler 
protein markers (Thermo Scientific, UK).  
 
Statistical analysis  
 
Results are presented as means ± SEM. For statistical analysis, one-way-ANOVA coupled with 
Tukey’s post hoc test for independent samples was used. A value of P<0.05 was regarded as 
statistically significant. The analysis and presentation were performed using Prism 5 (GraphPad, 
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USA). 
 
 
3.4. Results 
 
3.4.1. LPS-stimulated THP-1-macrophages secrete a variety of cytokines  
 
In the initial experiments, cytokines released from LPS-stimulated THP-1 macrophages were 
screened by cytokine array (Figure 3.1, Appendix 9.1). Several pro-inflammatory factors were 
secreted including GRO-α, RANTES (chemoattractants), IL-8 and slCAM-1 (mainly expressed by 
neutrophils). 
 
 
3.4.2. THP-1-MacCM enhances cytokine secretion from human preadipocytes, but IL-1β 
antibody partially blocks the pro-inflammatory effects  
 
A variety of pro-inflammatory factors were secreted including IL-6, IL-8, MCP-1 and RANTES 
from (25%) THP-1-MacCM-stimulated preadipocytes, but the levels of these cytokines were 
discernibly reduced by IL-1β antibody (15 μg/ml) (Figure 3.1, Appendix 9.1). 
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Figure 3.1 Effects of THP-1-MacCM on cytokine release from human white preadipocytes. 
(A) Cytokines [in (25%) THP-1-MacCM] secreted from THP-1-macrophages were screened by 
cytokine array. Preadipocytes were either cultured alone, with (25%) THP-1-MacCM alone, or in 
the presence of IL-1β neutralizing antibody (15 μg/ml) for 24 h. Cytokines released from (B) 
control, (C) (25%) THP-1-MacCM, (D) IL-1β neutralizing antibody (15 μg/ml) were screened by 
cytokine array. Data are presented as pixel density relative to the reference controls on the arrays. 
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3.4.3. THP-1-MacCM enhances the secretion of the pro-inflammatory factors from human 
preadipocytes 
 
According to the result on the cytokine array, the pro-inflammatory factors including IL-6, IL-8, 
MCP-1 and RANTES were selected as indicators of the inflammatory response (metaflammation) 
of preadipocytes induced by (25%) THP-1-MacCM; IL-1β was also included (though having not 
included in the cytokine array, it was later confirmed by ELISA that the concentration of IL-1β 
was approximately 2 ng/ml in THP-1-MacCM). 
 
The ELISA result (Figure 3.2) shows that the secretion levels of these pro-inflammatory factors 
were dramatically increased by (25%) THP-1-MacCM.  
 
 
3.4.4. IL-1β and IL-6 neutralization inhibit the secretion of the pro-inflammatory factors 
from THP-1-MacCM-stimulated preadipocytes  
 
The ELISA result (Figure 3.2) shows that IL-1β antibody (15 μg/ml) markedly reduced the 
secretion levels of IL-1β, IL-6 and IL-8 of (25%) THP-1-MacCM-stimulated preadipocytes, but it 
did not reduce the secretion levels of MCP-1 and RANTES.   
 
In parallel, the presence of IL-6 antibody (300 ng/ml) exhibited a broader range of blocking 
effects, since the secretion levels of IL-6, IL-8, MCP-1 and RANTES of (25%) 
THP-1-MacCM-stimulated preadipocytes were all moderately reduced, but the effects are still 
partial, as the secretion level of IL-1β was not affected. 
 
 
3.4.5. 1α,25(OH)2D3 inhibits the secretion of the pro-inflammatory factors from 
THP-1-MacCM-stimulated preadipocytes  
 
The effects of 1α,25(OH)2D3 on the cytokine secretion from (25%) THP-1-MacCM-stimulated 
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preadipocytes are quite complex (Figure 3.2). Firstly, 1α,25(OH)2D3 (0.01-10 nM) has no effect of 
the secretion levels of IL-1β and MCP-1. Secondly, the secretion levels of IL-6, IL-8 and 
RANTES were universally reduced by 1α,25(OH)2D3 (0.01-10 nM), though some of reductions 
did not reach the statistical significance. For instance, the level of IL-8 and RANTES by 0.01 nM 
of 1α,25(OH)2D3, the level of IL-6 and RANTES by 0.1 nM of 1α,25(OH)2D3, and IL-8 level by 1 
nM of 1α,25(OH)2D3. Finally, only 10 nM of 1α,25(OH)2D3 significantly reduced the secretion of 
MCP-1. In conclusion, 1α,25(OH)2D3 has an anti-inflammatory effect on 
THP-1-MacCM-stimulated preadipocytes, in terms of reducing the secretion levels of some 
pro-inflammatory cytokines. However, there is no straightforward dose-response relationship 
between the secretion levels of the cytokines and the doses of 1α,25(OH)2D3 used in these 
experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
118 
 
Figure 3.2 Effects of 1α,25(OH)2D3 on cytokine release from THP-1-MacCM-stimulated 
human white preadipocytes.  
Preadipocytes were either cultured alone (control), with (25%) THP-1-MacCM alone, or in the 
presence of IL-1β neutralizing antibody (15 μg/ml) for 24 h. Further groups of cells were 
pretreated with 1α,25(OH)2D3 (0.01-10 nM) for 24 h, followed by treatments with (25%) 
THP-1-MacCM and 1α,25(OH)2D3 (0.01-10 nM) for a further 24 h before medium collection. The 
release levels of pro-inflammatory factors (A) IL-1β, (B) IL-6, (C) IL-8, (D) MCP-1 and (E) 
RANTES were measured by ELISA and normalized by protein content in the cellular lysate. Data 
are means ± SEM for groups of 6. A significant difference to control was indicated by 
***(p<0.001); to (25%) THP-1-MacCM by #(p<0.05), ##(p<0.01), ###(p<0.001). The results 
were determined using one-way ANOVA with Tukey’s post hoc test and confirmed by two 
independent experiments. 
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3.4.6. THP-1-MacCM enhances the gene expression of the pro-inflammatory factors in 
human preadipocytes 
 
Similar to the secretion levels, the qPCR result (Figure 3.3) shows that the mRNA levels of the 
pro-inflammatory factors including IL-1β, IL-6, IL-8, MCP-1 and RANTES, were massively 
increased by (25%) THP-1-MacCM. 
 
 
3.4.7. IL-1β and IL-6 neutralization inhibit the gene expression of the pro-inflammatory 
factors in THP-1-MacCM-stimulated preadipocytes  
 
(Figure 3.3) IL-1β (15 μg/ml) and IL-6 (300 ng/ml) antibodies also exhibited distinguishable 
blocking effects on the mRNA levels of IL-1β, IL-6 and IL-8 in (25%) THP-1-MacCM-stimulated 
preadipocytes. However, the effects are partial, for the levels of MCP-1 are not significant. In 
addition, though IL-6 antibody markedly decreased the mRNA level of RANTES, whilst IL-1β 
antibody had no statistically significant effect.  
 
 
3.4.8. 1α,25(OH)2D3 inhibits the gene expression of the pro-inflammatory factors in 
THP-1-MacCM-stimulated preadipocytes  
 
As with the effects on cytokine secretion, the effects of 1α,25(OH)2D3 on the mRNA levels of 
(25%) THP-1-MacCM-stimulated preadipocytes are also complicated (Figure 3.3). Firstly, 
1α,25(OH)2D3 (0.01-10 nM) treatment was associated with lower mRNA levels of IL-1β and 
RANTES, and these reducing effects were similar across the range of doses. Secondly, the mRNA 
levels of IL-6 and IL-8 were only significantly reduced by 1α,25(OH)2D3 (1-10 nM). Finally, 
1α,25(OH)2D3 (0.01-10 nM) had no effect on the mRNA levels of RANTES. Taken together, 
1α,25(OH)2D3 has an anti-inflammatory effect on THP-1-MacCM-stimulated preadipocytes, with 
respect to reducing the mRNA levels of IL-1β, IL-6, IL-8 and RANTES. However, there is no 
consistent dose-response relationship between the mRNA levels of these pro-inflammatory factors 
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and the doses of 1α,25(OH)2D3 used in these experiments.  
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Figure 3.3 Effects of 1α,25(OH)2D3 on cytokine gene expression in 
THP-1-MacCM-stimulated human white preadipocytes. 
Preadipocytes were either cultured alone (control), with (25%) THP-1-MacCM alone, or in the 
presence of IL-1β neutralizing antibody (15 μg/ml) or IL-6 neutralizing antibody (300 ng/ml) for 
24 h. Further groups of cells were pretreated with 1α,25(OH)2D3 (0.01-10 nM) for 24 h, followed 
by treatments with (25%) THP-1-MacCM and 1α,25(OH)2D3 (0.01-10 nM) for a further 24 h 
before Trizol-dissolved lysate collection. The mRNA levels of pro-inflammatory factors (A) IL-1β, 
(B) IL-6, (C) IL-8, (D) MCP-1 and (E) RANTES were measured by qPCR. Data are means ± 
SEM for groups of 6. A significant difference to control was indicated by ***(p<0.001); to (25%) 
THP-1-MacCM by #(p<0.05), ##(p<0.01), ###(p<0.001). The results were determined using 
one-way ANOVA with Tukey’s post hoc test and confirmed by two independent experiments. 
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3.4.9. THP-1-MacCM increases the level of phosphorylated relA in human preadipocytes 
 
To test whether THP-1-MacCM could modulate the NF-κB pathway, the level of phosphorylated 
relA was measured by western blotting. The result (Figure 3.4) shows that the level of 
phosphorylated relA was markedly higher in the presence of (25%) THP-1-MacCM, compared to 
the untreated preadipocytes.  
 
 
3.4.10. IL-1β neutralization reduces the level of phosphorylated relA in 
THP-1-MacCM-stimulated preadipocytes  
 
By contrast, (Figure 3.4) IL-1β antibody (15 μg/ml) was associated with moderately lower 
phosphorylated relA in (25%) THP-1-MacCM-stimulated preadipocytes. 
 
 
3.4.11. 1α,25(OH)2D3 (10 nM) reduces the levels of phosphorylated relA in  
THP-1-MacCM-stimulated preadipocytes 
 
Only 1α,25(OH)2D3 (10 nM) discernibly reduced the level of phosphorylated relA of (25%) 
THP-1-MacCM-stimulated preadipocytes, while the other doses (0.01-1 nM) had no effect on the 
levels of phosphorylated relA (Figure 3.4).  
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Figure 3.4 Effects of 1α,25(OH)2D3 on phosphorylated relA in THP-1-MacCM-stimulated 
human white preadipocytes.  
Preadipocytes were either cultured alone (control), with (25%) THP-1-MacCM alone, or in the 
presence of IL-1β neutralizing antibody (15 μg/ml) for 24 h. Further groups of cells were 
pretreated with 1α,25(OH)2D3 (0.01-10 nM) for 24 h, followed by treatments with (25%) 
THP-1-MacCM and 1α,25(OH)2D3 (0.01-10 nM) for a further 24 h before lysate collection. The 
levels of phosphorylated relA of the NF-κB signaling pathway were measured by western blotting. 
Data are means ± SEM for groups of 3. A significant difference to control was indicated by 
***(p<0.001); to (25%) THP-1-MacCM by #(p<0.05). The results were determined using 
one-way ANOVA with Tukey’s post hoc test and confirmed by two independent experiments. 
 
 
 
 
 
 
126 
 
3.4.12. THP-1-MacCM increases the levels of phosphorylated ERK and p38 in human 
preadipocytes 
 
Like that of phosphorylated relA, (Figure 3.5) the levels of phosphorylated ERK (p44/42) and p38 
of the MAPK signaling pathways were significantly increased by (25%) THP-1-MacCM. 
However, IL-1β antibody (15 μg/ml) did not affect the levels of these signaling molecules in (25%) 
THP-1-MacCM-stimulated preadipocytes.    
 
 
3.4.13. 1α,25(OH)2D3 (10 nM) reduces the level of phosphorylated ERK in  
THP-1-MacCM-stimulated preadipocytes 
 
Only 1α,25(OH)2D3 (10 nM) moderately reduced the level of phosphorylated ERK of (25%) 
THP-1-MacCM-stimulated preadipocytes, while the other doses (0.01-1 nM) had no effect on the 
levels of phosphorylated ERK or p38; [1α,25(OH)2D3 (10 nM) had no effect on the level of p38, 
either] (Figure 3.5).  
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Figure 3.5 Effects of 1α,25(OH)2D3 on signaling molecules of the MAPK pathways in 
THP-1-MacCM-stimulated human white preadipocytes.  
Preadipocytes were either cultured alone (control), with (25%) THP-1-MacCM alone, or in the 
presence of IL-1β neutralizing antibody (15 μg/ml) for 24 h. Further groups of cells were 
pretreated with 1α,25(OH)2D3 (0.01-10 nM) for 24 h, followed by treatments with (25%) 
THP-1-MacCM and 1α,25(OH)2D3 (0.01-10 nM) for a further 24 h before lysate collection. The 
levels of (A) phosphorylated ERK and (B) phosphorylated p38 were measured by western blotting. 
Data are means ± SEM for groups of 3. A significant difference to control was indicated by 
***(p<0.001); to (25%) THP-1-MacCM by ###(p<0.001). The results were determined using 
one-way ANOVA with Tukey’s post hoc test and confirmed by two independent experiments. 
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3.4.14. THP-1-MacCM increases the level of phosphorylated eIF-2α in human 
preadipocytes 
 
To test whether THP-1-MacCM could modulate the UPR pathway, the expression levels of 
phosphorylated eIF-2α were measured by western blotting. The results (Figure 3.6-8) shows that 
the levels of phosphorylated eIF-2α were markedly increased by (25%) THP-1-MacCM, compared 
to the untreated preadipocytes.  
 
 
3.4.15. IL-1β neutralization reduces the level of phosphorylated eIF-2α in 
THP-1-MacCM-stimulated preadipocytes  
 
(Figure 3.6-8) IL-1β antibody (15 μg/ml) moderately reduced the levels of phosphorylated eIF-2α 
in (25%) THP-1-MacCM-stimulated preadipocytes. 
 
 
3.4.16. 1α,25(OH)2D3 reduces the expression of phosphorylated eIF-2α in 
THP-1-MacCM-stimulated preadipocytes 
 
(Figure 3.6-8) 1α,25(OH)2D3 (0.01-10 nM) universally reduced the levels of phosphorylated 
eIF-2α in (25%) THP-1-MacCM-stimulated preadipocytes, and the reducing effects are similar 
across the range of doses.   
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Figure 3.6-8 Effects of 1α,25(OH)2D3 on phosphorylated eIF-2α in 
THP-1-MacCM-stimulated human white preadipocytes.  
Preadipocytes were either cultured alone (control), with (25%) THP-1-MacCM alone, or in the 
presence of IL-1β neutralizing antibody (15 μg/ml) for 24 h. Further groups of cells were 
pretreated with 1α,25(OH)2D3 (0.01-10 nM) for 24 h, followed by treatments with (25%) 
THP-1-MacCM and 1α,25(OH)2D3 (0.01-10 nM) for a further 24 h before lysate collection. The 
levels of phosphorylated eIF-2α in the PERK induced arm of the UPR signaling pathways were 
measured by western blotting. Data are means ± SEM for groups of 3. A significant difference to 
control was indicated by ***(p<0.001); to (25%) THP-1-MacCM by #(p<0.05), ##(p<0.01), 
###(p<0.001). The results were determined using one-way ANOVA with Tukey’s post hoc test. 
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3.5. Discussion 
 
According to the results of the cytokine array in our study, several pro-inflammatory factors 
secreted including GRO-α, RANTES, IL-8 and slCAM-1, were secreted from LPS-stimulated 
THP-1-macrophages. Though having not been screened out by cytokine array, it was later 
measured by ELISA that the concentration of IL-1β of THP-1-MacCM was 2 ng/ml. It has been 
reported that microbial products (i.e. LPS and other TLR ligands) or pro-inflammatory cytokines 
(i.e. IFN-γ and TNF) could stimulate classic M1 macrophages to produce many pro-inflammatory 
cytokines including TNF-α, IL-1, IL-6, IL-12, Type I IFN, CXCL1-3, CXCL-5 and CXCL-8-10 
(235, 237).  
 
In the obese condition, infiltrated macrophages can make up to 40% of all cells of adipose tissue, 
compared with 10% in the lean controls (21). Interestingly, pre/adipocyte and 
monocyte/macrophage lineages display many features in common. Moreover, 3T3-L1 
preadipocyte cell line rapidly and massively acquired high phagocytic activity, and 60-70% of 
preadipocytes expressed five macrophage-specific antigens: F4/80, Mac-1, CD80, CD86 and 
CD45, after having been injected into the peritoneal cavity of nude mice (135). Noteworthy, 
mouse adipocytes are sensitive to LPS activation and by which could secrete numerous 
pro-inflammatory factors (such as IL-6) (134). Obesity is also tightly associated with elevated 
serum levels of FFAs, cholesterol, and especially LPS (242). Hence, the hypothesis that whether 
metaflammation could be aggravated by the interaction of preadipocytes and macrophages was 
formed, and was to be tested by in vitro model of treating human white preadipocytes with 
THP-MacCM (collected from LPS-stimulated macrophages) for 24 h. Several cytokines including 
IL-1β, IL-6, IL-8, MCP-1 and RANTES were selected as indicators of the macrophage-induced 
inflammatory response of preadipocytes.  
 
It has been demonstrated that adipose tissue can secrete the chemokine IL-8, which predominantly 
attracts neutrophils (30). Furthermore, the number of infiltrated neutrophils in the VAT of mice 
transiently increased at 3 and 7 days after initiating HFD feeding (31). Therefore, IL-8 is a 
potential contributor to metaflammation in obesity. Moreover, MCP-1 secretion by hypertrophic 
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adipocytes is responsible for macrophage infiltration in WAT of obese rodents and humans (185). 
CCR-5 also plays a critical role in the regulation of obesity-induced inflammatory response and 
insulin resistance in WAT, as recent studies have shown that the expression level of CCR-5 was 
positively correlated with the number of infiltrated macrophage in the WAT of morbidly obese 
individuals (194). In accordance with the evidence above, the results of qPCR and ELISA show 
that the gene expression and secretion levels of these pro-inflammatory factors were significantly 
enhanced by THP-1-MacCM compared to the untreated control. 
 
It has been reported that the expression level of activated IL-1β was significantly enhanced in the 
VAT and SAT of the overweight subjects (161). Similarly, the gene expression and secretion of 
IL-1β by preadipocytes was significantly enhanced by THP-1-MacCM in the present study. 
However, whether IL-1β is pivotal in mediating the macrophage-induced inflammatory response 
in preadipocytes remains to be clarified. By treating preadipocytes with IL-1β antibody (15 μg/ml) 
and (25%) THP-1-MacCM, the results show that the gene expression and secretion levels of IL-1β, 
IL-6 and IL-8 were all significantly reduced by IL-1β neutralization. The levels of MCP-1 and 
RANTES were also numerically lower but not significantly different compared with the untreated 
control.  
 
An interesting observation of the current study is that IL-6 could play a role in mediating 
macrophage-induced inflammatory response in preadipocytes. Like IL-1β, IL-6 is likely to be 
essential in mediating pro-inflammatory signaling in adipose tissue. Firstly, the plasma level of 
IL-6 is almost exclusively determined by whole-body adiposity. Secondly, IL-6 is closely 
associated with obesity induced abnormal metabolism, particularly metaflammation (175). Thirdly, 
in human hepatocytes, IL-6 has been found to stimulate the synthesis of CRP (one of the strongest 
indicators of metabolic risk), which was measured by immunoprecipitation (176). The present 
study has demonstrated that the gene expression and secretion levels of IL-6 and IL-8 were 
inhibited by IL-6 neutralizing antibody (300 ng/ml). Interestingly, the gene expression level of 
IL-1β was also significantly inhibited by IL-6 neutralization, though the secretion was not.  
 
In obesity, TNF-α together with FFA, can stimulate the conversion of fatty-acyl-CoA to DAG and 
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ceramides, thereby activating serine/threonine kinases including MAPK family members (i.e. JNK 
and ERK), IKK, mTOR, and PKCs in adipose tissue, liver and skeletal muscle, to trigger 
inflammation and insulin resistance (6, 66). The levels of phosphorylated relA, phosphorylated 
ERK and p38 were all significantly enhanced by THP-1-MacCM compared to the untreated 
control, which suggests that the pro-inflammatory factors secreted by macrophages induce 
metaflammation in preadipocytes by activating the NF-κB and MAPK signaling pathways. 
Noteworthy, preadipocytes were treated with (25%) MacCM for 24 h and this duration is too long 
for measurement of IκBa protein due to its complex kinetics. In addition, the interpretation of 
IκBa levels in this experiment is redundant, as phosphorylated relA alone can be taken as the 
indicator of NF-κB activation in this experiment. However, the effects of (25%) MacCM or in the 
presence 1α,25(OH)2D3 (0.01-10 nM) on the levels of IκBa in human preadipocytes, could be 
studied by undertaking a time-course analysis of western blotting. For example, the levels of IκBa 
were measured in 2, 5 and 10 min after the stimulation.  
 
It has been shown that 1α,25(OH)2D3 (10-7, -8 M) has anti-inflammatory effects on LPS-stimulated 
3T3-L1 adipocytes or THP-1-MacCM-stimulated human adipocytes (352, 354). Likewise, the data 
from our study suggest that 1α,25(OH)2D3 has an inhibitory effect on THP-macrophage-induced 
production of the major pro-inflammatory factors from human preadipocytes. This is 
demonstrated by the significant reduction in THP-1-MacCM-triggered gene expression of IL-1β, 
IL-6, IL-8 and RANTES in preadipocytes treated with 1α,25(OH)2D3 (1, 10 nM). In parallel, the 
secretion levels of IL-6, IL-8, MCP-1 and RANTES were also significantly inhibited by 
1α,25(OH)2D3 (10 nM). Importantly, 1α,25(OH)2D3 (10 nM) had the most potent 
anti-inflammatory effect compared the other doses (0.01-1 nM). However, there was no obvious 
dose-response relationship between 1α,25(OH)2D3 and the gene expression or secretion of the 
pro-inflammatory factors. This is probably because the anti-inflammatory effects of 1α,25(OH)2D3 
could be exerted on THP-1-MacCM (IL-1β in Chapter 4 and 5)-stimulated preadipocytes in single 
or multiple manners (e.g. directly inhibiting the gene expression of the pro-inflammatory factors, 
genomically or non-genomically blocking inflammatory signaling, increasing eIF-2α of the UPR 
pathway to abate the translation of the pro-inflammatory factors), the same reason is applied in the 
late chapters.  
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The current study has also shown that the NF-κB, MAPK and UPR signaling pathways are 
involved in the anti-inflammatory action of 1α,25(OH)2D3 in preadipocytes. It has been reported 
that the VDR transcriptional complex can modulate the expression of vitamin D-responsive genes. 
These genes include the cytokines such as IL-2, IL-12, TNF-α, IFN-γ, GM-CSF, which are critical 
in modulating inflammatory response in tissue (307-310). Though, we didn’t test whether the 
regulatory sequence of those pro-inflammatory factor encoding genes were among VDREs, there’s 
a possibility that 1α,25(OH)2D3-VDR transcriptional complex could bind to the regulatory regions 
(i.e. inhibitor) of IL-1β, IL-6, IL-8 and RANTES, since the results showed that 1α,25(OH)2D3 
significantly reduced the gene expression levels of these cytokines. Further assays of chromatin 
immunoprecipitation could be conducted to investigate that whether the VDR (transcription 
complex) binds to the regulatory regions of these pro-inflammatory factors. Moreover, 
VDR-1α,25(OH)2D3 complex could directly inhibit the expression of some genes by antagonizing 
the action of certain transcription factors (e.g.NF-AT and NF-κB) (297, 298). The results also 
show that 1α,25(OH)2D3 (10 nM) significantly reduced the expression levels of phosphorylated 
relA compared to THP-1-MacCM treated preadipocytes. In addition, it has been shown that relA 
binds to the promoters of IL-6 and IL-1β, thereby up-regulating the gene transcription (388, 389) 
Further assays of protein complex immunoprecipitation and chromatin immunoprecipitation could 
be applied to demonstrate that whether the VDR (transcription complex) binds to phosphorylated 
relA and the promoter regions of these pro-inflammatory factors. Taken together, 1α,25(OH)2D3 
inhibits the gene expression of the pro-inflammatory factors probably by: directly attenuating the 
transcription by VDRE binding; or blocking the transcription factor relA (NF-κB p65) and 
attenuating its post translational modification (phosphorylation in this case), thus to indirectly 
inhibit the gene expression. 
 
Besides the genomic effect of 1α,25(OH)2D3, it has been recognized that by binding VDR on the 
plasma membrane, 1α,25(OH)2D3 can exert non-genomic actions and the signaling molecules 
involved include protein kinases, especially MAPKs (311). Moreover, it has been demonstrated 
that 1α,25(OH)2D3 (10-8 M) reduced the levels of phosphorylated ERK and p38 of the MAPK 
signaling pathways in THP-1-MacCM-stimulated human white subcutaneous adipocytes (24 h) 
(354). Therefore, the levels of these two signaling molecules were measured by western blotting in 
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the current study. Like phosphorylated relA, the expression level of phosphorylated ERK were 
significantly inhibited by 1α,25(OH)2D3 (10 nM). Phosphorylated p38 was also numerically 
reduced, but this was not statistically significant. In conclusion, 1α,25(OH)2D3 could also inhibit 
the gene expression of the MacCM-induced pro-inflammatory factors, by attenuating the 
phosphorylated ERK of the MAPK pathway. 
 
Last but not the least, regarding ER stress is a potential contributor to metaflammation in obesity, 
so the signaling of the UPR pathways was also measured by western blotting. ER stress can be 
relieved by UPR. The accumulation of incorrectly folded proteins in cytosol triggers the UPR by 
activating three arms: PERK induced phosphorylated eIF-2α; IRE-1 induced transcription factor 
XBP-1; and ATF-6 (48). When the arm of PERK is stimulated, the phosphorylated eIF-2α will 
ubiquinate the incorrectly folded protein thus to attenuate the translation and relieve ER stress (48). 
Paradoxically, the results showed that the levels of phosphorylated eIF-2α was significantly 
increased by THP-1-MacCM compared to the control, whilst 1α,25(OH)2D3 (0.01-10 nM) 
significantly reduced the levels compared to THP-1-MacCM treated preadipocytes. It has been 
demonstrated that by activating PERK or IRE-1, UPR can induce a crosstalk with the NF-κB 
pathway (52). Subsequently the phosphorylation of IKK releases NF-κB, which in nucleus acts as 
a key transcription factor mediating the inflammatory (54). Though THP-1-MacCM significantly 
increased the levels of phosphorylated eIF-2α which can attenuate the secretion of the 
pro-inflammatory factors, it could also interact with the NF-κB signaling pathway to increase the 
expression of phosphorylated relA, which results in the net effect of enhancing the inflammatory 
response induced by LPS-stimulated macrophages, whereas by decreasing phosphorylated eIF-2α, 
1α,25(OH)2D3 (0.01-10 nM) might lower the levels of phosphorylated relA to exert the 
anti-inflammatory effects on human white preadipocytes. 
 
Limitations 
1. Only preadipocytes studied, as these have similarity to macrophages. The effects might be 
different in mature adipocytes that make up the majority of human adipose tissue. 
2. Although a wide range of 1α,25(OH)2D3 doses were studied, there is no clear dose-response 
for many of the observed effects, and the physiological concentrations that are relevant are 
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unknown at present. 
3. Further experiments would be needed to precisely identify the sites and pathways through 
which 1α,25(OH)2D3 exerts the observed effects; some of these questions are explored in 
subsequent chapters. 
4. The levels of total unphosphorylated protein(s) including relA, ERK (p42/44), p38 and 
eIF-2α have not been determined, which is a limitation of the current experiment design. 
Elevated or decreased phosphorylation levels may be accompanied by increased or decreased 
protein levels.  
 
In summary, this study demonstrates that THP-1-MacCM significantly enhanced the gene 
expression and secretion of the pro-inflammatory factors from human preadipocytes. This is 
probably through increasing the levels of phosphorylated relA of the NF-κB signaling pathway, 
phosphorylated ERK (p42/44) and p38 of the MAPK pathways, and phosphorylated eIF-2α of the 
UPR pathway. Among the pro-inflammatory factors, IL-1β and IL-6 are critical in maintaining the 
inflammatory response. Moreover, 1α,25(OH)2D3 could inhibit the inflammatory response 
probably by:  
1. Directly attenuating the pro-inflammatory gene expression;  
2. Blocking phosphorylated relA to attenuate the pro-inflammatory gene expression;  
3. Blocking phosphorylated ERK to attenuate the pro-inflammatory gene expression;  
4. Reducing the level of phosphorylated eIF-2α to attenuate phosphorylated relA.  
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4. The effects of 1α,25(OH)2D3 on IL-1β-stimulated human white 
preadipocytes 
 
4.1. Introduction 
 
Several studies suggest that an array of moderately expressed TNF-α, IL-1β, IL-6, MCP-1 and 
other chemoattractants are responsible for the infiltration of immune cells into metabolic tissues 
during obesity, which is critical in the induction and maintenance of metaflammation in human 
adipose tissue (24, 25). Although the underlying mechanisms remain to be established, several 
signaling pathways have been implicated. For instance, during metaflammation in human 
adipocytes, TNF-α or IL-1β activates the JNK, IKKβ and their down-stream cascades including 
the transcription factors AP-1 as well as NF-κB in the classical receptor-mediated way, thereby 
up-regulating the gene expression and secretion of the pro-inflammatory factors (24), whereas the 
expression of the nuclear-receptor PPARγ is down-regulated (26), which may partly explain that 
the circulating level of adiponectin was negatively correlated with fat mass.  
 
IL-1β is a pleiotropic pro-inflammatory factor that appears to have an important role in initiating 
and sustaining metabolic abnormalities in obesity, especially metaflammation and insulin 
resistance (for the specific details, please refer to Introduction Page 25-26). Similarly, previous 
studies from our groups and others have demonstrated that IL-1β stimulated an inflammatory 
response and dampened insulin sensitivity in human preadipocytes (390). The data from the study 
described in Chapter 3 also suggest that IL-1β is a major mediator of the macrophage-induced 
inflammatory response in human preadipocytes (the concentration of IL-1β of THP-1-MacCM 
was 2 ng/ml measured by ELISA). Furthermore, the interaction of MCP-1 with its receptor CCR-2 
and CCR-5 with its ligands (CCL-3, CCL-4 and CCL-5), have also been demonstrated to be 
crucial for the recruitment of macrophages and the pathogenesis of insulin resistance in obesity 
(185-187, 193) (for the specific details, please refer to Introduction Page 27-29). 
 
It has been shown that 1α,25(OH)2D3 has a wide range of effects on adipogenesis, adipocyte 
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apoptosis and metaflammation in adipose tissue (for the specific details, please refer to 
Introduction Page 54-56). Notably, a recent study suggests that pretreatment (24 h) and treatment 
(24 h) with 1α,25(OH)2D3 (10 and 100 nM) significantly decreased the expression and secretion of 
MCP-1 in THP-1-MacCM, TNF-α or IL-1β-stimulated human white preadipocytes (355). 
 
 
 
4.2. Aims 
 
This study aimed to investigate whether 1α,25(OH)2D3 has an inhibitory effect on 
IL-1β-stimulated inflammatory response in human preadipocytes. The experiments were designed 
to examine whether:  
1. IL-1β could enhance the gene expression of IL-1β, IL-8, IL-6, MCP-1 and RANTES in 
human white preadipocytes;  
2. IL-1β enhances the secretion of the pro-inflammatory factors from human white 
preadipocytes;  
3. 1α,25(OH)2D3 inhibits the secretion or gene expression of the pro-inflammatory cytokines in 
IL-1β-stimulated preadipocytes;  
4. IL-1β increases the level of phosphorylated relA of the NF-κB pathway in preadipocytes;  
5. 1α,25(OH)2D3 could modulate the level of phosphorylated relA of the NF-κB pathway as 
well as phosphorylated eIF-2α or XBP-1 of the UPR pathways to exert the anti-inflammatory 
effects on IL-1β-stimulated preadipocytes. 
 
 
 
4.3. Materials and Methods 
 
Preadipocyte pretreatment and treatment  
 
Culture of human preadipocytes was performed as described in Chapter 3. To investigate the effect 
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of 1α,25(OH)2D3 on IL-1β-stimulated preadipocytes, preadipocytes were either cultured alone 
(control), or with IL-1β (0.5 and 2 ng/ml, Sigma-Aldrich, UK) alone for 24 h. Further groups of 
cells were pretreated with 1α,25(OH)2D3 (0.01-10 nM, ENZO Life Sciences, USA) for 24 h [using 
an established protocol (355)], followed by treatments with IL-1β (0.5 and 2 ng/ml) and 
1α,25(OH)2D3 (0.01-10 nM) for a further 24 h [using an established protocol (355)] at 37°C in 95% 
air and 5% CO2. When the experiment was completed, cell media were collected for ELISA; 
preadipocytes were lysed with Trizol for qPCR or lysed with a lysis buffer for western blotting. 
All samples were stored at -80 °C. 
 
Measurements 
 
ELISA was performed for determining the secretion levels of pro-inflammatory factors including 
IL-6, IL-8, MCP-1 and RANTES and corrected by total protein content in cellular lysate. 
Real-time PCR was used to measure the gene expression levels of pro-inflammatory factors 
including IL-1β, IL-6, IL-8, MCP-1 and internal reference PPIA. For measuring protein levels of 
phosphorylated relA of the NF-κB signaling pathway, phosphorylated eIF-2α (in the PERK 
induced arm of the UPR), XBP-1 (at the concentration of 2 µg/ml in the IRE-1 inducted arm of the 
UPR), western blotting was performed. The laboratory procedures and statistical analyses are 
described in detail in Chapter 3.  
 
 
 
4.4. Results 
 
4.4.1. IL-1β enhances the secretion of the pro-inflammatory factors from human white 
preadipocytes 
 
Since the secretion levels of IL-1β, IL-6, IL-8, MCP-1 and RANTES were significantly increased 
in (25%) THP-1-MacCM-stimulated preadipocytes in Chapter 3, these pro-inflammatory factors 
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were selected as the indicators of inflammatory response of preadipocytes induced by IL-1β. An 
ELISA to measure concentrations of IL-1β was not performed, because its secretion level can’t be 
measured accurately in this experiment (the autocrine effect of IL-1β secretion from 
IL-1β-stimulated preadipocytes is not a simple subtraction).  
 
The results (Figure 4.1, 2) show that IL-1β (0.5 and 2 ng/ml) markedly increased the secretion 
levels of IL-6, IL-8, MCP-1 and RANTES.  
 
 
4.4.2. 1α,25(OH)2D3 reduces the secretion of the pro-inflammatory factors from 
IL-1β-stimulated preadipocytes  
 
In general, 1α,25(OH)2D3 (0.01-10 nM) reduced cytokine secretion from (both 0.5 and 2 ng/ml) 
IL-1β-stimulated preadipocytes, although the effects appeared less consistent in (0.5 ng/ml) 
IL-1β-stimulated preadipocytes (figures 4.1, 2). 
 
From (0.5 ng/ml) IL-1β-stimulated preadipocytes (Figure 4.1), only the levels of IL-6 were 
moderately decreased by the full range of doses; the others were partially significantly decreased 
by 1α,25(OH)2D3. For instance, the levels of IL-8 by 0.1 and 10 nM of 1α,25(OH)2D3, MCP-1 by 
1 and 10 nM of 1α,25(OH)2D3 and RANTES by 0.01 and 10 nM of 1α,25(OH)2D3. However, 
there is no straightforward dose-response relationship between the secretion levels of the 
cytokines and the doses of 1α,25(OH)2D3 used in these experiments. 
 
In parallel (Figure 4.2), though the levels of IL-8 were only significantly decreased by 0.01 and 
0.1 nM of 1α,25(OH)2D3, the levels of IL-6, RANTES (dramatically); and MCP-1 (moderately) 
were all reduced by all doses (tested) of 1α,25(OH)2D3 (0.01-10 nM) from (2 ng/ml) 
IL-1β-stimulated preadipocytes. Moreover, the anti-inflammatory effects of 1α,25(OH)2D3 
(0.01-10 nM) on cytokine secretion are quite similar across the dose range (0.01-10 nM).  
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Figure 4.1 Effects of 1α,25(OH)2D3 on cytokine release from (0.5 ng/ml) IL-1β-stimulated 
human white preadipocytes. 
Preadipocytes were either cultured alone (control), or with IL-1β (0.5 ng/ml) alone for 24 h. 
Further groups of cells were pretreated with 1α,25(OH)2D3 (0.01-10 nM) for 24 h, followed by 
treatments with IL-1β (0.5 ng/ml) and 1α,25(OH)2D3 (0.01-10 nM) for a further 24 h before 
medium collection. The release levels of pro-inflammatory factors (A) IL-6, (B) IL-8, (C) MCP-1 
and (D) RANTES were measured by ELISA and normalized by protein content in the cellular 
lysate. Data are means ± SEM for groups of 6. A significant difference to control was indicated by 
***(p<0.001); to (0.5 ng/ml) IL-1β by #(p<0.05), ##(p<0.01), ###(p<0.001). The results were 
determined using one-way ANOVA with Tukey’s post hoc test and confirmed by two independent 
experiments. 
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Figure 4.2 Effects of 1α,25(OH)2D3 on cytokine release from (2 ng/ml) IL-1β-stimulated 
human white preadipocytes.  
Preadipocytes were either cultured alone (control), or with IL-1β (2 ng/ml) alone for 24 h. Further 
groups of cells were pretreated with 1α,25(OH)2D3 (0.01-10 nM) for 24 h, followed by treatments 
with IL-1β (2 ng/ml) and 1α,25(OH)2D3 (0.01-10 nM) for a further 24 h before medium collection. 
The release levels of pro-inflammatory factors (A) IL-6, (B) IL-8, (C) MCP-1 and (D) RANTES 
were measured by ELISA and normalized by protein content in the cellular lysate. Data are means 
± SEM for groups of 6. A significant difference to control was indicated by ***(p<0.001); to (2 
ng/ml) IL-1β by #(p<0.05), ##(p<0.01), ###(p<0.001). The results were determined using 
one-way ANOVA with Tukey’s post hoc test and confirmed by two independent experiments. 
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4.4.2. IL-1β enhances the gene expression of the pro-inflammatory factors in human white 
preadipocytes 
 
Similar to the secretion levels, the qPCR results (Figure 4.3, 4) show that the mRNA levels of the 
pro-inflammatory factors including IL-1β, IL-6, IL-8, MCP-1 and RANTES, were massively 
increased in (both 0.5 and 2 ng/ml) IL-1β-stimulated preadipocytes. 
 
 
4.4.3. 1α,25(OH)2D3 reduces the gene expression of pro-inflammatory cytokines in 
IL-1β-stimulated preadipocytes 
 
Except for the mRNA levels of RANTES, which was significantly decreased by all doses, 
1α,25(OH)2D3 (0.01-10 nM) had no consistent effects on the mRNA levels of IL-1β, IL-6, IL-8 or 
MCP-1 in (0.5 ng/ml) IL-1β-stimulated preadipocytes, and in some cases, there appeared to be a 
modest increase in mRNA levels at low doses of 1α,25(OH)2D3 (IL-8 and MCP-1) (Figure 4.3).  
 
(Figure 4.4) In contrast, 1α,25(OH)2D3 (0.01-10 nM) exhibited extensive anti-inflammatory 
effects on pro-inflammatory gene transcription in (2 ng/ml) IL-1β-stimulated preadipocytes, apart 
from 1α,25(OH)2D3 (10 nM) not affecting the mRNA level of IL-6, the rest were all significantly 
decreased. In addition, the reducing effects of 1α,25(OH)2D3 on the mRNA levels of IL-1β and 
MCP-1 were marked and similar across the dose range 1α,25(OH)2D3 (0.01-10 nM). However, 
there is no consistent dose-response relationship between the mRNA levels of the 
pro-inflammatory cytokines and the doses of 1α,25(OH)2D3 used in these experiments. 
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Figure 4.3 Effects of 1α,25(OH)2D3 on cytokine gene expression in (0.5 ng/ml) 
IL-1β-stimulated human white preadipocytes.  
Preadipocytes were either cultured alone (control), or with IL-1β (0.5 ng/ml) alone for 24 h. 
Further groups of cells were pretreated with 1α,25(OH)2D3 (0.01-10 nM) for 24 h, followed by 
treatments with IL-1β (0.5 ng/ml) and 1α,25(OH)2D3 (0.01-10 nM) for a further 24 h before 
Trizol-dissolved lysate collection. The mRNA levels of pro-inflammatory factors (A) IL-1β, (B) 
IL-6, (C) IL-8, (D) MCP-1 and (E) RANTES were measured by qPCR. Data are means ± SEM for 
groups of 6. A significant difference to control was indicated by **(p<0.01), ***(p<0.001); to (0.5 
ng/ml) IL-1β by #(p<0.05), ##(p<0.01), ###(p<0.001). The results were determined using 
one-way ANOVA with Tukey’s post hoc test and confirmed by two independent experiments. 
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Figure 4.4 Effects of 1α,25(OH)2D3 on gene expression of cytokine in (2 ng/ml) 
IL-1β-stimulated human white preadipocytes.  
Preadipocytes were either cultured alone (control), or with IL-1β (2 ng/ml) alone for 24 h. Further 
groups of cells were pretreated with 1α,25(OH)2D3 (0.01-10 nM) for 24 h, followed by treatments 
with IL-1β (2 ng/ml) and 1α,25(OH)2D3 (0.01-10 nM) for a further 24 h before Trizol-dissolved 
lysate collection. The mRNA levels of pro-inflammatory factors (A) IL-1β, (B) IL-6 (B), (C) IL-8, 
(D) MCP-1 and (E) RANTES were measured by qPCR. Data are means ± SEM for groups of 6. A 
significant difference to control was indicated by ***(p<0.001); to (2 ng/ml) IL-1β by #(p<0.05), 
##(p<0.01), ###(p<0.001). The results were determined using one-way ANOVA with Tukey’s post 
hoc test and confirmed by two independent experiments. 
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4.4.4. IL-1β increases phosphorylated relA of the NF-κB pathways in human preadipocytes 
 
To test whether IL-1β could modulate the NF-κB pathway, the expression levels of phosphorylated 
relA were measured by western blotting. The result (Figure 4.5) shows that the levels of 
phosphorylated relA were markedly higher in the presence of IL-1β (0.5 and 2 ng/ml), compared 
to the untreated preadipocytes.  
 
However, 1α,25(OH)2D3 (0.01-10 nM) had no effect on the levels of phosphorylated relA in (0.5 
and 2 ng/ml) IL-1β-stimulated preadipocytes. 
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Figure 4.5 Effects of 1α,25(OH)2D3 on phosphorylated relA in (0.5 and 2 ng/ml) 
IL-1β-stimulated human white preadipocytes.  
Preadipocytes were either cultured alone (control), or with IL-1β (0.5 and 2 ng/ml) alone for 24 h. 
Further groups of cells were pretreated with 1α,25(OH)2D3 (0.01-10 nM) for 24 h, followed by 
treatments with IL-1β (0.5 and 2 ng/ml) and 1α,25(OH)2D3 (0.01-10 nM) for a further 24 h before 
lysate collection. The levels of phosphorylated relA (A) (IL-1β 0.5 ng/ml) and (B) (IL-1β 2 ng/ml) 
were measured by western blotting. Data are means ± SEM for groups of 3. A significant 
difference to control was indicated by ***(p<0.001). The results were determined using one-way 
ANOVA with Tukey’s post hoc test and confirmed by two independent experiments. 
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4.4.5. 1α,25(OH)2D3 increases the levels of phosphorylated eIF-2α and XBP-1 of the UPR 
signaling pathways in IL-1β-stimulated preadipocytes  
 
To test whether IL-1β or 1α,25(OH)2D3 could modulate signaling of the UPR pathways, the 
expression of phosphorylated eIF-2α and transcription factor XBP-1 were examined (Figure 4.6).  
 
Firstly, IL-1β (0.5 ng/ml) had no effect on the level of phosphorylated eIF-2α, compared to the 
untreated preadipocytes (Figure 4.6 A). 
 
Secondly, compared to (0.5 ng/ml) IL-1β-stimulated preadipocytes, 1α,25(OH)2D3 (0.01-10 nM) 
moderately increased the levels of phosphorylated eIF-2α, though the difference by 1 nM of 
1α,25(OH)2D3 did not reach the statistical significance (Figure 4.6 A). 
 
Thirdly, the levels of XBP-1 were undetectable in the untreated and (0.5 ng/ml) IL-1β-stimulated 
preadipocytes, while the levels were markedly increased by 1α,25(OH)2D3 (0.01-10 nM) in (0.5 
ng/ml) IL-1β-stimulated preadipocytes (Figure 4.6 B). 
 
Finally, there is no consistent dose-response relationship between the levels of these signaling 
molecules and the doses of 1α,25(OH)2D3 used in these experiments. 
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Figure 4.6 Effects of 1α,25(OH)2D3 on signaling molecules of the UPR signaling pathways in 
(0.5 ng/ml) IL-1β-stimulated human white preadipocytes. 
Preadipocytes were either cultured alone (control), or with IL-1β (0.5 ng/ml) alone for 24 h. 
Further groups of cells were pretreated with 1α,25(OH)2D3 (0.01-10 nM) for 24 h, followed by 
treatments with IL-1β (0.5 ng/ml) and 1α,25(OH)2D3 (0.01-10 nM) for a further 24 h before lysate 
collection. The levels of (A) phosphorylated eIF-2α and (B) XBP-1 were measured by western 
blotting. Data are means ± SEM for groups of 3. A significant difference to (0.5 ng/ml) IL-1β was 
indicated by ###(p<0.001). The results were determined using one-way ANOVA with Tukey’s 
post hoc test and confirmed by two independent experiments. 
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4.4.6. 1α,25(OH)2D3 increases the levels of phosphorylated eIF-2α of the UPR signaling 
pathway in IL-1β-stimulated preadipocytes  
 
IL-1β (2 ng/ml) had no effect on the level of phosphorylated eIF-2α, compared to the untreated 
preadipocytes. While 1α,25(OH)2D3 (0.1-10 nM) was associated with significantly higher levels of 
phosphorylated eIF-2α in (2 ng/ml) IL-1β-stimulated preadipocytes (Figure 4.7 A).  
 
 
4.4.7. 1α,25(OH)2D3 increases the levels of XBP-1 of the UPR signaling pathway in 
IL-1β-stimulated preadipocytes  
 
Unlike that of IL-1β (0.5 ng/ml), the increasing effect of XBP-1 level on preadipocytes by IL-1β 
(2 ng/ml) was distinguishable (Figure 4.7 B). 
 
In parallel, compared to (2 ng/ml) IL-1β-stimulated preadipocytes, 1α,25(OH)2D3 (0.01, 1 and 10 
nM) significantly increased the levels of XBP-1, but there is no straightforward dose-response 
relationship between the levels of XBP-1 and these doses (Figure 4.7 B). 
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Figure 4.7 Effects of 1α,25(OH)2D3 on signaling of the UPR signaling pathways in (2 ng/ml) 
IL-1β-stimulated human white preadipocytes. 
Preadipocytes were either cultured alone (control), or with IL-1β (2 ng/ml) alone for 24 h. Further 
groups of cells were pretreated with 1α,25(OH)2D3 (0.01-10 nM) for 24 h, followed by treatments 
with IL-1β (2 ng/ml) and 1α,25(OH)2D3 (0.01-10 nM) for a further 24 h before lysate collection. 
The levels of (A) phosphorylated eIF-2α and (B) XBP-1 were measured by western blotting. Data 
are means ± SEM for groups of 3. A significant difference to control was indicated by 
***(p<0.001); to (2 ng/ml) IL-1β was indicated by ##(p<0.01), ###(p<0.001). The results were 
determined using one-way ANOVA with Tukey’s post hoc test and confirmed by two independent 
experiments. 
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4.5. Discussion 
 
The study described in Chapter 3 has demonstrated that the gene expression and secretion levels 
of the pro-inflammatory factors of THP-1-stimulated preadipocytes were significantly reduced by 
IL-1β neutralizing antibody. The experiments described in this chapter first aimed to test whether 
IL-1β (0.5 and 2 ng/ml) alone could induce the inflammatory response from preadipocytes to the 
same extent as that of LPS-induced macrophages. The dosages of IL-1β were selected according 
to the results of ELISA (data not shown): the baseline secretion level of IL-1β from 
LPS-stimulated THP-1-MacCM was approximately 2 ng/ml; preadipocytes were treated with 
(25%) THP-1-MacCM (the concentration of IL-1β was 0.5 ng/ml) in the study described in 
Chapter 3. Like (25%) THP-1-MacCM, (0.5 and 2 ng/ml) IL-1β significantly enhanced the gene 
expression and secretion levels of IL-1β, IL-6, IL-8, MCP-1 and RANTES. 
 
IL-6 stimulates lipolysis, increases FFA levels and whole body fat oxidation (178), whilst it 
inhibits the secretion of other adipokines, especially adiponectin, an important marker of 
adipocyte differentiation in human adipocytes (179). Moreover, IL-6 induces metaflammation by 
up-regulating SOCS3, which in turn impairs the phosphorylation of IRS1 in HepG2 cells (391). 
Like leptin, the levels of circulating IL-6 are positively correlated with percentage of body fat in 
human (172). Mice with genetic deletion of IL-6 developed adult-onset obesity, which suggests 
that IL-6 is involved in the chronic physiological regulation of energy balance; decreased IL-6 
signaling is highly associated with weight gain (173). Paradoxically, IL-6 has also an 
anti-inflammatory effect, since it has been demonstrated that elevated plasma IL-6 by skeletal 
muscle during exercise inhibited endotoxin-induced plasma TNF-α in humans (392). In addition, 
IL-6 activates AMPK in rat skeletal muscle by increasing the concentration of cAMP and the 
AMP to ATP ratio, which suggest that substantial increases in IL-6 concentrations by muscles 
during exercise, may play a role in glycogen breakdown and lipolysis within skeletal muscle (183). 
Therefore, in the present study, we selected IL-1β over IL-6 to trigger the inflammatory response 
in preadipocytes, mainly for the supposed beneficial effects of IL-6. 
 
To test whether IL-1β exerts the pro-inflammatory effects on preadipocytes by increasing the 
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signaling of the NF-κB pathway, the level of phosphorylated NF-κB was measured by western 
blotting. We didn’t select the signaling with the MAPK pathways because according to the results 
of Chapter 3, the levels of phosphorylated ERK and p38 were not significantly inhibited by IL-1β 
neutralization. The NF-κB signaling pathway is activated by a cascade of kinases. When upstream 
signals converge at the IKK complex and activate IKKβ via phosphorylation, the activated IKKβ 
phosphorylates and degrades I-κB to release NF-κB p65/p50 heterodimer into the nucleus and 
binds unto the promoters of inflammatory genes (including TNF-α, IL-1β,COX2, IL-6, IL-12, 
MCP-1, CCR-2 and CCR-5), which in turn augment metaflammation by recruiting more immune 
cells into adipose tissue (244). In the present study, like that in THP-1-MacCM-stimulated 
preadipocytes, the expression levels of phosphorylated NF-κB were significantly enhanced by 
IL-1β (both 0.5 and 2 ng/ml) compared with the untreated control. Taken together, IL-1β increases 
the levels of phosphorylated NF-κB, which may lead to enhance the gene expression and secretion 
of the pro-inflammatory factors in human preadipocytes. 
 
The study described in Chapter 3 also demonstrated that 1α,25(OH)2D3 (10 nM) significantly 
inhibited the gene expression and secretion levels of IL-1β, IL-6, IL-8 and RANTES. To 
investigate whether 1α,25(OH)2D3 (0.1-10 nM) could inhibit the gene expression and secretion 
levels of the pro-inflammatory factors, preadipocytes were pre-treated with 1α,25(OH)2D3 (0.1-10 
nM) for 24h, followed by the treatment with IL-1β (0.5, 2 ng/ml) in the presence of 1α,25(OH)2D3 
(0.1-10 nM) for a further 24h. The results show that 1α,25(OH)2D3 (0.1-10 nM) significantly 
inhibited the secretion but not the gene expression levels of IL-1β, IL-6, IL-8, MCP-1 and 
RANTES, compared with IL-1β (0.5 ng/ml) only treated preadipocytes. Surprisingly, the gene 
expression and secretion levels of these pro-inflammatory factors were significantly inhibited by 
1α,25(OH)2D3 (0.1-10 nM), compared with IL-1β (2 ng/ml) treated preadipocytes. The mechanism 
underlying 1α,25(OH)2D3 down-regulating the gene expression of pro-inflammatory factors in an 
IL-1β dose dependent manner needs to be investigated in the future; although not formally 
compared, the higher concentration of IL-1β results in a greater inflammatory response (e.g. 
approx.158-fold increase in IL-6 at 0.5 ng/ml, compared to a 361-fold increase at 2ng/ml), and it 
may be that the inhibitory effects of 1α,25(OH)2D3 are only apparent when there is a strong 
inflammatory response. Like the anti-inflammatory effects on THP-MacCM-stimulated 
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preadipocytes, there was no apparent dose-response relationship between 1α,25(OH)2D3 and the 
gene expression or secretion of the pro-inflammatory factors.  
 
In obesity, as an outcome of excessive intake of energy, enhanced protein synthesis and 
insufficient chaperone proteins triggers ER stress, but which can be relieved by UPR (48). The 
activation of UPR is conducted by three arms consisting of PERK, IRE-1 and ATF-6. The 
consequence of the activation includes inhibition of protein synthesis, enhanced expression of 
chaperones and clearance of incorrectly folded proteins, and stimulated ER biogenesis (51). In the 
current study, to test whether 1α,25(OH)2D3 could modulate the signaling of the UPR pathways, 
the levels of transcription factors XBP-1 induced by IRE-1, and phosphorylated eIF-2α inducted 
by PERK, were measured by western blotting. The results show that the level of XBP-1 couldn’t 
be detected in (0.5 ng/ml) IL-1β-stimulated preadipocytes, while 1α,25(OH)2D3 (0.1-10 nM) 
increased the levels. Likewise, 1α,25(OH)2D3 (0.1-10 nM) significantly enhanced the levels of 
XBP-1 compared to that of (2 ng/ml) IL-1β-stimulated preadipocytes. It has been reported that 
processing of pro-IL-1β is fully dependent on caspase-8, but neither the UPR proteins (XBP-1 and 
CHOP) nor the TLR4 adaptor molecule MyD88 are necessary for caspase-8 activation (393). 
Therefore, the current results suggest that the levels of XBP-1 increased by 1α,25(OH)2D3 neither 
contributes nor inhibits the inflammatory response induced by IL-1β.  
 
The study described in Chapter 3 shows that 1α,25(OH)2D3 may exert the anti-inflammatory 
effects by reducing the levels of phosphorylated eIF-2α. Paradoxically, the levels of 
phosphorylated eIF-2α were significantly increased by 1α,25(OH)2D3, compared with (0.5 and 2 
ng/ml) IL-1β-stimulated preadipocytes. This is accentuated by the ELISA and qPCR results, which 
show that although the gene expression of the pro-inflammatory factors were not significantly 
reduced by 1α,25(OH)2D3, the secretion was compared to (0.5 ng/ml) IL-1β-stimulated 
preadipocytes; and suggest that the increased phosphorylated eIF-2α could ubiquinate the 
increased levels of mRNA translated products by IL-1β (48), thus significantly inhibiting the 
secretion of the pro-inflammatory factors. In this sense, 1α,25(OH)2D3 could also exert 
anti-inflammatory effects by increasing the levels of phosphorylated eIF-2α of the UPR pathway. 
In addition, the results might also explain why although 1α,25(OH)2D3 (10 nM) significantly 
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reduced the levels of phosphorylated relA in THP-1-MacCM-stimulated preadipocytes in Chapter 
3 (the reduced levels of phosphorylated eIF-2α inhibiting the NF-κB pathway), but not by 
1α,25(OH)2D3 in (0.5 and 2 ng/ml) IL-1β-stimulated preadipocytes (the increased levels of 
phosphorylated eIF-2α enhancing the NF-κB pathway). 
 
As demonstrated by the current study, the gene expression levels of the pro-inflammatory factors 
were significantly inhibited by 1α,25(OH)2D3 (i.e. 10 nM) in (2 ng/ml) IL-1β-stimulated 
preadipocytes. It has been shown that the VDR transcriptional complex can modulate the 
expression of vitamin D-responsive genes including cytokines such as IL-2, IL-12, TNF-α, IFN-γ, 
GM-CSF, which are critical in modulating inflammatory response in tissue (307-310). Therefore, 
the results suggest that the 1α,25(OH)2D3-VDR transcriptional complex could bind to the 
promoters of IL-1β, IL-6, IL-8, MCP-1 and RANTES, thereby reducing the gene expression. 
Further chromatin immunoprecipitation assays are required to clarify this notion. 
 
Limitations 
1. The levels of total unphosphorylated protein(s) including relA and eIF-2α have not been 
determined, which is a limitation of the current experiment design. Elevated or decreased 
phosphorylation levels may be accompanied by increased or decreased protein levels.  
 
In summary, this study demonstrates that IL-1β significantly increased the gene expression and 
secretion of the pro-inflammatory cytokines, including IL-1β, IL-6, IL-8, MCP-1 and RANTES, 
from human preadipocytes. This is probably through increasing the level of phosphorylated relA 
of the NF-κB pathway. 1α,25(OH)2D3 could inhibit the inflammatory response probably by:   
1. Directly attenuating the pro-inflammatory gene expression;  
2. Increasing the level of phosphorylated eIF-2α of the UPR pathway to attenuate the 
pro-inflammatory translation. 
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5. The effects of VDR agonists on IL-1β-stimulated human white 
preadipocytes 
 
5.1. Introduction 
 
VDR are generally expressed in a variety of cell lines and primary cells. A large number of studies 
suggest that it’s involved in a variety of processes including cell proliferation, differentiation, and 
immune-regulation (292). By binding to VDR complex, 1α,25(OH)2D3 modulates the genomic 
response of numerous cells as well as tissues throughout the body in an endocrine, autocrine or 
paracrine manner (285). As mentioned before, a large body of evidence suggests that 
1α,25(OH)2D3 exerts an anti-inflammatory action on preadipocytes and adipocytes (352-356) (for 
the specific details, please refer to Introduction Page 56).  
 
Though 1α,25(OH)2D3 has anti-inflammatory efficacy in different animal models, which were 
summarized as systemic lupus erythematosus in lpr/lpr mice; type I diabetes in non-obese diabetic 
mice; collagen-induced arthritis, experimental allergic encephalomyelitis and inflammatory bowel 
disease mouse and rat (292), the immuno-modulatory properties are mostly achieved only if very 
high doses are applied, which can unfortunately lead to the side effect of hypercalcemia. Hence, 
based on knowledge about the specific interactions between 1α,25(OH)2D3 and the ligand binding 
pocket in the LBD of the VDR (283), many VDR agonists with the improved biological profile for 
a potential therapeutic application, have been synthesized (316), and among which are ZK159222 
and ZK191784 (318-320, 323, 324) (for the specific details, please refer to Introduction Page 
50-52).  
 
Noteworthy, a recent study from our group indicates that pretreatment (48 h) and treatment (24 h) 
with ZK159222 and ZK191784 (100 nM and 1 μM) may have anti-inflammatory actions in 
THP-1-MacCM-stimulated human white adipocytes (322).  
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5.2. Aims  
 
This study was aimed to investigate whether ZK159222 and ZK191784 have an inhibitory effect 
on the IL-1β-stimulated inflammatory response in human preadipocytes. Human preadipocytes 
treated with IL-1β served as an in vitro model and 1α,25(OH)2D3 as a positive control to study 
effects of ZK159222 and ZK191784. The experiments were set up to examine whether:  
1. ZK159222 or ZK191784 could inhibit the secretion of the pro-inflammatory factors from 
IL-1β-stimulated preadipocytes;  
2. ZK159222 or ZK191784 could inhibit the gene expression of the pro-inflammatory factors in 
IL-1β-stimulated preadipocytes;  
3. ZK159222 or K191784 could modulate the level of phosphorylated relA or methylated relA 
of the NF-κB pathway as well as phosphorylated eIF-2α of the UPR pathway. 
 
 
 
5.3. Materials and Methods 
 
Preadipocyte pretreatment and treatment  
 
Culture of human preadipocytes was performed as described in Chapter 3. To investigate the effect 
of VDR agonists on IL-1β-stimulated preadipocytes, preadipocytes were either cultured alone 
(control), or with IL-1β (0.5 ng/ml, Sigma-Aldrich, UK) alone for 24 h. Further groups of cells 
were pretreated with 1α,25(OH)2D3 (10 nM, ENZO Life Sciences, USA), ZK 159222 (10 nM and 
1 μM, Bayer, Germany) or ZK191784 (10 nM and 1 μM, Bayer, Germany) for 48 h [using an 
established protocol (322)], followed by treatments with IL-1β (0.5 ng/ml) and 1α,25(OH)2D3 (10 
nM), ZK 159222 (10 nM and 1 μM) or ZK191784 (10 nM and 1 μM) for a further 24 h [the 
established protocol (322)] at 37°C in 95% air and 5% CO2. When the experiment was completed, 
cell media were collected for cytokine array and ELISA; preadipocytes were lysed with Trizol for 
qPCR or lysed with a lysis buffer for western blotting. All samples were stored at -80 °C. 
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Cytokine array  
 
Secreted cytokines from the treated preadipocytes were screened using Proteome Profiler Human 
XL Cytokine Array (R&D Systems) following the manufacturer’s instructions. Before the assays, 
100 μl of each of the collected media from the treated preadipocytes were pooled (n = 6, per group) 
as the samples to be measured. The cytokine signals were captured by Molecular Imager 
ChemiDoc XRS+ System (Bio-Rad, Hertfordshire, UK), and the results were presented as pixel 
density relative to the reference controls on the arrays.  
 
Other measurements 
 
ELISA was performed for determining the secretion levels of pro-inflammatory factors including 
IL-6, IL-8, MCP-1 and RANTES and corrected by total protein content in cellular lysate. 
Real-time PCR was used to measure the gene expression levels of pro-inflammatory factors 
including IL-1β, IL-6, IL-8, MCP-1 and internal reference PPIA. For measuring protein levels of 
phosphorylated relA and methylated relA (at 1:1000 dilution) of the NF-κB signaling pathway (the 
rationale for testing these indictors has been specified in Discussion Page 181-182, 183), 
phosphorylated eIF-2α (in the PERK inducted arm of the UPR), western blotting was performed. 
The laboratory procedures and statistical analyses are described in detail in Chapter 3.  
 
 
 
5.4. Results 
 
5.4.1. IL-1β enhances the secretion of cytokines from human preadipocytes 
 
In the initial experiments, cytokines released from (0.5 ng/ml) IL-1β-stimulated preadipocytes 
were screened by cytokine array (Figure 5.1, Appendix 9.4). A variety of cytokines were secreted 
including pro-inflammatory factors: IL-1β, IL-6, MIF, MIP-1α (specifically expressed by 
macrophages), GRO-α, MCP-1, MCP-3, RANTES (chemoattractants), IL-8, slCAM-1 (mainly 
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expressed by neutrophils) and growth factors including angiogenin, EGF, G-CSF, HGF, GDF1, 
etc. 
 
 
5.4.2. ZK159222 and ZK191784 inhibit the secretion of pro-inflammatory factors from 
IL-1β-stimulated human preadipocytes 
 
Cytokine release from ZK15922 (1 μM) and ZK191784 (1 μM)-stimulated preadipocytes was also 
screened by cytokine array. The results (Figure 5.1, Appendix 9.4) show that the secretion of the 
pro-inflammatory factors including IL-6, IL-8, MCP-1, MCP-3 and RANTES from (0.5 ng/ml) 
IL-1β-stimulated preadipocytes, were discernibly reduced by the two VDR agonists.  
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Figure 5.1 Effects of ZK159222 and ZK191784 on cytokine release from IL-1β-stimulated 
human white preadipocytes.  
Preadipocytes were pretreated with ZK159222 (1 μM) or ZK191784 (1 μM) for 48 h, followed by 
treatments with IL-1β (0.5 ng/ml) in the presence of ZK159222 (1 μM) or ZK191784 (1 μM) for a 
further 24 h before medium collection. The cytokine release levels from (A) control, (B) IL-1β 
(0.5 ng/ml), (C) ZK159222 (1 μM) and (D) ZK191784 (1 μM) were screened by cytokine array. 
The results are presented as pixel density relative to the reference controls on the arrays. 
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5.4.3. IL-1β increases the secretion of pro-inflammatory factors from human 
preadipocytes 
 
According to the result on the cytokine array, the pro-inflammatory factors including IL-6, IL-8, 
MCP-1 and RANTES were selected as indicators of the inflammatory response, and the result 
(Figure 5.2) shows that the secretion levels of these pro-inflammatory factors were dramatically 
increased by IL-1β (0.5 ng/ml) from human preadipocytes.  
 
 
5.4.4. 1α,25(OH)2D3 reduces the secretion of pro-inflammatory factors from 
IL-1β-stimulated human preadipocytes 
 
(Figure 5.2) 1α,25(OH)2D3 (10 nM) significantly reduced the secretion levels of IL-6, IL-8, 
MCP-1 and RANTES from (0.5 ng/ml) IL-1β-stimulated preadipocytes.  
 
 
5.4.5. ZK159222 reduces the secretion of pro-inflammatory factors from IL-1β-stimulated 
human preadipocytes 
 
(Figure 5.2) Firstly, ZK159222 (10 nM and 1 μM) markedly reduced the levels of IL-8 and 
RANTES from (0.5 ng/ml) IL-1β-stimulated preadipocytes. Secondly, the levels of IL-6 were 
moderately reduced by ZK159222 (10 nM and 1 μM). Noteworthy, the reducing effects on these 
pro-inflammatory factors are consistent between the doses. Finally, though the levels of MCP-1 
were also moderately reduced by ZK159222 (10 nM and 1 μM), only the difference by ZK159222 
(10 nM) was statistically significant, compared to (0.5 ng/ml) IL-1β-stimulated preadipocytes. 
 
 
5.4.6. ZK191784 reduces the secretion of pro-inflammatory factors from IL-1β-stimulated 
human preadipocytes 
 
170 
 
(Figure 5.2) The levels of IL-6, IL-8, MCP-1 and RANTES were moderately reduced by 
ZK191784 (10 nM and 1 μM) compared to (0.5 ng/ml) IL-1β-stimulated preadipocytes, and the 
reducing effects on these pro-inflammatory factors are consistent between the doses.  
. 
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Figure 5.2 Effects of VDR agonists on cytokine release from (0.5 ng/ml) IL-1β-stimulated 
human white preadipocytes.  
Preadipocytes were either cultured alone (control), or with IL-1β (0.5 ng/ml) alone for 24 h. 
Further groups of cells were pretreated with 1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM and 1 
μM) or ZK191784 (10 nM and 1 μM) for 48 h, followed by treatments with IL-1β (0.5 ng/ml) and 
1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM and 1 μM) or ZK191784 (10 nM and 1 μM) for a 
further 24 h before medium collection. The release levels of pro-inflammatory factors (A) IL-6, (B) 
IL-8, (C) MCP-1 and (D) RANTES were measured by ELISA and normalized by protein content 
in the cellular lysate. Data are means ± SEM for groups of 6. A significant difference to control 
was indicated by ***(p<0.001); to (0.5 ng/ml) IL-1β by #(p<0.05), ##(p<0.01),###(p<0.001). The 
results were determined using one-way ANOVA with Tukey’s post hoc test and confirmed by two 
independent experiments. 
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5.4.7. IL-1β enhances the gene expression of the pro-inflammatory factors in human 
preadipocytes 
 
Similar to the secretion levels, the qPCR result (Figure 5.3) shows that the mRNA levels of the 
pro-inflammatory factors including IL-1β, IL-6, IL-8, MCP-1 and RANTES, were dramatically 
increased by (0.5 ng/ml) IL-1β in human preadipocytes. 
 
 
5.4.8. 1α,25(OH)2D3 inhibits the gene expression the pro-inflammatory factors in 
IL-1β-stimulated human preadipocytes  
 
(Figure 5.3) 1α,25(OH)2D3 (10 nM) exhibited distinguishable reducing effects on the mRNA 
levels of IL-1β, IL-6, IL-8, MCP-1 and RANTES in (0.5 ng/ml) IL-1β-stimulated preadipocytes.  
 
 
5.4.9. ZK159222 inhibits the gene expression the pro-inflammatory factors in 
IL-1β-stimulated human preadipocytes  
 
(Figure 5.3) Firstly, ZK159222 (10 nM and 1 μM) significantly reduced the mRNA levels of IL-8 
in (0.5 ng/ml) IL-1β-stimulated preadipocytes. Secondly, the mRNA levels of IL-6 and MCP-1 
were moderately reduced by ZK159222 (10 nM and 1 μM) and the reducing effects on these 
pro-inflammatory factors are consistent between the doses. Finally, the mRNA level of IL-1β was 
drastically reduced by ZK159222 (10 nM), but ZK159222 (1 μM) had no effect on the mRNA 
level of IL-1β in (0.5 ng/ml) IL-1β-stimulated preadipocytes. 
 
 
5.4.10. ZK191784 inhibits the gene expression of the pro-inflammatory factors in 
IL-1β-stimulated human preadipocytes  
 
(Figure 5.3) ZK191784 (10 nM and 1 μM) markedly reduced the mRNA levels of all the 
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pro-inflammatory factors in (0.5 ng/ml) IL-1β-stimulated preadipocytes. Moreover, the reducing 
effects on these pro-inflammatory factors are consistent between the doses. 
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Figure 5.3 Effects of VDR agonists on cytokine gene expression in (0.5 ng/ml) 
IL-1β-stimulated human white preadipocytes.  
Preadipocytes were pretreated with 1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM, 1 μM) or 
ZK191784 (10 nM, 1 μM) for 48 h, followed by treatments with IL-1β (0.5 ng/ml) in the presence 
of 1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM, 1 μM) or ZK191784 (10 nM, 1 μM) for a further 
24 h before Trizol-dissolved lysate collection. The mRNA levels of pro-inflammatory factors (A) 
IL-1β, (B) IL-6, (C) IL-8, (D) MCP-1 and (E) RANTES were measured by qPCR. Data are means 
± SEM for groups of 6. A significant difference to control was indicated by ***(p<0.001); to (0.5 
ng/ml) IL-1β by #(p<0.05), ##(p<0.01), ###(p<0.001). The results were determined using 
one-way ANOVA with Tukey’s post hoc test and confirmed by two independent experiments. 
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5.4.11. IL-1β stimulates the NF-κB signaling in human preadipocytes 
 
To test whether IL-1β could regulate the post-translational transcription factor relA, the levels of 
phosphorylated relA and methylated relA of the NF-κB pathway were measured by western 
blotting. The results (Figure 5.4) show that the level of phosphorylated relA was moderately 
higher in the presence of (0.5 ng/ml) IL-1β, compared to the untreated preadipocytes. By contrast, 
the level methylated relA was markedly lower in (0.5 ng/ml) IL-1β-stimulated preadipocytes.  
 
 
5.4.12. ZK159222 and ZK191784 modulate the NF-κB signaling in IL-1β-stimulated 
preadipocytes 
 
The results (Figure 5.4) show that ZK159222 (1 μM) and ZK191784 (1 μM) mildly reduced the 
levels of phosphorylated relA, but levels were not affected by 1α,25(OH)2D3 (10 nM), ZK159222 
(10 nM) or ZK191784 (10 nM) in (0.5 ng/ml) IL-1β-stimulated preadipocytes.  
 
In parallel, ZK159222 (10 nM and 1 μM) and ZK191784 (10 nM) were associated with 
moderately higher levels of methylated relA in (0.5 ng/ml) IL-1β-stimulated preadipocytes. 
However, ZK191784 (1 μM) and 1α,25(OH)2D3 (10 nM) had no effect on the levels of methylated 
relA in (0.5 ng/ml) IL-1β-stimulated preadipocytes. 
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Figure 5.4 Effects of VDR agonists on signaling molecules of the NF-κB signaling pathway in 
(0.5 ng/ml) IL-1β-stimulated human white preadipocytes.  
Preadipocytes were either cultured alone (control), or with IL-1β (0.5 ng/ml) alone for 24 h. 
Further groups of cells were pretreated with 1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM and 1 
μM) or ZK191784 (10 nM and 1 μM) for 48 h, followed by treatments with IL-1β (0.5 ng/ml) and 
1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM and 1 μM) or ZK191784 (10 nM and 1 μM) for a 
further 24 h before lysate collection. The levels of (A) phosphorylated relA and (B) methylated 
relA were measured by western blotting. Data are means ± SEM for groups of 3. A significant 
difference to control was indicated by ***(p<0.001); to (0.5 ng/ml) IL-1β by #(p<0.05), 
##(p<0.01), ###(p<0.001). The results were determined using one-way ANOVA with Tukey’s post 
hoc test and confirmed by two independent experiments. 
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5.4.13. ZK159222 and ZK191784 increase the levels of phosphorylated eIF-2α in 
IL-1β-stimulated preadipocytes 
 
To test whether IL-1β (0.5 ng/ml), 1α,25(OH)2D3 (10 nM), ZK159222 and ZK191784 (10 nM and 
1 μM) could modulate signaling of the UPR pathways, the levels of phosphorylated eIF-2α were 
examined. The result (Figure 5.5) shows that the level of phosphorylated eIF-2α was not affected 
in (0.5 ng/ml) IL-1β-stimulated preadipocytes.  
 
Only ZK159222 (10 nM) and ZK191784 (1 μM) significantly increased the levels of 
phosphorylated eIF-2α compared to (0.5 ng/ml), while ZK159222 (1 μM), ZK191784 (10 nM) 
and 1α,25(OH)2D3 (10 nM) had no effect on the levels of phosphorylated eIF-2α in (0.5 ng/ml) 
IL-1β-stimulated preadipocytes.  
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Figure 5.5 Effects of VDR agonists on phosphorylated eIF-2α of the UPR signaling pathway 
in IL-1β-stimulated human white preadipocytes.  
Preadipocytes were either cultured alone (control), or with IL-1β (0.5 ng/ml) alone for 24 h. 
Further groups of cells were pretreated with 1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM and 1 
μM) or ZK191784 (10 nM and 1 μM) for 48 h, followed by treatments with IL-1β (0.5 ng/ml) and 
1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM and 1 μM) or ZK191784 (10 nM and 1 μM) for a 
further 24 h before lysate collection. The levels of phosphorylated eIF-2α were measured by 
western blotting. Data are means ± SEM for groups of 3. A significant difference to (0.5 ng/ml) 
IL-1β was indicated by ###(p<0.001). The results were determined using one-way ANOVA with 
Tukey’s post hoc test and confirmed by two independent experiments. 
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5.5. Discussion 
 
The studies described in Chapter 3 and 4 suggested that IL-1β is critical in maintaining the 
inflammatory response induced by THP-1-MacCM in preadipocytes, since the gene expression 
and secretion levels of IL-1β, IL-6, IL-8, MCP-1 and RANTES were significantly inhibited by 
IL-1β neutralization. Moreover, as shown in Chapter 4, the gene expression and secretion levels of 
these pro-inflammatory factors were significantly enhanced by IL-1β (0.5 and 2 ng/ml). Similarly, 
the current results of the cytokine array show that IL-1β-stimulated preadipocytes secreted a 
variety of pro-inflammatory factors including IL-1β, IL-6, IL-8, slCAM-1 (mainly expressed by 
neutrophils), MIF, MIP-1α (specifically expressed by macrophages), GRO-α, MCP-1, MCP-3 and 
RANTES, as well as growth factors including angiogenin, EGF, G-CSF, HGF, GDF1, etc. 
Furthermore, the results of ELISA show that the secretion of the major pro-inflammatory factors 
was significantly enhanced. Likewise, the gene expression levels of IL-1β, IL-6, IL-8, MCP-1 and 
RANTES were also significantly enhanced by IL-1β.  
 
To investigate whether IL-1β could modulate the post-translational modified transcription factor 
relA, thereby enhancing the gene expression of these pro-inflammatory factors, the levels of 
phosphorylated relA as well as the methylated relA were measured by western blotting. It has been 
summarized that during metaflammation, TNF-α or IL-1β stimulates JNK, IKKβ, and their 
down-stream cascades including the transcription factors AP-1 and NF-κB, which process results 
in elevated pro-inflammatory gene transcription and secretion (24). Similarly, the results of the 
current study show that IL-1β significantly increased the levels of phosphorylated relA, but 
reduced the levels of methylated relA. Notably, a very recent study has demonstrated that the SET 
domain-containing methyltransferase SETD6-mediated methylation attenuates NF-κB gene 
expression by establishing a G9a-like protein -mediated repressed chromatin state within NF-κB 
target genes. And in a screen of over 40 human SET domains containing lysine methyltransferases, 
SETD6 specifically monomethylated relA at Lys310 was only detected in the 
chromatin-associated fraction of the nucleus, and it occupied the promoters of a subset of NF-κB 
target genes under basal conditions. However, unlike the methylations of other relA lysines, which 
are induced by TNF-α-stimulation, TNF-α dramatically reduced the level of methylated relA at 
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Lys310 in primary immune cells (394), thus methylated relA acts in the opposite way to 
phosphorylated relA and acts to reduce the inflammatory response. Taken together, IL-1β 
enhances the gene expression and secretion levels of the pro-inflammatory factors; it also 
increases phosphorylated relA while reduces methylated relA of the NF-κB signaling pathway. 
 
To investigate whether ZK159222 or ZK191784 could exert anti-inflammatory effects on 
IL-1β-stimulated preadipocytes, preadipocytes pretreated and treated with 1α,25(OH)2D3 (10 nM) 
was used as a positive control in the current study. Consistent with the results shown in Chapter 4, 
in this study, 1α,25(OH)2D3 (10 nM) significantly inhibited the secretion levels of IL-6, IL-8, 
MCP-1 and RANTES compared to (0.5 ng/ml) IL-1β-stimulated preadipocytes. Noteworthy, 
1α,25(OH)2D3 (10 nM) also significantly inhibited the gene expression levels of IL-1β, IL-6, IL-8, 
MCP-1 and RANTES, which suggests that the prolonged duration of pretreatment [48 h, which 
was established in the study to explore the anti-inflammatory effects of VDR agonists (ZK159222 
and ZK191784) on THP-1-MacCM-stimulated adipocytes (322), compared to 24 h in chapters 3 
and 4] could enhance the anti-inflammatory effects on gene inhibition of the pro-inflammatory 
factors. 
 
A recent study from our group shows that ZK159222 or ZK191784 reduced the production of the 
pro-inflammatory factors in THP-1-MacCM-stimulated adipocytes (322). Likewise, the results of 
the current study show that ZK159222 (10 nM and 1 μM) significantly inhibited the gene 
expression and secretion of the major-pro-inflammatory factors in (0.5 ng/ml) IL-1β-stimulated 
preadipocytes. It has been reported that ZK191784 exhibited potent immune-suppressive as well 
as anti-inflammatory activity by inhibiting antigen-induced lymphocyte proliferation and cytokine 
secretion in vitro (323, 324). Similar to the action of ZK159222, this study shows that the gene 
expression and secretion of the major-pro-inflammatory factors was also significantly inhibited by 
ZK191784 (10 nM and 1 μM) in (0.5 ng/ml) IL-1β-stimulated preadipocytes. Taken together, the 
data from the current study suggest that like 1α,25(OH)2D3, ZK159222 or ZK191784 has 
anti-inflammatory effects by inhibiting the secretion and gene expression of the pro-inflammatory 
factors on IL-1β-stimulated preadipocytes. 
 
183 
 
Moreover, it has been reported that ZK159222 or ZK191784 reduces the levels of phosphorylated 
relA in THP-1-MacCM-stimulated adipocytes (322). To test whether ZK159222 or ZK191784, 
like 1α,25(OH)2D3, could modulate NF-κB signaling in IL-1β-stimulated preadipocytes, the levels 
of phosphorylated relA and methylated relA were measured in the current study. The results show 
the levels of phosphorylated relA were significantly inhibited by ZK159222 (1 μM) and 
ZK191784 (1 μM) in (0.5 ng/ml) IL-1β-stimulated preadipocytes. By contrast, the levels of 
methylated relA were significantly enhanced by ZK159222 (10 nM and 1 μM) as well as 
ZK191784 (10 nM). It has been shown that the VDR-1α,25(OH)2D3 complex directly inhibits the 
expression (transcription) of some genes by antagonizing the action of certain transcription factors 
(e.g. NF-AT and NF-κB) (297, 298). Therefore, Like 1α,25(OH)2D3, ZK15922 and ZK191784 
could exert anti-inflammatory effects by inhibiting the expression of phosphorylated relA and/or 
enhancing methylated relA.  
 
Since the study described in Chapter 4 has demonstrated that 1α,25(OH)2D3 increases the levels of 
phosphorylated eIF-2α of the UPR pathway, the current study also examined if ZK159222 or 
ZK191784 could exert the same effect. The results show that ZK159222 (10 nM) and ZK191784 
(1 μM) significantly enhanced the levels of phosphorylated eIF-2α in (0.5 ng/ml) IL-1β-stimulated 
preadipocytes. Hence, ZK15922 and ZK191784 could also exert the anti-inflammatory by 
enhancing the levels of phosphorylated eIF-2α of the UPR pathway.  
 
Although 1α,25(OH)2D3 did not modulate any of the above mentioned signaling pathways in the 
current study, the results of qPCR suggests that 1α,25(OH)2D3 probably directly inhibited the gene 
expression (transcription) of these pro-inflammatory factors by: forming transcriptional 
complex-corepressor complex, recruiting histone deacetylase activities then deacetylating the 
lysine residues present in the N-terminal located in histone tails, thus to compact the chromatin 
and silence those pro-inflammatory genes (303). The same mechanism also applies to ZK159222 
and ZK1991784 according the qPCR results. 
 
Limitations 
1. Not only preadipocytes responding to IL-1β appears to be dose-dependent, but also the 
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effects of 1α,25(OH)2D3 seem to be time-dependent [might be caused by the stability of VDR 
agonists (though unknown)]. A full exploration of this would require repeating the 
experiment with 
1) Average of time exposure (i.e. pretreatment) with 1α,25(OH)2D3 (e. g. from 6 to 72 h); 
2) At a range of doses of IL-1β (e. g. from 0.2 to 5 ng/ml). 
2. Likewise, the effects of VDR agonists seem to be dependent on the strength of the 
inflammatory response, and a minimally effective dose of 1α,25(OH)2D3 has not been 
established in dose experiment. Further experiment exploring lower doses of 1α,25(OH)2D3 
might be informative. 
3. The levels of total unphosphorylated protein(s) including relA and eIF-2α have not been 
determined, which is a limitation of the current experiment design. Elevated or decreased 
phosphorylation levels may be accompanied by increased or decreased protein levels.  
 
In summary, this study demonstrates that IL-1β could potently enhance the gene expression and 
secretion of the pro-inflammatory factors) in human preadipocytes, by increasing the 
phosphorylated relA, and reducing the methylated relA of the NF-κB pathway. ZK159222 and 
ZK191784 might inhibit the inflammatory response by: 
1. Directly attenuating the pro-inflammatory gene expression;  
2. Reducing level of phosphorylated relA while increasing methylated relA of the NF-κB 
signaling pathway, to inhibit the pro-inflammatory gene expression; 
3. Increasing the level of phosphorylated eIF-2α of the UPR pathway to reduce the 
pro-inflammatory translation. 
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6. The effects of the combination of VDR agonists and VDR 
agonist-MacCM on human white preadipocytes 
 
6.1. Introduction 
 
The expression of TLR was significantly higher in both immune cells and adipose tissue from 
overweight and obese human subjects, compared with lean control (395). Moreover, the TLR 
signaling switches macrophages to M1 phenotype by activating the NF-κB signaling pathway 
(244), which increases gene transcription and secretion of a variety of pro-inflammatory factors 
(for the specific details, please refer to Introduction Page 36-38), as shown in human and murine 
adipose tissue (243, 396), but 1α,25(OH)2D3 (1 μM) could exert an anti-inflammatory effect by 
inhibiting the gene expression of TLR-2 and TLR-4 in LPS or TNF-α-stimulated human monocyte 
and macrophages from fresh buffy coats of healthy volunteers (24 h) (397). 
 
The anti-inflammatory effects of 1α,25(OH)2D3 have been thoroughly explored in human and 
murine monocytes/macrophages. For example, 1α,25(OH)2D3 (40 nM) could suppress the 
listericidal activity, inhibit phagocyte oxidase-mediated oxidative burst and transcription of 
important IFN-induced genes [including Ccl5, Cxcl10, Cxcl9, Irf2, (Fc gamma receptor) Fcgr1, 
Fcgr3, and Tlr2] in IFN-stimulated murine BMDMs (48 h). Subsequently, the inhibition of the 
pro-inflammatory genes was shown to be dependent on a functional VDR and 1α,25(OH)2D3 
acting specifically on IFN-stimulated macrophages. In conclusion, the overall results suggest that 
the production of 1α,25(OH)2D3 by IFN-stimulated macrophages might be an important negative 
feedback mechanism to control innate and inflammatory responses of activated macrophages 
(398). Furthermore, a recent study has demonstrated that 1α,25(OH)2D3 and 25(OH)D3 dose 
dependently (not specified in the paper) inhibited LPS-induced p38 phosphorylation at 
physiologic concentrations, and the secretion of IL-6 and TNF-α from human monocytes. In 
parallel, the mRNA level of MAPK phosphatase-1 was significantly up-regulated in human 
monocytes and murine BMDMs, by increased binding of the VDR and increased histone H4 
acetylation at the identified VDRE of the murine and human MKP-1 promoters (399).  
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It is noteworthy that 1α,25(OH)2D3 also reduced the inflammatory response by polarizing 
pro-inflammatory M1 macrophages towards anti-inflammatory M2 via the VDR-PPARγ pathway 
in vitro. Zhang et al. reported that under high glucose conditions, RAW264.7 macrophages tend to 
switch to M1 phenotype characterized by expressing higher iNOS (inducible nitric oxide synthase) 
as well as pro-inflammatory cytokines including TNF-α and IL-12, whereas 1α,25(OH)2D3 (10-8 M) 
significantly inhibited M1 activation whilst enhanced M2 polarization, demonstrated by 
up-regulated gene expression of MR (mannose receptor) and (Abelson-related gene) Arg-1; 
secretion of anti-inflammatory cytokine IL-10, and down-regulated gene expression of M1 marker 
(iNOS) (24 h) .In addition, the polarizing effect of 1α,25(OH)2D3 could be inhibited by VDR 
siRNA in RAW264.7 macrophages (24 h) (400). 
 
 
 
6.2. Aims  
 
This study aimed to investigate whether the combination of pretreatment with VDR agonists and 
treatment with VDR agonist-MacCM could ameliorate THP-1-MacCM-stimulated 
pro-inflammatory effects in human preadipocytes. The experiments were set up to examine 
whether:  
1. THP-1-MacCM could enhance the gene expression of IL-1β, IL-8, IL-6, MCP-1 and 
RANTES in human white preadipocytes;  
2. THP-1-MacCM could enhance the secretion of the pro-inflammatory factors from human 
white preadipocytes;  
3. The combination of pretreatment with VDR agonists and treatment with VDR 
agonist-MacCM could ameliorate the secretion or gene expression of the pro-inflammatory 
factors in preadipocytes;  
4. THP-1-MacCM could increase the levels of phosphorylated relA of the NF-κB pathway as 
well as phosphorylated ERK or p38 of the MAPK pathways in preadipocytes  
5. The combination of pretreatment with VDR agonists and treatment with VDR 
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agonist-MacCM could reduce the levels of the signaling molecules of the NF-κB and MAPK 
pathways in preadipocytes. 
 
 
 
6.3. Materials and Methods 
 
Generation of THP-1-MacCM and VDR agonist-MacCM 
 
Culture of THP-1 monocytes and generation of THP-1-MacCM were performed as described in 
Chapter 2. The VDR agonist-MacCM were thus generated: ZK159222 (10 nM)-MacCM 
(generated from THP-1-macrophages treated with 10 nM ZK159222); ZK159222 (1 μM)-MacCM 
(generated from THP-1-macrophages treated with 1 μM ZK159222); ZK191784 (10 nM)-MacCM 
(generated from THP-1-macrophages treated with 10 nM ZK191784); ZK191784 (1 μM)-MacCM 
(generated from THP-1-macrophages treated with 1 μM ZK191784); 1α,25(OH)2D3 (10 
nM)-MacCM (generated from THP-1-macrophages treated with 10 nM of 1α,25(OH)2D3). All the 
treatments lasted for 24 h before the VDR agonist-MacCM were collected, filtered through a 0.22 
μm filter and then stored at −80°C for preadipocyte treatment. 
 
Preadipocyte pretreatment and treatment  
 
Culture of human preadipocytes was performed as described in Chapter 3. To investigate the 
effects of the combination of combination of pretreatment with VDR agonists and treatment with 
VDR agonist-MacCM, preadipocytes were either cultured alone (control), or with (25%) 
THP-1-MacCM alone for 24 h. Further groups of cells were pretreated with 1α,25(OH)2D3 (10 nM, 
ENZO Life Sciences, USA), ZK 159222 (10 nM and 1 μM, Bayer, Germany) or ZK191784 (10 
nM and 1 μM, Bayer, Germany) for 48 h [using an established protocol (322)], followed by 
treatments with (25%) THP-1-MacCM and (25%) VDR agonist-MacCM for a further 24 h [the 
established protocol (322)] at 37°C in 95% air and 5% CO2 before medium and lysate collection. 
The cell media for ELISA; the treated preadipocytes lysed with Trizol for qPCR; lysed with lysis 
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buffer for western blotting, were stored at −80°C. 
 
Measurements 
 
ELISA was performed for determining the secretion levels of pro-inflammatory factors including 
IL-1β, IL-6, IL-8, MCP-1 and RANTES and corrected by total protein content in cellular lysate. 
Real-time PCR was used to measure the gene expression levels of pro-inflammatory factors 
including IL-1β, IL-6, IL-8, MCP-1 and internal reference PPIA. For measuring protein levels of 
phosphorylated relA of the NF-κB signaling pathway, phosphorylated ERK and p38 of the MAPK 
signaling pathway, western blotting was performed. The laboratory procedures and statistical 
analyses are described in detail in Chapter 3.  
 
 
 
6.4. Results 
 
6.4.1. THP-1-MacCM enhances the secretion of the pro-inflammatory factors from human 
preadipocytes 
 
The ELISA result (Figure 6.1) shows that the secretion levels of IL-1β, IL-6, IL-8, MCP-1 and 
RANTES were dramatically increased by THP-1-MacCM.  
 
 
6.4.2. The combination of pretreatment with 1α,25(OH)2D3 and treatment with 
1α,25(OH)2D3-MacCM ameliorates the secretion of the pro-inflammatory factors 
from human preadipocytes  
 
(Figure 6.1) The secretion levels of IL-1β, IL-6, IL-8, MCP-1 and RANTES were significantly 
reduced by the combination of pretreatment with 1α,25(OH)2D3 (10 nM) and treatment with  
1α,25(OH)2D3(10nM)-MacCM, compared to the untreated preadipocytes.  
189 
 
6.4.3. The combination of pretreatment with ZK159222 and treatment with 
ZK159222-MacCM ameliorates the secretion of the pro-inflammatory factors from 
human preadipocytes 
 
(Figure 6.1) Firstly, pretreatments with ZK159222 (10 nM and 1 μM) and treatments with 
ZK159222 (10 nM and 1 μM)-MacCM dramatically reduced the levels of IL-1β, IL-6 and IL-8. 
Secondly, the levels of RANTES were moderately reduced by the pre- and treatments compared to 
the untreated preadipocytes. Noteworthy, the reducing effects on these pro-inflammatory factors 
are consistent between the groups. Finally, though the levels of MCP-1 were also moderately 
reduced by the pre- and treatments, only the difference by pretreatment with ZK159222 (10 nM) 
and treatment with ZK159222(10 nM )-MacCM was statistically significant. 
 
 
6.4.4. The combination of pretreatment with ZK191784 and treatment with 
ZK191784-MacCM ameliorates the secretion of the pro-inflammatory factors from 
preadipocytes 
  
(Figure 6.1) Pretreatments with ZK191784 (10 nM and 1 μM) and treatments with ZK191784(10 
nM and 1 μM)-MacCM significantly reduced the levels of IL-1β, IL-6, IL-8, MCP-1 and 
RANTES, and except IL-6, the reducing effects on these pro-inflammatory factors are consistent 
between the groups.  
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Figure 6.1 Effects of the combination of pretreatment with VDR agonists and treatment with 
VDR agonist-MacCM on cytokine release from human white preadipocytes (after 
adjustment of ELISA results for total protein).  
Preadipocytes were either cultured alone (control), or with (25%) THP-1-MacCM alone for 24 h. 
Further groups of cells were pretreated with 1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM and 1 
μM) or ZK191784 (10 nM and 1 μM) for 48 h, followed by treatments with 1α,25(OH)2D3 (10 nM) 
or ZK159222 (10 nM and 1 μM) or ZK191784 (10 nM and 1 μM)-MacCM for a further 24 h 
before medium collection. The release levels of pro-inflammatory factors (A) IL-1β, (B) IL-6, (C) 
IL-8, (D) MCP-1 and (E) RANTES were measured by ELISA and normalized by protein content 
in the cellular lysate. Data are means ± SEM for groups of 6. A significant difference to control 
was indicated by ***(p<0.001); to (25%) THP-1-MacCM by #(p<0.05), ##(p<0.01), 
###(p<0.001). The results were determined using one-way ANOVA with Tukey’s post hoc test and 
confirmed by two independent experiments. 
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6.4.5. THP-1-MacCM enhances the gene expression of the pro-inflammatory factors in 
human preadipocytes 
 
Similar to the secretion levels, the qPCR result (Figure 6.2) shows that the mRNA levels of IL-1β, 
IL-6, IL-8, MCP-1 and RANTES, were dramatically increased by THP-1-MacCM in human 
preadipocytes. 
 
 
6.4.6. Pretreatment with 1α,25(OH)2D3 and treatment with 1α,25(OH)2D3-MacCM reduces 
the gene expression of pro-inflammatory factors in human preadipocytes  
 
(Figure 6.2) The combination of pretreatment with 1α,25(OH)2D3 (10 nM) and treatment with 
1α,25(OH)2D3(10 nM)-MacCM exhibited distinguishable reducing effects on the mRNA levels of 
IL-1β, IL-6, IL-8, MCP-1 and RANTES, compared to those in THP-1-MacCM-stimulated 
preadipocytes. 
 
 
6.4.7. Pretreatment with ZK159222 followed by treatment with ZK159222-MacCM 
reduces the gene expression of pro-inflammatory factors in human preadipocytes 
 
Firstly, the mRNA levels of IL-1β were drastically reduced to a similar extent by pretreatments 
with both doses of ZK159222 (10 nM and 1 μM) and treatments with ZK159222(10 nM and 1 
μM)-MacCM, compared to THP-1-MacCM-stimulated preadipocytes (Figure 6.2). Secondly, the 
combination of pre- and treatment moderately reduced the mRNA levels of IL-6, IL-8 and 
RANTES, again with no obvious dose-response pattern [though the difference of IL-8 by 
pretreatment with ZK159222 (10 nM) and treatment with ZK159222(10 nM)-MacCM, is not 
statistically significant]. Finally, the combination of pre- and treatment had no significant effect on 
the mRNA levels of MCP-1. 
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6.4.8. The combination of pretreatment with ZK191784 and treatment with 
ZK191784-MacCM ameliorates the gene expression of pro-inflammatory factors in 
human preadipocytes, compared to MacCM alone 
  
(Figure 6.2) The mRNA levels of IL-1β, IL-6, IL-8, MCP-1 and RANTES were markedly reduced 
by pretreatments with ZK191784 (10 nM and 1 μM) and treatments with ZK191784(10 nM and 1 
μM)-MacCM, compared to THP-1-MacCM-stimulated preadipocytes [except that of MCP-1 by 
pretreatment with ZK191784 (1 μM) and treatment with ZK191784(1 μM)-MacCM], with no 
apparent dose-response relationship.  
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Figure 6.2 Effects of the combination of pretreatment with VDR agonists and treatment with 
VDR agonist-MacCM on cytokine gene expression in human white preadipocytes.  
Preadipocytes were either cultured alone (control), or with (25%) THP-1-MacCM alone for 24 h. 
Further groups of cells were pretreated with 1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM and 1 
μM) or ZK191784 (10 nM and 1 μM) for 48 h, followed by treatments with 1α,25(OH)2D3 (10 nM) 
or ZK159222 (10 nM and 1 μM) or ZK191784 (10 nM and 1 μM)-MacCM for a further 24 h 
before Trizol-dissolved lysate collection. The mRNA levels of pro-inflammatory factors (A) IL-1β, 
(B) IL-6, (C) IL-8, (D) MCP-1 and (E) RANTES were measured by qPCR. Data are means ± 
SEM for groups of 6. A significant difference to control was indicated by ***(p<0.001); to (25%) 
THP-1-MacCM by #(p<0.05), ##(p<0.01), ###(p<0.001). The results were determined using 
one-way ANOVA with Tukey’s post hoc test and confirmed by two independent experiments. 
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6.4.9. THP-1-MacCM increases the level of phosphorylated relA in human preadipocytes 
 
To test whether THP-1-MacCM could modulate the NF-κB pathway, the level of phosphorylated 
relA was measured by western blotting. The result (Figure 6.3) shows that the level of 
phosphorylated relA was dramatically higher in the presence of THP-1-MacCM, compared to the 
untreated preadipocytes.  
 
 
6.4.10. The combination of pretreatment with VDR agonists and treatment with VDR 
agonist-MacCM reduces the levels of phosphorylated relA in human preadipocytes, 
compared to MacCM alone 
 
The result (Figure 6.3) shows that the levels of phosphorylated relA were moderately and 
significantly decreased only by pretreatments with 1α,25(OH)2D3 (10 nM), ZK159222 (1 μM) and 
ZK191784 (1 μM) and treatments with 1α,25(OH)2D3(10 nM), ZK159222(1 μM) and ZK191784 
(1 μM)-MacCM, compared with THP-1-MacCM treated preadipocytes.  
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Figure 6.3 Effects of the combination of pretreatment with VDR agonists and treatment with 
VDR agonist-MacCM on phosphorylated relA of the NF-κB signaling pathway in human 
white preadipocytes.  
Preadipocytes were either cultured alone (control), or with (25%) THP-1-MacCM alone for 24 h. 
Further groups of cells were pretreated with 1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM and 1 
μM) or ZK191784 (10 nM and 1 μM) for 48 h, followed by treatments with 1α,25(OH)2D3 (10 nM) 
or ZK159222 (10 nM and 1 μM) or ZK191784 (10 nM and 1 μM)-MacCM for a further 24 h 
before lysate collection. The levels of phosphorylated relA were measured by western blotting. 
Data are means ± SEM for groups of 3. A significant difference to control was indicated by 
***(p<0.001); to (25%) THP-1-MacCM by ##(p<0.01), ###(p<0.001). The results were 
determined using one-way ANOVA with Tukey’s post hoc test and confirmed by two independent 
experiments. 
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6.4.11. THP-1-MacCM increases the levels of phosphorylated ERK and p38 in human 
preadipocytes 
 
Like that of phosphorylated relA, (Figure 6.4) the levels of phosphorylated ERK (p44/42) and p38 
of the MAPK signaling pathways were significantly increased by THP-1-MacCM.  
 
 
6.4.12. The combination of pretreatment with 1α,25(OH)2D3 and treatment with 
1α,25(OH)2D3-MacCM reduces the levels of phosphorylated ERK and p38 in human 
preadipocytes, compared to MacCM alone 
 
(Figure 6.4 A) The level of phosphorylated ERK was moderately reduced by pretreatment with 
1α,25(OH)2D3 (10 nM) and treatment with 1α,25(OH)2D3(10 nM)-MacCM in human 
preadipocytes. (Figure 6.4 B) Moreover, the pre- and treatment dramatically reduced the level of 
phosphorylated p38, compared to THP-1-MacCM-stimulated preadipocytes.   
 
 
6.4.13. The combination of pretreatment with ZK159222 and treatment with 
ZK159222-MacCM reduces the levels of phosphorylated ERK and p38 in human 
preadipocytes 
 
(Figure 6.4 A) Only pretreatment with ZK159222 (1 μM) and treatment with ZK159222 (1 
μM)-MacCM significantly reduced the level of phosphorylated ERK in human preadipocytes. 
(Figure 6.4 B) In parallel, the levels of phosphorylated p38 were moderately reduced by 
pretreatments with ZK159222 (10 nM and 1 μM) and treatments with ZK159222(10 nM and 1 
μM)-MacCM, compared to THP-1-MacCM-stimulated preadipocytes. 
 
 
6.4.14. The combination of pretreatment with ZK191784 and treatment with 
ZK191784-MacCM ameliorates the levels of phosphorylated p38 in human 
preadipocytes 
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(Figure 6.4 B) The levels of phosphorylated p38 were distinguishably and consistently reduced by 
pretreatments with ZK191784 (10 nM and 1 μM) and treatments with ZK191784(10 nM and 1 
μM)-MacCM, compared to THP-1-MacCM-stimulated preadipocytes. (Figure 6.4 A) However, 
the pre- and treatment had no ameliorating effect on the levels of phosphorylated ERK in human 
preadipocytes.  
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Figure 6.4 Effects of the combination of pretreatment with VDR agonists and treatment with 
VDR agonist-MacCM on signaling molecules of the MAPK signaling pathways in human 
white preadipocytes.  
Preadipocytes were either cultured alone (control), or with (25%) THP-1-MacCM alone for 24 h. 
Further groups of cells were pretreated with 1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM and 1 
μM) or ZK191784 (10 nM and 1 μM) for 48 h, followed by treatments with 1α,25(OH)2D3 (10 nM) 
or ZK159222 (10 nM and 1 μM) or ZK191784 (10 nM and 1 μM)-MacCM for a further 24 h 
before lysate collection. The levels of (A) phosphorylated ERK and (B) phosphorylated p38 were 
measured by western blotting. Data are means ± SEM for groups of 3. A significant difference to 
control was indicated by **(p<0.01), ***(p<0.001); to (25%) THP-1-MacCM by #(p<0.05),  
##(p<0.01), ###(p<0.001). The results were determined using one-way ANOVA with Tukey’s post 
hoc test and confirmed by two independent experiments. 
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6.5. Discussion 
 
The current study shows that the gene expression and secretion of IL-1β, IL-6, IL-8, MCP-1 and 
RANTES were markedly reduced by pretreatment with 1α,25(OH)2D3 (10 nM) and treatment  
with 1α,25(OH)2D3(10 nM)-MacCM, compared to THP-1-MacCM-stimulated preadipocytes. 
Likewise, the pretreatment with the synthesized VDR agonists [ZK159222 (10 nM and 1μM) and 
ZK191784 (10 nM and 1μM)] and treatment with the synthesized VDR agonist-MacCM 
significantly ameliorated the gene expression and secretion of these pro-inflammatory factors. In 
conclusion, the pretreatment with VDR agonists and treatment with VDR agonist-MacCM could 
attenuate THP-1-MacCM-stimulated inflammatory response in preadipocytes. 
 
Moreover, pretreatments with VDR agonists [1α,25(OH)2D3 (10 nM), ZK159222 (1 μM) and 
ZK191784 (1 μM)] and treatments with VDR agonists-MacCM significantly reduced the levels of 
phosphorylated relA compared with THP-1-MacCM treated preadipocytes. In parallel, the 
pretreatment with VDR agonists [1α,25(OH)2D3 (10 nM), ZK159222 (10 nM and 1 μM) and 
ZK191784 (10 nM and 1 μM)] and treatment with VDR agonists-MacCM dramatically reduced 
the levels of phosphorylated p38, while the pretreatment with VDR agonists [1α,25(OH)2D3 (10 
nM) and ZK159222 (1 μM)] and treatment with VDR agonists-MacCM significantly reduced the 
levels of phosphorylated ERK. Taken together, pretreatment with VDR agonists and treatment 
with VDR agonists-MacCM could lower the levels of phosphorylated relA of the NF-κB pathway, 
phosphorylated ERK and p38 of the MAPK pathways. 
 
Limitations 
1. It can’t be specified at this stage that whether the ameliorating effects exerted on 
preadipocytes were by pretreatment with VDR agonists or treatment with 
VDR-agonist-MacCM. Separate experiments including treating (24 h) human preadipocytes 
with VDR-agonist-MacCM alone (the pilot study has been done, and the data shown in 
Appendix 9.5, 6); and pretreating (48 h) and treating (24 h) human preadipocytes with VDR 
agonists, are to be carried out in the future. 
2. To thoroughly examine the potential anti-inflammatory effects of VDR agonist-MacCM 
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(since the anti-inflammatory effects of VDR agonists on IL-1β-stimulated preadipocytes have 
been demonstrated in Chapter 5): 
a) The secretion and gene expression levels of pro-inflammatory factors (IL-1β, IL-6, IL-8, 
MCP-1 and RANTES in VDR agonist-MacCM-treated THP-1-macrophages (24 h) 
should be measured. Moreover, to explore the underlying anti-inflammatory mechanism, 
the levels of pro-inflammatory signaling molecules (phosphorylated relA of the NF-κB 
pathway, phosphorylated ERK and p38 of the MAPK pathways) should also be 
determined. 
b) It was mentioned before that 1α,25(OH)2D3 could polarize pro-inflammatory M1 
macrophages towards anti-inflammatory M2 (400). To test whether VDR agonists have 
the polarizing effect on LPS-stimulated THP-1-macrophages, the secretion and gene 
expression levels of anti-inflammatory factors (i.e. IL-10) in VDR agonist-treated 
THP-1-macrophages should be measured (24 h). Furthermore, to detect whether M2 
markers [Arg-1, CD163, (major histocompatibility complex) MHC II and IL-1R II] on 
the surface of VDR agonist-treated THP-1-macrophages (24 h), flow cytometry is 
required for the purpose.  
3. The levels of total unphosphorylated protein(s) including relA, ERK (p42/44) and p38 have 
not been determined, which is a limitation of the current experiment design. Elevated or 
decreased phosphorylation levels may be accompanied by increased or decreased protein 
levels.  
 
In summary, this study demonstrates that THP-1-MacCM-stimulated preadipocytes could 
significantly enhance the gene expression and secretion of the pro-inflammatory factors, by 
increasing the signaling levels of the NF-κB (phosphorylated relA) and MAPK (phosphorylated 
ERK and p38) pathways. The combination of pretreatment with VDR agonists and treatment with 
the VDR agonist-MacCM might decrease the pro-inflammatory secretion and gene expression 
(compared to THP-1-MacCM-stimulated preadipocytes) by: 
1. Directly attenuating the gene expression;  
2. Reducing the levels of phosphorylated relA of the NF-κB signaling pathway; 
3. Reducing the levels of phosphorylated p38 and ERK of the MAPK signaling pathways. 
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7. Discussion 
 
7.1. The inflammatory synergy of preadipocytes 
 
It has been demonstrated that MacCM could increase the pro-inflammatory gene expression and 
release in mature human adipocytes (322, 354). Likewise, our study shows that MacCM 
significantly enhanced the gene expression and secretion levels of IL-1β, IL-6, IL-8, MCP-1 and 
RANTES in human preadipocytes, which suggests that preadipocytes could synergize 
metaflammation induced by infiltrated macrophages in obesity. In parallel, the gene expression 
and secretion of the major pro-inflammatory factors were significantly inhibited by IL-1β and IL-6 
neutralization. Moreover, IL-1β (0.5 and 2 ng/ml) alone significantly induced the inflammatory 
response in preadipocytes to a similar extent as that by MacCM. These results are in accordance 
with good evidence that IL-1β as well as IL-6 could mediate inflammatory response in human 
adipose tissue (21, 161, 171), and also imply that IL-6 and especially IL-1β secreted from M1 
macrophages or preadipocytes are critical in maintaining and aggravating metaflammation in 
obesity.  
 
The NF-κB and MAPK signaling have been established as pro-inflammatory pathways activated 
in metaflammation by a number of studies using murine and human 
MacCM/IL-1β/LPS-stimulated pre/adipocytes and LPS-activated macrophages (134, 141, 144-146, 
243, 244, 322, 354, 355). Similarly, the current results show that the levels of phosphorylated relA 
of the NF-κB pathway, and phosphorylated ERK and p38 of the MAPK pathways, were 
significantly increased in THP-1-MacCM-stimulated preadipocytes. Though exerting no effect on 
the signaling molecules of the MAPK pathways (as demonstrated by IL-1β neutralization on Page 
130-131), IL-1β (0.5 ng/ml) not only significantly increased the level of phosphorylated relA of 
the NF-κB pathway [also by IL-1β (2 ng/ml)], but also reduced the levels of methylated relA at 
Lys 310, which acts in the opposite way (to phosphorylated relA) to enhance the gene 
transcription of the pro-inflammatory factors (394), and could be added as a new ‘member’ in 
future research regarding signaling molecules involved in metaflammation.  
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7.2. The anti-inflammatory effects of VDR agonists 
 
The anti-inflammatory effects of 1α,25(OH)2D3 and its synthesized analogues including 
ZK159222 and ZK191784 have been shown on mature human adipocytes and murine pre- and 
adipocytes (322, 352-356). Likewise, pre- (24 h) and treatments (24 h) with 1α,25(OH)2D3 (0.1-10 
nM) significantly inhibited the mRNA levels of IL-1β, IL-6, IL-8 and RANTES in 
THP-1-MacCM-stimulated preadipocytes (24 h). In parallel with the gene expression, the 
secretion levels of IL-6, IL-8, MCP-1 and RANTES were also significantly inhibited by the pre- 
and treatment. However, there was no obvious dose-response relationship between the mRNA or 
secretion levels of the pro-inflammatory factors and the doses of 1α,25(OH)2D3. 
 
It is noteworthy that our study also suggests that not only the inflammatory responses induced by 
IL-1β are dose-dependent, but also the anti-inflammatory effects of 1α,25(OH)2D3 is 
time-dependent. For though 1α,25(OH)2D3 (0.1-10 nM) significantly inhibited the secretion but 
not the gene expression levels of IL-1β, IL-6, IL-8, MCP-1 and RANTES in (0.5 ng/ml) 
IL-1β-stimulated preadipocytes, the gene expression and secretion levels of these 
pro-inflammatory factors were significantly inhibited by 1α,25(OH)2D3 (0.1-10 nM) in IL-1β (2 
ng/ml) treated preadipocytes. Moreover, the gene expression levels of IL-1β, IL-6, IL-8, MCP-1 
and RANTES were significantly reduced in (0.5 ng/ml) IL-1β-stimulated preadipocytes that 
received pre- (48 h) and treatment (24 h) with 1α,25(OH)2D3 (10 nM), but not in those received 
pre- (24 h) and treatment (24 h). Again there was no dose-response relationship between the 
mRNA or secretion level of the pro-inflammatory factors and the dose of 1α,25(OH)2D3. Hence, to 
fully explore the nature of inflammatory responses induced by IL-1β and anti-inflammatory 
efficacies of 1α,25(OH)2D3, further study with a broadened range of IL-1β and 1α,25(OH)2D3 
doses and pre- and treatment duration is to be carried out.   
 
In addition, similar to the anti-inflammatory effects exerted by pre- (24 and 48 h) and treatments 
(24 h) with 1α,25(OH)2D3 (0.1-10 nM), pre- (48 h) and treatments (24 h) with ZK191784 (10 nM 
and 1 μM) and ZK159222 (10 nM and 1 μM) also significantly reduced the secretion and gene 
transcription levels of the pro-inflammatory factors in (0.5 ng/ml) IL-1β-stimulated preadipocytes.  
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Finally, compared to THP-1-MacCM-stimulated preadipocytes, the anti-inflammatory effects of 
pretreatment with VDR agonists [1α,25(OH)2D3 (10 nM), ZK15922 (10 nM and 1 μM) and 
ZK191784 (10 nM and 1 μM)] (48 h) and treatment with VDR agonist-MacCM (24 h) on the 
pro-inflammatory secretion and gene expression, were also achieved by our study. Whether the 
effects exerted were by pretreatment with VDR agonists or treatment with VDR-agonist-MacCM 
is still to be unraveled [the preliminary data (shown in Appendix 9.5, 6) indicate that VDR 
agonist-MacCM could reduce the pro-inflammatory secretion and gene expression, compared to 
those by THP-1-MacCM-stimulated preadipocytes], although the anti-inflammatory effects and 
characterized working mechanism of 1α,25(OH)2D3 have been demonstrated on murine and 
human monocytes/macrophages (398-400). 
 
 
 
7.3. The mechanisms  
 
Similar to the effects of VDR agonists on signaling molecules of NF-κB and MAPK pathways in 
human adipocytes (322, 354), the western blotting results show that 1α,25(OH)2D3 (10 nM) 
significantly inhibited the levels of phosphorylated relA and ERK, compared to 
THP-1-MacCM-stimulated preadipocytes (24 h). Moreover, ZK15922 and ZK191784 not only 
reduced the levels of phosphorylated relA, but also increased methylated relA in (0.5 ng/ml) 
IL-1β-stimulated preadipocytes.  
 
Since ER stress and the coping response-UPR is a potential trigger of metaflammation in obesity 
(401), the levels of signaling molecules of the UPR pathways were determined in our study. The 
results show that the levels of phosphorylated eIF-2α were markedly reduced by 1α,25(OH)2D3 
(0.01-10 nM), which indicates that by decreasing phosphorylated eIF-2α, 1α,25(OH)2D3 could 
inhibit the UPR-induced NF-κB signaling pathway (52, 53) to exert anti-inflammatory effects on 
human white preadipocytes. However, in contrast to the effects of 1α,25(OH)2D3 (0.01-10 nM) in 
THP-1-MacCM-stimulated preadipocytes, the levels of phosphorylated eIF-2α were significantly 
increased by 1α,25(OH)2D3 in (0.5 and 2 ng/ml) IL-1β-stimulated preadipocytes, which could also 
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be taken as an anti-inflammatory mechanism of 1α,25(OH)2D3 since phosphorylated eIF-2α could 
abate the general translation (402). Hence, although the mRNA levels of the pro-inflammatory 
factors were not significantly inhibited by 1α,25(OH)2D3 (0.01-10 nM) in (0.5 ng/ml) 
IL-1β-stimulated preadipocytes (24 h), the secretion could still be reduced (as the ELISA results 
show) by increasing the level of phosphorylated eIF-2α. Similarly, the reducing effects on the 
pro-inflammatory production could be exerted by ZK159222 (10 nM) and ZK191784 (1 μM) on 
(0.5 ng/ml) IL-1β-stimulated preadipocytes in the same way (24 h) (as the western blotting results 
show). In addition, it could be proposed that VDR agonists activate the UPR pathways in 
IL-1β-stimulated human preadipocytes and that 1α,25(OH)2D3 (or ZK159222 and ZK191784) 
could trigger Ca2+ depletion by releasing it from ER stores through IP3R and RyR/Ca2+ release 
channels (349), while the loss of ER Ca2+ stores by itself is sufficient to trigger ER stress and 
apoptosis (403). The evidence of intracellular Ca2+ also playing a central role in regulating and 
sensing key cellular processes, especially the UPR (404, 405) , further supports that VDR agonists 
might regulate the transportation of ER associated Ca2+ to induce the ER stress and the UPR .  
 
In summary,  
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1. Pre- (24 h) and treatment (24 h) with 1α,25(OH)2D3 (0.1-10 nM) might inhibit (25%) 
THP-1-MacCM-stimulated inflammatory response in human preadipocytes by:  
a) Directly attenuating the pro-inflammatory gene expression;  
b) Blocking phosphorylated relA of the NF-κB signaling pathway to attenuate the 
pro-inflammatory gene expression;  
c) Blocking phosphorylated ERK in a non-genomic way to attenuate the pro-inflammatory 
gene expression;  
d) Reducing phosphorylated eIF-2α to inhibit the NF-κB signaling pathway; 
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2. Pre- (24 and 48 h) and treatment (24 h) with VDR agonists [1α,25(OH)2D3 (0.01-10 nM), 
ZK15922 (10 nM and 1 μM) and ZK191784 (10 nM and 1 μM)] might inhibit (0.5 and 2 
ng/ml) IL-1β-stimulated inflammatory response in human preadipocytes by:  
a) Directly attenuating the pro-inflammatory gene expression;  
b) Blocking phosphorylated relA of the NF-κB signaling pathway to attenuate the 
pro-inflammatory gene expression;  
c) Increasing methylated relA at Lys 310 of the NF-κB signaling pathway to attenuate the 
pro-inflammatory gene expression  
d) Increasing phosphorylated eIF-2α to abate the pro-inflammatory translation. 
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7.4. The limitations 
 
1. Separate experiments with different time frames should be carried out to address the 
anti-inflammatory effects of VDR agonists on the pro-inflammatory gene expression and 
secretion (for 12, 24, 48 and 72 h) and pro- and anti-signaling molecules including un- and 
modified (phosphorylated and methylated) relA, and phosphorylated ERK, p38 and eIF-2α 
(for 5, 10, 15, 30 and 60 min);    
2. The disparities noted in some experiments regarding gene expression (measured by qPCR) 
and secretion (measured by ELISA) might be considered a limitation of the study, however 
there are some possible explanations for this that should be considered. As noted in Chapter 4 
and 5, the anti-inflammatory mechanisms involving 1α,25(OH)2D3 in IL-1β-stimulated 
preadipocytes could be at gene expression level (forming VDR-transcription complex, 
blocking phosphorylated relA and increasing methylated relA to inhibit the pro-inflammatory 
gene expression) and secretion level (increasing phosphorylated eIF-2α to directly inhibit the 
pro-inflammatory translation, and then to reduce the pro-inflammatory release), so the 
disparity between the secretion and expression data [especially inhibited secretion but 
unchanged gene expression in (0.01-10 nM) 1α,25(OH)2D3-treated IL-1β-stimulated 
preadipocytes (24 h)], and even no obvious dose (used in our study)-response relationship 
between 1α,25(OH)2D3 and the pro-inflammatory mRNA or release levels, might be due to 
the promiscuity of 1α,25(OH)2D3 in its anti-inflammatory effects on human preadipocytes; 
3. Since the cell lysates extracted in the experiments were of the whole cell, only the level of 
phosphorylated/methylated relA could be measured to determine the activation of the NF-κB 
signaling pathway, for these post-translationally modified signaling molecules can represent 
relA the transcription factor in the cell nucleus. To further unravel the mystery of VDR 
agonists interacting with IL-1β/THP-1-MacCM-induced NF-κB signaling pathway, the 
nuclear lysates should be extracted and the levels of un- and modified (including 
phosphorylated and methylated) relA should be measured, to compare with vinculin of the 
whole cell (the loading control). Likewise, cytoplasmic lysates should also be extracted for 
the compare among the levels of ERK/p38, phosphorylated ERK/p38 and vinculin of the 
whole cell; 
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4. It could be questioned whether total protein or vinculin are the most appropriate methods to 
help assess whether a specific protein changes in response to treatment. Firstly, the total 
protein level can be compared across treatment conditions and to untreated cells, which acts 
as control. Total protein levels should be monitored in reference to a protein that does not 
change, usually a cytoskeletal protein, for example vinculin, as used in this thesis as a loading 
control for western blotting. Secondly, western blotting (like qPCR) is a technique to estimate 
what has happened in a single cell by ruling out influence of cell quantity, so a loading 
control is necessary to correct for possible differences in the amount of material loaded onto 
the gel. 
 
 
 
7.5. Future directions 
 
Animal experiments to be established 
1. To generate adipose tissue inflammation in vivo: 
a) LPS injection to mouse; 
b) IL-1β injection/infusion to mouse; 
c) Obese mouse models: by HFD or genetic modification (i.e. ob/ob) 
2. To block the inflammatory response: 
a) IL-1β antibody injection to the mouse; 
b) IL-1β knockout to the mouse; 
c) VDR agonist (1α,25(OH)2D3, ZK159222 and ZK191784) treatment (by feeding or 
injection) to the mouse; 
3. To measure the outcomes: 
a) Assess the inflammatory status by histology (examine macrophage infiltration) or qPCR 
(measure the mRNA levels of IL-1β, IL-6, IL-8, MCP-1 and RANTES) in the mouse 
adipose tissue; 
b) Determine the insulin sensitivity of the mouse by hyperinsulinemic-euglycemic clamp. 
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7.6. Final remarks 
 
The studies aimed to investigate the anti-inflammatory properties of VDR agonists. The results 
show that pre- (24 and 48 h) and treatment (24 h) with VDR agonists [1α,25(OH)2D3 (0.01-10 
nM), ZK159222 (10 nM and 1 μM) and ZK191784 (10 nM and 1 μM)] significantly inhibited the 
gene expression and secretion of IL-1β, IL-6, IL-8, MCP-1 and RANTES in (0.5 and 2 ng/ml) 
IL-1β/(25%) MacCM-stimulated human preadipocytes (24 h). Moreover, pretreatment with VDR 
agonists [1α,25(OH)2D3 (0.01-10 nM), ZK159222 (10 nM and 1 μM) and ZK191784 (10 nM and 
1 μM)] (48 h) and treatment (24 h) with VDR agonist-MacCM significantly ameliorates the gene 
expression and secretion of the major inflammatory factors, compared to those of 
THP-1-MacCM-stimulated preadipocytes. Besides directly attenuating the gene expression of the 
pro-inflammatory factors, the anti-inflammatory actions of VDR agonists were probably mediated 
by modulating the NF-κB, MAPK and UPR pathways. The anti-inflammatory mechanism needs to 
be clarified in the future. In addition, the effects of VDR agonists on insulin resistance also remain 
to be addressed. 
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9. Appendix 
 
9.1. The summary of cytokine secretion of Chapter 3 
 
 
THP-1-MacCM  
(25%)* 
Control 
 
THP-1-MacCM  
(25%) 
IL-1β antibody  
(15 μg/ml) 
G-CSF - - - 0.1185404 
GRO-α 0.1319586 - - 0.7023741 
IL-1Ra - - - 0.1953415 
IL-6 - - 0.9698434 0.5358791 
IL-8 1.031219 0.2082694 0.8538878 0.5741403 
MCP-1 - - 1.075745 0.8201016 
MIF - - - 0.1598375 
MIP-1β - - - 0.1129619 
MIP-1α - - - 0.2468504 
RANTES 0.1786312 - 2.221326 0.6981524 
Serpin E1 - 1.188645 0.990583 0.5595829 
sICAM-1 0.2167966 - - 0.1913958 
The results are presented in fold change of pixel density (relative to the references on the proteome 
array). 
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9.2. Effects of IL-6 antibody on cytokine release from 
THP-1-MacCM-stimulated human white preadipocytes 
 
 
Preadipocytes were either cultured alone (control), with (25%) THP-1-MacCM alone, or in the 
presence of IL-6 neutralizing antibody (300, 350 and 400 ng/ml) for 24 h before medium 
collection. The release levels of pro-inflammatory factors (A) IL-6, (B) IL-8, (C) MCP-1 and (D) 
RANTES were measured by ELISA. Data are means ± SEM for groups of 6. A significant 
difference to control was indicated by ***(p<0.001); to (25%) THP-1-MacCM by #(p<0.05), 
##(p<0.01), ###(p<0.001). The results were determined using one-way ANOVA with Tukey’s post 
hoc test. 
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9.3. Effects of IL-6 antibody on cytokine gene expression in 
THP-1-MacCM-stimulated human white preadipocytes 
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Preadipocytes were either cultured alone (control), with (25%) THP-1-MacCM alone, or in the 
presence of IL-6 neutralizing antibody (300, 350 and 400 ng/ml) for 24 h before Trizol-dissolved 
lysate collection. The mRNA levels of pro-inflammatory factors (A) IL-1β, (B) IL-6, (C) IL-8, (D) 
MCP-1 and (E) RANTES were measured by qPCR. Data are means ± SEM for groups of 6. A 
significant difference to control was indicated by ***(p<0.001); to (25%) THP-1-MacCM by 
#(p<0.05), ##(p<0.01), ###(p<0.001). The results were determined using one-way ANOVA with 
Tukey’s post hoc test. 
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9.4. The summary of cytokine secretion of Chapter 5 
 
 
Control 
 
IL-1β 
(0.5 ng/ml) 
ZK159222 
(1 μM) 
ZK191784 
(1 μM) 
Angiogenin 0.2125524 0.2038048 0.09923838 0.1524558 
CD 40 Ligand - - 0.8288996 - 
Chitinas 3-like 1 0.935989 0.8394657 - 0.6883796 
Complement Component C5/C5a 0.303930 0.294674 0.2249955 0.2249371 
Dkk-1 0.2813234 - 0.1055688 0.1644258 
EGF 0.5809314 0.6144629 0.5926872 0.4367681 
ENA-78 1.905615 1.721861 1.642727 1.349148 
FGF-7 - - - - 
Flt-3 Ligand - 0.1448068 - - 
G-CSF - 0.503077 0.3989667 0.4587737 
GDF-15 0.1764942 0.1647092 
 
0.1012699 
GRO-α 0.233063 0.422392 0.3582508 0.2398946 
HGF 0.8961962 0.7456259 0.7454289 0.5537399 
ICAM-1 - - - - 
IGFBP-2 0.1367003 - - - 
IGFBP-3 0.1681335 - - 0.1029851 
IL-6 - 0.420650 0.3334813 0.3584065 
IL-8 0.1798735 0.486144 0.3954694 0.4225234 
IP-10 - 0.1664159 - 0.100023 
LIF - 0.1029121 - - 
MCP-1 0.4498097 0.5610289 0.4734685 0.5295422 
MCP-3 - 0.3525286 0.1744396 0.2575721 
MIF 0.106795 0.1033987 - - 
MIP-3α 0.4598199 1.093482 0.8006401 0.8811694 
PENTRAXIN-3 0.1215895 0.1763251 - 0.1394787 
RANTES - 0.2716343 0.1065614 0.1761037 
Serpin 1.862303 1.783751 1.522748 1.558629 
SHBG - 0.1165364 - - 
Thrombospondin-1 - 0.1832954 0.1113202 0.1194948 
The results are presented in fold change of pixel density (relative to the references on the proteome 
array). 
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9.5. Effects of VDR agonist-MacCM on cytokine release from human white 
preadipocytes  
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Preadipocytes were either cultured alone (control), or with (25%) THP-1-MacCM alone, or with 
[1α,25(OH)2D3 (10 nM), ZK159222 (10 nM and 1 μM) and ZK191784 (10 nM and 1 μM)] VDR 
agonist-MacCM for 24 h before medium collection. The release levels of pro-inflammatory factors 
(A) IL-1β, (B) IL-6, (C) IL-8, (D) MCP-1 and (E) RANTES were measured by ELISA. Data are 
means ± SEM for groups of 6. A significant difference to control was indicated by ***(p<0.001); 
to (25%) THP-1-MacCM by ##(p<0.01), ###(p<0.001). The results were determined using 
one-way ANOVA with Tukey’s post hoc test. 
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9.6. Effects of VDR agonist-MacCM on cytokine gene expression in human 
white preadipocytes  
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Preadipocytes were either cultured alone (control), or with (25%) THP-1-MacCM alone, or with 
[1α,25(OH)2D3 (10 nM), ZK159222 (10 nM and 1 μM) and ZK191784 (10 nM and 1 μM)] VDR 
agonist-MacCM for 24 h before Trizol-dissolved lysate collection. The mRNA levels of 
pro-inflammatory factors (A) IL-1β, (B) IL-6, (C) IL-8, (D) MCP-1 and (E) RANTES were 
measured by ELISA. Data are means ± SEM for groups of 6. A significant difference to control 
was indicated by ***(p<0.001); to (25%) THP-1-MacCM by ##(p<0.01), ###(p<0.001). The 
results were determined using one-way ANOVA with Tukey’s post hoc test. 
 
